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Stellingen 
behorende bij het proefschrift "Interactions of polyhalogenated aromatic 
hydrocarbons with thyroid hormone metabolism" van Gerlienke Schuur 
te verdedigen op dinsdag 17 november 1998 
1. De schildklierhormoonverlaging die gevonden wordt in plasma van proefdieren na 
blootstelling aan sommige organohalogenen is niet betrokken bij een toename in de 
omzetting van deze organohalogenen. 
{dit proefschrift) 
2. De expressie en activiteit van cytochroom P4501A worden riiet gereguleerd door 
schildklierhormoon. 
(dit proefschrift) 
3. Ondanks het feit dat blootstelling aan organohalogenen effecten heeft op verschillende 
routes van schildklierhormoon-metabolisme, wordt de concentratie van aktief 
schildklierhormoon in de hersenen niet aangetast. 
(ditproefschrift, proefschriftD.C. Morse) 
4. Pentachloorfenol is behalve een goede sulfateringsremmer ook in staat de hoeveelheid 
sulfotransferase enzym in de lever van ratten te verhogen. 
(dit proefschrift) 
5. In het onderzoek naar pseudo-oestrogenen worden de mogelijke effecten op het 
metabolisme van oestrogenen onderschat. 
6. De omvang van onderzoek naar hormoonverstorende effecten van industriele 
chemicalien is in tegenspraak met de veel grotere blootstelling aan natuurlijke 
hormoonverstorende stoffen via het dieet. 
7. De remmende werking van stoffen uit rode wijn op fenolsulfotransferase activiteit kan 
hoofdpijn veroorzaken. 
(J.T. Littlewoodet al., Lancet 1 (8585), p. 558, 1988 andA.L, Jones et al., Eur. J. Clin. 
Pharmacol. 49, p. 109, 1995) 
8. Een milde jodide deficientie, onder andere veroorzaakt door het eten van te weinig 
brood, kan mogelijk effecten hebben op de foetale ontwikkeling bij de algemene 
populatie. 
(J.G. Hollowell& W.H. Hannon, Teratology 55, p. 389, 1997) 
9. TCDD is niet alleen vanuit toxicologische oogpunt een interessante stof maar is 
daarnaast een handvat voor het onderzoeken van vele werkingsmechanismen. 
(M. Holloway, Scientific American, november, p. 16, 1990) 
10. Een RARE ("retinoic acid response element") is niet zo zeldzaam of vreemd als het 
klinkt. 
11. De bezuiniging, die via de studietijdverkorting is bereikt, resulteert later in een hogere 
uitgave van de overheid aan ziekteverzuim en werkloosheidsuitkeringen. 
(naar aanleiding van een Loesje poster "Twijfelen doe je maar na je studie") 
12. Het goed bedoelde advies van de overheid aan vrouwen om kinderen voor je dertigste te 
krijgen is in conflict met de eerder gebrachte slogan "een slimme meid is op haar 
toekomst voorbereid". 
13. Het toenemend gebruik van Email is de oorzaak van meer spelfouten en een 
verslechtering van de stijl door de gebruikers. 
14. Naamswijzigingen binnen een organisatie zijn vaak een aanwijzing voor bezuinigingen. 
15. Nu vaatwassers zuinig zijn met water en energie, is de mogelijkheid van het houden van 
een goed gesprek tijdens de afwas een laatste argument om ze niet aan te schaffen. 
(nav Volkskrant 1 maart 1997) 
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CHAPTER 1 
GENERAL INTRODUCTION 
The research described in this thesis concerns the possible interactive effects between thyroid 
hormones and polyhalogenated aromatic hydrocarbons (PHAHs), with emphasis on 
metabolism. In particular, the possible regulatory role of thyroid hormone on PHAH-induced 
biotransformation enzymes. Secondly, the possible inhibition of thyroid hormone sulfation by 
hydroxylated PHAHs was investigated. This research was performed at the department of 
Toxicology, Agricultural University Wageningen in close collaboration with the department 
of Internal Medicine III of the Erasmus University Rotterdam. 
In this Chapter, some information on the toxic effects of PHAHs is given, followed 
by an introduction into thyroid hormone metabolism. In addition, the effects of PHAHs on 
thyroid hormone metabolism are discussed. Finally, the outline of the thesis is given. 
Figure 1.1 The chemical structures of 
PCBs, PCDDs and PCDFs. 
Polyhalogenated aromatic hydrocarbons 
(PHAHs) 
Polyhalogenated aromatic hydrocarbons such as 
polychlorinated biphenyls (PCBs), dibenzo-p-
dioxins (PCDDs) and dibenzofurans (PCDFs) are 
persistent environmental pollutants (for general 
structures see Figure 1.1). PCBs were used as 
plasticizers, flame retardants and as dielectric 
fluids in transformers and capacitors, but are 
banned since the early eighties (De Voogt and 
Brinkman, 1989). PCDDs and PCDFs are formed 
as unwanted byproducts during organochlorine 
synthesis or during waste incineration, but recent 
measures taken have reduced their emissions. All 
PCB, PCDD and PCDF structures consist of two 
halogenated phenyl rings, with respectively 209, 
75 and 135 possible congeners dependent on the 
degree and position of chlorine substituents. 
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PCDDs and PCDFs are rigid planar structures, while the phenyl rings of the PCBs can rotate 
along the central C-C bond. 
PHAHs are highly lipophilic and extremely resistant to breakdown by acids, alkali, 
heat, and hydrolysis. Therefore, they are very persistent and widely present in the environment, 
including fish, wildlife and humans. The accumulation of PHAHs depends on their metabolism, 
which is dependent on the degree of chlorination (Safe, 1989). Hydroxylation by cytochrome 
P450 enzymes is the main route of metabolism of PHAHs and occurs preferentially at the para 
position. The presence of two vicinal unsubstituted carbon atoms facilitates oxidative 
metabolism. Hydroxylated metabolites can be further metabolized to glucuronic acid or sulfate 
conjugates. The formation of mercapturic acid metabolites of PCBs is thought to start with the 
reaction of glutathione with an PCB-arene oxide, followed by metabolization to the cysteine-
adduct, and thiol-adduct. This thiol-adduct is converted to the methylthio-derivative, followed 
by oxidation to first a methylsulfinyl- and ultimately to a methylsulfonyl-metabolite. (Sipes 
and Schnellmann, 1987; Safe, 1989) 
PHAHs induce a number of toxic effects, including body weight loss, thymic atrophy, 
impairment of immune responses (Tryphonas, 1994), hepatoxicity, chloracne and related dermal 
lesions, tissue-specific hypo- and hyperplastic responses, carcinogenesis, developmental 
toxicity (Peterson et al., 1993), neurobehavioral responses and neurotoxicity (Seegal, 1996; 
Schantz, 1996), teratogenicity, and reproductive toxicity (Peterson et al, 1993). These toxic 
effects are congener-, species-, sex- or age-dependent (Safe, 1990; 1994; DeVito and Birnbaum, 
1994). In Table 1.1, biochemical effects caused by PHAHs are summarized. 
Table 1.1 PHAH induced biochemical effects. 
induction of CYP1A1, CYP1A2, and CYP4A1 
suppression of CYP2C11 
induction of GSTs 
induction of UDP-glucuronyl transferases 
increased cytochrome P450 levels 
induction of epoxide hydrolase 
inhibition of uroporphyrinogen decarboxylase activity 
induction of ALA synthetase activity 
decreased ALA dehydratase 
decreased thyroxine levels 
decreased hepatic/ plasma vitamin A levels 
induction of c-Ha-ras, c-raf, C-yes, c-erbA and c-erbB protooncogen 
increased serum lipids and HMG CoA reductase 
decreased serum chlolesterol 
increased aldehyde dehydrogenase 
increased serum SGPT, SGOT 
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The common mechanism of action for PHAH toxicity is generally accepted to be the Ah 
receptor pathway (Poland and Knutson, 1982; Okey et al, 1994). PCDDs, PCDFs and all planar 
PCBs have been shown to be ligands of this cytosolic receptor. After binding of a ligand, the 
Ah receptor complex loses its heat shock proteins and it is transported together with the Ah 
receptor nuclear translocator (ARNT) protein into the nucleus where it binds to specific DNA 
enhancer sequences, the dioxin response elements (DRE). This binding results in the increased 
expression of certain proteins, including CYP1 Al/2, UGT1A6 (Owens, 1977; Munzel et al, 
1996) and GST1 (Pimental et al, 1993) (Safe, 1995). Planar structures such as 2,3,7,8-chlorine 
substitution of PCDDs and PCDFs, non-ortho substituted PCBs as well as mono-ortho PCBs 
are shown to be Ah-receptor agonists (Safe, 1992). 
Non-planar, di- to tetra-ortho PCBs which do not exhibit Ah-receptor agonistic 
activity, and have been shown to induce CYP2B and the UGT1A2 isozyme (Safe, 1995). These 
phenobarbital-like PCBs induce toxic effects such as alterations in plasma thyroid hormone 
(McClainera/., 1989; Barter and Klaassen, 1992a; 1994), neurotoxicity (Seegal et al, 1990; 
Shain et al., 1991), and tumor promotion (Silberhorn et al., 1990). The mono-ortho substituted 
PCBs are able to induce both PB-like and Ah-receptor-like biotransformation enzymes. 
In addition, effects caused by hydroxylated PHAH metabolites may add to the 
spectrum of toxic effects. These effects include 1) competitive inhibition of thyroxine (T4) 
binding to transthyretin (TTR), a thyroid hormone transport protein, as demonstrated in vitro 
(McKinney et al, 1985; Rickenbacher et al, 1986; Lans et al, 1993; 1994) and in vivo 
(Brouwer and van den Berg, 1986; Lans, 1995), 2) reduction of vitamin A and retinol-binding 
protein (RBP) levels in rat plasma as a result of the binding of PHAH-OHs to TTR, which 
causes a weakening of the plasma protein TTR-RBP complex carrying both retinol and T4, 
(Brouwer et al., 1988), 3) uncoupling of mitochrondrial phosphorylation (Lans et al, 1990; 
Narasimhan et al., 1991), 4) estrogenic or anti-estrogenic activity (Korach et ah, 1988; Connor 
et al, 1997; Fielden et al, 1997), 5) inhibition of gap junctional intercellular communication 
(GJIC) (De Haan et al., 1994), and 6) inhibition of cytochrome P450 activities. For 
methylsulfonyl PHAH metabolites also some distinct effects have been shown, such as 1) 
induction of cytochrome P450 activities (Kato et al, 1995) and 2) the binding to a specific 
protein in lung (Stripp et al, 1996). 
Thyroid hormone metabolism 
Thyroid hormone is essential for the normal fetal development of several organs, and for the 
regulation of growth and basal metabolism throughout life. The active hormone is 3,3',5-
triiodothyronine (T3), which acts through binding to a nuclear thyroid hormone receptor, 
followed by binding to a thyroid hormone responsive element (TRE). Its precursor, thyroxine 
11 
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(T4) is produced mostly by the thyroid gland and is transported via plasma to the various 
tissues. Because of the importance of thyroid hormone in numerous processes, the intracellular 
thyroid hormone levels are tightly regulated in various ways, e.g. plasma transport, cellular 
metabolism and synthesis and feed-back regulation via the hypothalamus-pituitary-thyroid 
gland axis. The metabolism of iodothyronines is mediated by several different metabolic 
enzyme systems: 1) deiodinases, 2) UDP-glucuronyltransferases, and 3) sulfotransferases 
(Visser, 1990), as is presented in Figure 1.2. 
The first metabolic pathway is deiodination, which has been reviewed several times 
(Kohrle etal, 1987; Visser, 1990; Braverman, 1994; Kohrle, 1996; Larsen, 1997; St. Germain 
and Galton, 1997). Three types of membrane-bound deiodinases are known. Type I deiodinase 
(Dl) is present especially in liver, but also in kidney and thyroid. Dl is able to deiodinate both 
the outer and inner ring of iodothyronines, with rT3 as the preferred substrate. It is a 
selenocysteine-containing enzyme, and can be inhibited by 6-propylthiouracil (PTU). It is most 
important for the production of plasma T3 levels and for the removal of plasma rT3. In 
hypothyroidism, Dl activity is decreased, following a reduced T3 concentration in plasma and 
tissue. 
Type II deiodinase (D2) is present in the CNS, pituitary, brown fat, placenta, and in 
humans in thyroid, skeletal muscle and heart (only proven by mRNA detection). It deiodinates 
only the outer ring of thyroid hormones, with T4 as the preferred substrate. D2 is also an 
selenocysteine-containing enzyme, but is insensitive to PTU. Its function is to provide 
intercellular T3 in brain and pituitary. During hypothyroidism, D2 activity is increased, which 
can be returned to normal only with T4 infusion (Escobar-Morreale et al., 1997). 
Type III deiodinase (D3) is present in CNS, placenta, skin and in fetal tissues. It 
performs only inner ring deiodination, with T3 and T4 as the preferred substrates. The function 
of D3 is predominantly the degradation of T3 and T4, thereby regulating local T3 levels. 
Iodothyronines are also conjugated by glucuronidation or sulfation. Glucuronic acid 
delivered by the cofactor uridine diphosphate (UDP)-glucuronic acid (UDPGA) is transferred 
to the hydroxyl group of iodothyronines. Glucuronidation is catalysed by membrane bound 
UDP-glucuronyltransferases (UGTs). So far, three different UGT isozymes are known to be 
involved in glucuronidation of iodothyronines. Phenol UGT preferentially glucuronidates rT3, 
but is also able to glucuronidate T4. Bilirubin UGT also conjugates T4 and rT3. Finally, 
androsterone UGT prefers T3 as a substrate. When iodothyronines are glucuronidated, they 
are excreted into the bile. After hydrolysis in the intestine by P-glucuronidases, at least part 
of the iodothyronines is reabsorbed. (Visser, 1990; 1994a) 
A second conjugation reaction is sulfation. Sulfotransferases represent a family of 
homologous enzymes which catalyse the sulfation of various compounds with overlapping 
substrate specificity, using 3'-phosphoadenosine-5'-phosphosulfate (PAPS) as the sulfate donor. 
Sulfotransferases are soluble isozymes, some of which exist as monomer and others as 
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Figure 1.2 Thyroid hormone metabolism pathways. Glucuronidation and sulfation is 
only presented for T4, but T3, rT3 and T2 are also conjugated. 
homodimer or even multimeric complexes, which are localized in the cytoplasm of different 
tissues (Matsui and Homma, 1994). Iodothyronines are sulfated by phenol sulfotransferases, 
in the order 3,3-T2 » T3 > rT3 > T4 by rat liver. In vitro, it was demonstrated that the 
sulfotransferase isozymes rat SULT1C1 and human SULT1A1 and SULT1A3 were able to 
sulfate iodothyronines (Visser ef a/., 1996a; 1998a/b). 
Small amounts of thyroid hormone sulfates appear normally in bile or serum, because 
they are rapidly deiodinated in the liver. The inner ring deiodination by Dl is strongly enhanced 
for iodothyronine sulfates compared to non-sulfated iodothyronines themselves. However, high 
concentrations of iodothyronines sulfates have been found in plasma, bile and amniotic fluid 
of fetal sheep and humans (Chopra et al, 1992; Wu et al, 1992a/b; 1993; 1995; Santini et al, 
1993; 1994; Polk et al, 1994). When Dl activity is low, e.g. during fetal development, non-
thyroidal illness or fasting in rats, iodothyronine sulfate levels are increased. Non-sulfated 
hormones may then be recovered by sulfatase activity in tissues. This is suggested to play an 
important role in regulating thyroid hormone levels during fetal development (Santini et al, 
1992a). (Visser, 1990; 1994b) 
Different enzymes important in carbohydrate metabolism are regulated by thyroid 
status. Examples of such thyroid hormone-dependent enzymes are malic enzyme activity and 
a-glycerolphosphate dehydrogenase activity, both have been demonstrated to possess a TRE 
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in their promoter sequence (Oppenheimer et al, 1977; Pellizas et al, 1996). These activities 
can be used as a measure for thyroid hormone status in the tissue. 
Effects of PHAHs on thyroid hormone metabolism 
One aspect of the toxicity of PHAHs is their effect on thyroid hormone levels and metabolism. 
PHAHs are known to affect the thyroid hormone system on at least three different levels: 1) 
thyroidal hormone synthesis, 2) plasma transport, and 3) hepatic metabolism (for review, see 
Brouwer et al, 1998). 
Exposure to PHAHs results in a decrease in plasma total and free T4 levels in rats, 
mice and marmoset monkeys. This has been observed with TCDD (Bastomsky, 1977; Potter 
et al, 1983, 1986; Pazdernik and Rozman, 1985; Henry and Gasiewicz, 1986, 1987; Jones et 
al, 1987; Roth et al, 1988; Pohjanvirta et al, 1989; Lans et al, 1990), Aroclor 1254 
(Bastomsky, 1974; Byrne et al, 1987; Brouwer, 1989; Beetstra et al, 1991; Gray et al, 1993) 
and PBBs (Gupta et al., 1983). However, the T3 levels were sometimes reported to be increased 
(Bastomsky, 1977; Potter et al, 1986) or decreased (Pazdernik and Rozman, 1985), but most 
reports show that serum T3 is unchanged after PHAH treatment (Henry and Gasiewicz, 1987; 
Gorski and Rozman, 1987; Jones e/o/., 1987; Roth et al, 1988; Muzi etal, 1989; Lans, 1995; 
Morse, 1996). 
Firstly, PCBs and PCDDs could act directly on the thyroid gland. Gupta et al. (1973) 
and Rozman et al. (1986) described degenerative and necrotic changes in thyroid follicles in 
rats after TCDD treatment. Aroclor 1254 also showed effects on thyroid function and 
morphology in Gunn rats, and adult cynomolgus monkeys (Collins et al, 1977, Collins and 
Capen, 1980a/b/c; Sepkovic and Byrne, 1984; Tryphonas et al, 1984). The effects of PHAHs 
on thyroid gland function may be direct or secondary to decreases in plasma thyroid hormone 
levels, resulting in an increased TSH stimulation (suggested by Ness et al, 1993). However, 
the ultrastructural and functional alteration of rat thyroid glands after Aroclor 1254 exposure 
were dissimilar to thyroid gland alteration found after iodide excess or deficiency, or after a 
TSH or T4 administration (Collins and Capen, 1980c), suggesting an additional or specific 
effect of Aroclor 1254 exposure. 
Secondly, PHAHs are able to interfere with plasma thyroid hormone transport. 
McKinney et al. (1985) and Rickenbacher et al. (1986) described interactions of PHAHs and 
hydroxylated metabolites with TTR using in vitro binding studies and modelling studies. 
Brouwer and Van den Berg (1986) demonstrated a mechanism based on disturbed plasma 
transport for the decrease in plasma T4 levels in rats exposed to PCB77, a coplanar PCB 
congener. Lans et al. (1993; 1994) demonstrated that in vitro PHAH-OHs are able to inhibit 
T4 binding to TTR, but not to thyroxine-binding globulin (TBG). Lans (1995) confirmed the 
14 
General introduction 
binding of a PCB-OH to TTR, both by X-ray diffraction analysis of a crystal of the TTR-PCB-
OH complex and computer-assisted modelling studies. 
Finally, PHAHs are known for their modulating effects on thyroid hormone 
metabolism. Glucuronidation can be induced by PHAHs; planar and mono-ortho PCBs have 
been shown in rats to induce the phenol type (UGT1A6), while PB and PB-like inducers have 
been shown to induce the bilirubin type (UGT1A2) (Rozman et al, 1985a/b, 1988; Henry and 
Gasiewicz, 1987; Beetstra et al., 1991; Saito etal, 1991; De Sandra etal, 1992; Eltome/a/., 
1992; Barter and Klaassen, 1992a/b; 1994; Visser et al, 1993a; Van Birgelen et al, 1995). In 
Gunn rats, which are deficient in UGT activity towards bilirubin, phenolic compounds and T4 
(Visser et al, 1993a), the T4 UGT activity could be induced by Aroclor 1254 to some extent 
in the heterozygous rats but not in the homozygous rats. However, the decrease in plasma T4 
levels were similar in both strains, suggesting additional effects of the compound (Collins and 
Capen, 1980a). 
Dl activity in liver has been shown to be decreased in vivo following treatment of rats 
with several Ah-receptor agonists, such as 3-methylcholanthrene, 3,3',4,4'-TCB, TCDD and 
Aroclor 1254 (Adams et al, 1990; Eltom et al, 1992; Visser et al, 1993a; Lans, 1995; 
Raasmaja et al, 1996), but also after PB treatment (De Sandro et al, 1991). Hydroxylated 
PHAH metabolites also inhibit D1 activity in vitro using rat hepatic microsomes (Rickenbacher 
etal, 1989; Adams et al., 1990; Lans, 1995). In addition, brain D2 activity is increased in fetal 
and neonatal rats exposed to 3,3',4,4',5,5'-HCB or Aroclor 1254 (Morse et al, 1993; 1996). 
This increase is probably mediated by the severely reduced plasma and brain T4 levels. 
Outline of this thesis 
The major aim of this study is focussed on the possible interactions between thyroid hormones 
and PHAHs, with particular emphasis on metabolism. Two separate research questions were 
put forward and studied. 
Question I. Is it possible that the PHAH-induced decrease in plasma T4 is a mechanism to 
regulate the induction of biotransformation enzymes that metabolize the PHAHs? 
PHAH exposure results in the induction of biotransformation enzymes such as 
cytochrome P450 (CYP), glutathione S-transferases (GSTs) and UDP-glucuronyltransferases 
(UGTs). The mechanism for the induction is general accepted to be the Ah-receptor pathway. 
However, not all toxic effects caused by PHAH can be explained by this mechanism, such as 
hypovitaminosis A and neurotoxicity. 
Exposure to PHAHs also results in lower plasma T4 levels, while many of the signs 
of TCDD-induced toxicity resemble those observed for thyroid dysfunction, including body 
15 
Chapter 1 
weight loss, dermal toxicity and changes in cholesterol and triglyceride levels. It was 
demonstrated that thyroidectomy (Rozman et al., 1984; 1985a/b) offers some protection against 
mortality. Furthermore, it was reported that thyroid hormone is able to regulate cytochrome 
P450 isozymes (Kato and Takahashi et al, 1968; Rumbaugh et al, 1978; Leakey et al, 1982; 
Mttller et al., 1983a/b; Skett, 1987; Yamazoe et al, 1989; Arlotto and Parkinson, 1989), UGTs 
(Chowdhury etal, 1983; Moscioni and Gartner, 1983; Pennington et al, 1988; Goudonnet et 
al, 1990), and GSTs (Williams et al, 1986; Pimental et al, 1993). Therefore, we proposed 
that the induction of biotransformation enzymes by PHAHs via the Ah-receptor route is 
modulated by the PHAH-induced decreases in thyroid hormone levels. 
Approach: Thyroidectomized (Tx) rats, Tx rats replaced with T3 or T4 and control 
rats were exposed to TCDD. Thyroid hormone serum levels together with thyroid hormone 
parameters such as hepatic Dl activity, hepatic malic enzyme activity and brain D2 activity 
were measured (Chapter 2). In this same animal experiment, biotransformation enzyme 
activities such as CYP1 Al activity, UGT activity, GST activity, and sulfotransferase activities 
were analysed for their possible regulation by thyroid state {Chapter 3). 
To obtain more information about thyroid hormone regulation of different types of 
cytochrome P450, we designed an animal experiment with hypothyroid (Tx), euthyroid (Eu) 
and hyperthyroid (T3-treated) Sprague-Dawley rats and exposed them to a CYP1A inducer, 
PCB 126, and a CYP2B inducer, PCB 153. Thyroid hormone serum levels, thyroid hormone 
status parameters as well as CYP1A and CYP2B activities, protein and mRNA levels were 
investigated {Chapter 4). 
Question II. Are hydroxylated PHAHs able to inhibit thyroid hormone sulfation in vitro as well 
as in vivol 
Hydroxylated metabolites of PHAHs are known for their competitive inhibition of 
thyroid hormone binding to proteins such as TTR and Dl (Rickenbacher et al, 1989; Adams 
et al, 1990; Lans et al, 1993; 1994; Lans, 1995). Due to the structural resemblance of 
hydroxylated PHAHs with thyroid hormones, it was proposed that phenol sulfotransferase, 
which is another protein that binds iodothyronines, may be inhibited by PHAH-OHs. 
Approach: To start, thyroid hormone sulfation was assayed in vitro, using rat liver 
cytosol as enzyme source and T2 as substrate in the presence of different hydroxylated PHAHs. 
Some structure-activity relationships of PHAH-OHs for T2 sulfation inhibition were 
investigated (Chapter 5). More information was obtained about the role of different isozymes 
in inhibition of thyroid hormone sulfation by PHAH-OHs, using different enzyme sources, e.g. 
cytosolic preparations with specific SULT isozymes. The nature of the T2 sulfotransferase 
activity inhibition by PHAH-OHs was also investigated (Chapter 6). Secondly, a rat and human 
hepatoma cell line were used to investigate the in vitro inhibition of T2 sulfation by PHAH-
OHs in cells (Chapter 7). Finally, the possible inhibition of thyroid hormone sulfation was 
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tested in vivo in rats, using an experimental setup with prenatal exposure to PCBs or 
pentachlorophenol, which is a potent sulfotransferase inhibitor (Chapter 8). 
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PARTI 
THE EFFECTS OF THYROID HORMONE ON THE INDUCTION 
OF BIOTRANSFORMATION ENZYMES BY 
POLYHALOGENATED AROMATIC HYDROCARBONS 
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CHAPTER 2 
EXTRATHYROIDAL EFFECTS OF 2,3,7,8-
TETRACHLORODIBENZO-P-DIOXIN ON THYROID HORMONE 
TURNOVER IN MALE SPRAGUE-DAWLEY RATS 
Abstract 
Treatment of rats with different polyhalogenated aromatic hydrocarbons strongly decreases 
plasma T4, with little or no decrease in plasma T3. The extrathyroidal effects of TCDD on 
thyroid hormone turnover were studied by ip administration of a single dose of 10 ug TCDD/kg 
bw or vehicle (corn oil) to euthyroid (Eu) rats, thyroidectomized (Tx) rat, and Tx rats infused 
with 1 ug T4 (Tx+T4) or 0.4 ug T3 (Tx+T3) per 100 g bw per day by osmotic minipumps. Tx 
rats showed decreased plasma T4 and T3 and increased plasma TSH levels, decreased hepatic 
Dl and malic enzyme activities, and increased brain D2 activities. All parameters were largely 
restored to Eu levels in Tx+T4 rats and, except for plasma T4 and brain D2 activity, in Tx+T3 
rats, validating the thyroid hormone-replaced Tx rats as models to study the peripheral effects 
of TCDD. Three days after TCDD administration, plasma T4 and FT4 levels were significantly 
reduced in Eu rats and in Tx+T4 rats, and plasma T3 was significantly reduced in Tx+T3, but 
not in Eu or Tx+T4 rats. Plasma TSH was not affected by TCDD in any group. Hepatic T4 
UGT activity was induced approximately 5-fold by TCDD while T3 UGT activity was only 
increased by about 20% (p=NS) in the different groups. TCDD produced an insignificant 
decrease in liver Dl activity in Tx rats and an insignificant increase in brain D2 activity in Tx 
rats and hormone-replaced Tx rats. Hepatic malic enzyme activity was significantly increased 
by TCDD in all groups, except Tx rats. These results strongly suggest that the thyroid hormone-
decreasing effects of TCDD are predominantly extrathyroidal and mediated by the marked 
induction of hepatic T4 UGT activity. 
based on A. Gerlienke Schuur, Franklin M. Boekhorst, Abraham Brouwer, and Theo J. Visser 
(1997). Extrathyroidal effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on thyroid hormone 
turnover in male Sprague-Dawley rats. Endocrinology 128, 3727-3734. 
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Introduction 
It is well known that PHAHs, such as polychlorinated biphenyls (PCBs), polychlorinated 
dibenzo-/?-dioxins (PCDDs), and polychlorinated dibenzofurans (PCDFs), alter thyroid 
hormone levels and metabolism in rodents. Administration of TCDD to rats or mice results 
in reduced plasma T4 levels (Potter et al., 1983; 1986; Roth et al, 1988). The mechanisms 
involved in the thyroid hormone-decreasing effects of PHAHs are still not fully understood. 
TCDD markedly increased the biliary clearance of T4 (Bastomsky, 1977), which is associated 
with an increase in hepatic T4 glucuronidation due to the profound induction of UGTs by 
PHAHs (Beetstraef a/., 1991; Saito etal, 1991; De Sandro et al., 1992; Barter and Klaassen, 
1992a; Visser et al., 1993a). On the other hand, several investigations have presented 
histological evidence for a direct damaging effect of PHAHs on the thyroid gland (Gupta et 
al., 1973; Rozman et al., 1986). Finally, hydroxylated metabolites of PHAHs were found to 
compete with T4 for binding to plasma transthyretin, resulting in an increased plasma free T4 
fraction and, hence, a decreased plasma total T4. The latter effect is, however, highly dependent 
on the extent of metabolic conversion of PHAHs, and negligible for compounds such as TCDD 
(Brouwer et al., 1990; Lans et al., 1993). Perhaps, the most remarkable effect of PHAHs is their 
potent induction of hepatic detoxification enzymes, both phase I enzymes such as CYP 
isoenzymes, and phase II enzymes such as UGTs and GSTs (Safe, 1990; Sutter and Greenlee, 
1992). 
Thyroid hormones influence a variety of metabolic processes in most mammalian 
tissues, and may also have a significant effect on rates of drug metabolism. Studies of 
Rumbaugh et al. (1978) established a dose-dependent stimulating effect of thyroid hormones 
on hepatic mixed-function oxidases. CYP activities were lower in thyroidectomized (Tx) male 
and female Sprague-Dawley rats compared with those in euthyroid (Eu) controls. Substitution 
of Tx rats with T4 restored these activities to Eu levels. Muller et al. (1983a/b) showed that 
T3 treatment increases CYP1A activities in rat liver. This suggests that the effects of PHAHs 
on biotransformation enzymes may be modulated by the altered thyroid status associated with 
PHAH treatment. 
To further elucidate the peripheral mechanisms mediating the effects of PHAHs on 
thyroid hormone turnover, we investigated the effects of TCDD in Tx rats substituted with T4 
or T3. In addition, this model was used to study the role of changes in thyroid hormone status 
on the induction of hepatic cytochrome P450 isozymes and other biotransformation enzymes 
by PHAHs. For this purpose we used Tx male Sprague-Dawley rats infused with substitution 
doses of T3 (Tx+T3) or T4 (Tx+T4) by osmotic minipumps. Here, we describe the validation 
of this model as well as the effects of TCDD on plasma and tissue thyroid state-dependent 
parameters in Eu, Tx, Tx+T3, and Tx+T4 rats. The modulating effects of thyroid hormone on 
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the induction of hepatic phase I (CYP) and phase II (UGT and GST) detoxification enzymes 
are presented in Chapter 3 (Schuur et ah, 1998a). 
Materials and methods 
Chemicals 
TCDD (>99% pure) was purchased from Promochem (Wesel, Germany). Iodothyronines, 
dithiothreitol (DTT), uridinediphosphoglucuronic acid (UDPGA), propyl-2-thiouracil (PTU), 
and BSA were obtained from Sigma Chemicals Co. (St. Louis, MO). Malic acid was obtained 
from Janssen Chimica (Tilburg, the Netherlands). BioRad protein reagent was obtained from 
Bio-Rad Laboratories (BioRad, Richmond, CA). [125I]T4, [125I]T3, and [ 125I]rT3 were obtained 
from Amersham (Buckinghamshire, UK); they were purified on Sephadex LH-20 (Pharmacia, 
Woerden, the Netherlands) before each assay (Rutgers et al, 1989). All other chemicals were 
of analytical grade. 
Animals and treatment 
Male Sprague-Dawley rats, surgically thyroidectomized (Tx) or sham-operated by the supplier 
at 4 weeks of age, were purchased from Harlan/CPB (Zeist, the Netherlands). The complete 
resection of the thyroid in the Tx rats was confirmed at the end of the experiment by autopsy. 
The rats were obtained at 6 weeks of age and allowed to acclimatize for 2 weeks before the 
experiment. They were maintained at 50% humidity and 21 °C on bedding in plastic cages with 
a 12-h light/12-h dark cycle. Rat chow (Hope Farms, Woerden, the Netherlands) and tap water 
with 0.5% CaCl2 were supplied ad libitum. Model 2002 Alzet minipumps (Charles River Wiga, 
Sulzfeld, Germany), delivering 0.4 ug T3/100 g bw/day (Tx+T3 rats, n=15) or 1.0 ug T4/100 
g bw/day (Tx+T4 rats, n=15) in 0.1 M NaOH in 0.9% NaCl, were implanted ip at day 0 under 
ether anaesthesia. Five sham operated rats, 15 non-operated Eu rats, and 15 Tx rats received 
pumps with solvent only. Water and food consumption was recorded daily, and body weight 
was recorded twice a week. On day 7 after osmotic minipump implantation, 5 rats from each 
group (Eu, Tx, Tx+T3, and Tx+T4) were given an ip injection of 10 ug TCDD/kg bw in corn 
oil (5 ml/kg). Of each group, 5 control and 5 pair-fed control rats were given an ip injection 
with corn oil only. On the day before pump implantation (day -1), day 3, day 7, and day 10, 
blood (= 1 ml) was collected by orbital puncture in heparinized tubes and stored on ice until 
separation of plasma. On day 10, all rats were killed under ether anaesthesia. Livers were 
perfused with saline, dissected, weighed and frozen in 3 portions. Kidneys, thymuses, and 
brains were removed, weighed and frozen on dry ice. All tissues were stored at -80°C and 
plasma at -20°C until analysis. All procedures were approved by the Animal Welfare 
Committee of the Agricultural University Wageningen. 
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Tissue preparation 
Whole brains were homogenized in 8 volumes ice-cold 0.1 M Tris-HCl buffer, pH 7.5, 
containing 1 mM DTT, using a Potter tube, and stored at -80°C until analysis. Livers were 
homogenized on ice in 3 volumes ice-cold 0.1 M Tris-HCl buffer, pH 7.5, containing 0.25 M 
sucrose, using a Potter tube, and the homogenate was centrifuged for 30 min at 9,000xg and 
0-4°C. The resulting supernatant was centrifuged for 90 min at 105,000xg and 0-4°C, and the 
microsomal pellet was resuspended in ice-cold 0.1 M phosphate buffer, pH 7.5. Microsomes 
and cytosol were stored in aliquots at -80°C until further analysis. Protein levels of tissue 
fractions were determined using BioRad Protein reagent (Bradford, 1976) and BSA as a 
standard. 
Thyroid hormone analysis 
Plasma T4, FT4, and T3 were analyzed in duplicate using the Amerlite chemiluminescence 
kits (Amersham) according to the protocol of the supplier with the following modifications: 
the T4 and T3 assay buffer was diluted five times with demineralized water, and the standard 
curve for T4 ranged from 0 to 120 nmol T4/1. It was ascertained that TCDD does not interfere 
in the Amerlite assays. Plasma TSH was determined by RIA with the materials and protocols 
of the NIDDK, NIH, using TSH RP-2 as a standard. 
Enzyme assays 
Type I iodothyronine deiodinase (Dl). Hepatic Dl activity was determined as previously 
described (Mol and Visser, 1985). In short, microsomes (20 ug protein/ml) were incubated for 
30 min at 37°C with 1 uM rT3 and = 100,000 cpm [l25I]rT3 in 0.1 M phosphate buffer, pH 7.2, 
2 mM EDTA, and 5 mM DTT. The reaction was stopped on ice by the addition of 750 ul 0.1 
M HC1. The tubes were centrifuged, and radioiodide was determined in the supernatant by 
Sephadex LH-20 chromatography as described previously (Rutgers et al., 1989). 
Type II iodothyronine deiodinase (D2). Brain D2 activity was analyzed essentially as described 
by Visser et al. (1982) with slight modifications as described by Morse et al. (1993). The final 
incubation conditions were 0.8 mg brain homogenate protein/ml, 2 nM T4 with =50,000 cpm 
[l25I]T4,1 mM PTU, 0.5 uM T3,25 mM DTT, and 1 mM EDTA in 200 ul 0.1 M phosphate 
buffer, pH 7.2. After incubation for 60 min at 37°C, the reaction was stopped on ice by the 
addition of 100 ul 7% (wt/vol) BSA, followed by 500 ul 10% (wt/vol) trichloroacetic acid. The 
tubes were centrifuged and the radioiodide released was further isolated from the supernatant 
by Sephadex LH-20 chromatography as described previously (Mol and Visser, 1985). 
UDP-glucuronyltransferases (UGTs). Hepatic T4 and T3 UGT activities were determined 
essentially according to the method of Beetstra et al. (1991). Microsomes (1 mg protein/ml) 
were incubated for 30 min at 37°C with 1 uM T4 or T3 (plus =50,000 cpm 125I-labeled 
compound), 3.75 mM MgCl2, and 0.125% BSA in the presence or absence (blank) of 5 mM 
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UDPGA in 200 jul 75 mM Tris-HCl, pH 7.8 (Visser et ai, 1993b). Reactions were stopped by 
the addition of 0.2 ml ice-cold methanol. After centrifugation, 0.2 ml supernatant was mixed 
with 0.8 ml 0.1 M HC1 and analyzed for glucuronide formation on Sephadex LH-20 
minicolumns (Beetstra et al., 1991). 
Malic enzyme. Hepatic malic enzyme activity was determined according to the method of Hsu 
and Lardy (1967) by incubating 0.33 mg cytosolic protein/ml for 10 min at 25°C with 2 mM 
malic acid, 1.13 mM NADP, and 16 mM MnCl2 in 0.13 M triethanolamine buffer, pH 7.4, the 
formation of NADPH was determined at 340 nm using a 96-well plate spectrophotometer 
(Molecular Devices Corp., Menlo Park, CA). 
Statistics 
Treatment-related effects were first evaluated with a one-way analysis of variance followed 
by a least significant difference test (p<0.05) using the statistical software package SPSS/PC+™ 
(SPSS Inc, Chicago, IL). 
Results 
No significant differences were found for any of the parameters determined between sham-
operated and non-operated Eu rats. Therefore, only data from the latter will be presented. Body 
weights of the different groups are shown in Table 2.1. 
Table 2.1 Body weights and weight gains of the rats on the day before minipump implantation 
and on day 10 of the experimental period. 
body weight (g) body weight gain (g) body weight (g) on day 10 
on day 0 corn oil TCDD corn oil TCDD 
Eu 232.1 ±4.4 26.8 ±2.6 26.9 ±1.5 259.3 ± 5.5 258.1 ±8.7 
Tx 164.9 ±1.8* 23.2 ±2.6* 23.6 ±2.4* 188.5 ±3.6* 187.8 ±5.7* 
Tx+T3 165.9 ±2.1* 34.5 ± 3.5** 37.8 ± 2.6** 201.5 ±4.6* 201.7 ±4.8* 
Tx+T4 165.5 ±3.1* 34.1 ±4.0** 35.7 ±1.5* 201.1 ±4.9* 198.6 ±4.1* 
Note. Data are presented as means ± SEM. N=15 for Tx and Eu groups, and N=14 for Tx+T3 
and Tx+T4 groups. N=5 for all TCDD treated groups. *) Significantly different (p<0.05) from 
Eu group. #) Significantly different (p<0.05) fromTx group. 
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Figure 2.1 Plasma T4 (A), FT4 (B), T3 (C), and TSH (D) levels in Eu (• ), Tx (A), 
Tx+T3 (•) , and Tx+T4 (•) rats. The levels were measured before and 3 and 7 days after 
osmotic minipump implantation (day -1). Results represent the means ± SEM of 5 rats 
per group. *) Significantly different from Eu rats (p<0.05). #) Significantly different 
from Tx rats (p<0.05). 
Thyroidectomy performed 4 weeks earlier, i.e. at 4 weeks of age, caused an approximately 29% 
decrease (p<0.05) in body weight at the start of the infusion period. The increase in body weight 
of Tx rats infused with replacement doses of T3 (Tx+T3) or T4 (Tx+T4) during the 7-day 
period was greater than that of Tx or Eu rats (p<0.05). Body weights of Tx+T3 and Tx+T4 rats 
after 10 days of infusion were in between those of Tx and Eu rats. During the entire period, 
the daily food intake of Tx rats was about 70% of that of Eu, Tx+T3, and Tx+T4.andNo 
differences were found in water intake between the different groups. 
Plasma concentrations of T4, FT4, T3, and TSH in Eu, Tx, Tx+T3, and Tx+T4 in the 
7-day period preceding TCDD treatment are shown in Figure 2.1. Eu rats maintained constant 
levels of plasma T4 (=50 nM), T3 (= 1.3 nM), FT4 (=20 pM) and TSH (2.3 ng/ml) over the 
7-day period following osmotic minipump implantation. In the Tx rats, strongly reduced plasma 
T4 (to =30% of that in Eu rats) and FT4 (to =20% of that in Eu rats) levels were observed. 
Plasma T3 levels were less affected in Tx rats and maintained at about 50% of Eu values 
throughout the 7 day period preceding TCDD treatment. Plasma TSH levels were increased 
approximately 9-fold in Tx vs. Eu rats throughout this period, indicating a strongly decreased 
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negative feedback on hypophyseal TSH secretion. 
Infusion of Tx rats with 1 ug T4/100 g bw/day (Tx+T4 rats) resulted in a restoration 
of T4 and FT4 levels to almost Eu levels at both 3 and 7 days. There was also a significant 
increase in plasma T3 levels to almost Eu levels after 3 days of T4 replacement, but a 
subsequent decrease was observed after 7 days. Infusion of Tx rats with T3 had no effect on 
plasma T4 and FT4 levels. However, T3 replacement caused a quick restoration of plasma T3 
levels to slightly above normal Eu levels on day 3 and to Eu levels on day 7. Plasma TSH levels 
in Tx rats were progressively decreased to almost Eu levels after 3 and 7 days of substitution 
therapy with T3 or T4. 
No differences were found between pair-fed and ad libitum fed, corn oil-treated 
controls in all groups. Therefore, only data derived from pair-fed controls are presented. 
Treatment with TCDD had no significant effect on food intake, body weight or body weight 
gain compared with control rats in any of the groups. Thymus weight was decreased 
significantly by 6-20% and liver weight was increased significantly by 30-50% after TCDD 
treatment in the different groups (not shown). Results are presented as enzyme activities per 
mg protein. The significance of the effects of thyroid state and TCDD treatment were similar 
if results were expressed per g liver or per whole liver. No significant differences were found 
for brain and kidney weights between TCDD-treated rats and controls. 
The effects of TCDD on plasma thyroid hormone levels are presented in Figure 2.2. 
In the Eu and the Tx+T4 groups, TCDD significantly reduced plasma T4 levels by 38% and 
52%, respectively, compared with their respective control values. No significant effect of 
TCDD treatment was found on the low plasma T4 levels in the Tx and Tx+T3 groups (Figure 
2.2A). TCDD treatment caused a significant 28% decrease and an insignificant 38% decrease 
in plasma FT4 levels in Eu and Tx+T4 animals, respectively, compared with the corresponding 
controls (Figure 2.2B), whereas no effect was observed in the Tx and Tx+T3 groups. TCDD 
exposure resulted in a decrease in plasma T3 concentrations in the Tx, Tx+T3, and Tx+T4 rats, 
which was significant only for the Tx+T3 group (51% of control Tx+T3 rats; Figure 2.2C). 
TCDD tended to increase plasma T3 in Eu rats, but this was not significant. No TCDD-related 
changes were observed in plasma TSH in any of the groups (Figure 2.2D). 
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Figure 2.2. Effects of 
TCDD treatment on plasma 
T4 (A), FT4 (B), T3 (C), 
and TSH (D) levels in Eu, 
Tx, Tx+T3, and Tx+T4 
rats. The data shown are the 
values determined on day 
10, 3 days after 
administration of 10 ug 
TCDD/kg bw in corn oil, or 
corn oil alone (CTRL). 
Results are presented as the 
means ± SEM of 5 rats per 
group. *) Significantly 
different from Eu rats 
(p<0.05). #) Significantly 
different from CTRL rats 
(p<0.05). 
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Hepatic Dl activity was insignificantly decreased in control Tx rats compared with that in 
control Eu rats (Figure 2.3). In control Tx+T3 and Tx+T4 rats, hepatic D1 activity was the same 
as in Eu rats. TCDD treatment resulted in a further insignificant decrease in Dl activity in Tx 
rats. No effects of TCDD on Dl activity were observed in Eu, Tx+T3, and Tx+T4 rats. 
Figure 2.3 Effects of 
TCDD treatment on hepatic 
Dl activity in Eu, Tx, 
Tx+T3, and Tx+T4 rats. 
Livers were isolated on day 
10, 3 days after 
administration of TCDD in 
corn oil, or corn oil alone 
(CTRL). Results are 
presented as the means ± 
SEM of 5 rats per group. 
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Brain D2 activity was increased significantly in control Tx and Tx+T3 rats to about 250% of 
activity in control Eu rats (Figure 2.4). T4 replacement resulted in a return of D2 activity to 
control Eu levels. TCDD treatment tended to increase brain D2 activity in the Tx, Tx+T3, and 
Tx+T4 rats, although the differences with the respective controls were not significant. 
Figure 2.4 Effects of 
TCDD treatment on brain 
D2 activity in Eu, Tx, 
Tx+T3, and Tx+T4 rats. 
Brains were isolated on day 
10, 3 days after 
administration of TCDD in 
corn oil, or corn oil alone 
(CTRL). Results are 
presented as the means ± 
SEM of 5 rats per group. *) 
Significantly different from 
Eu rats (p<0.05). 
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Hepatic UGT activities were determined using T4 or T3 as substrates (Figure 2.5). With either 
substrate, UGT activities were similar in control Eu and Tx rats. T4 UGT activity was increased 
= 5 fold in all groups treated with TCDD. In contrast, T3 UGT activity was slightly but not 
significantly increased by TCDD treatment independent of thyroid state. 
B. 
Tx+T3 Tx+T4 
Eu Tx 
• CTRL 
Tx+T3 Tx+T4 
E3 TCDD 
Figure 2.5 Effect of 
TCDD treatment on hepatic 
T4 (A) or T3 (B) UGT 
activities in Eu, Tx, Tx+T3, 
and Tx+T4 rats. Livers 
were isolated on day 10, 3 
days after administration of 
TCDD in corn oil, or corn 
oil alone (CTRL). Results 
are presented as the means± 
SEM of 5 rats per group. #) 
Significantly different from 
CTRL rats (p<0.05). 
The activity of the T3-responsive malic enzyme was measured in liver cytosol (Figure 2.6). 
Malic enzyme activity was decreased by 67% in control Tx rats versus control Eu rats. Malic 
enzyme activity was partially restored in control Tx+T3 and Tx+T4 rats, with values in between 
those in control Tx and Eu rats. TCDD treatment increased the malic enzyme activity 
significantly in Eu, Tx+T3, and Tx+T4 rats to 148%, 244%, and 162%, respectively, of the 
corresponding controls. However, no effect of TCDD treatment on malic enzyme activity was 
found in the Tx group. 
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Figure 2.6 Effects of 
TCDD treatment on hepatic 
malic enzyme activity in 
Eu, Tx, Tx+T3, and Tx+T4 
rats. Livers were isolated 
on day 10, 3 days after 
administration of TCDD in 
corn oil, or corn oil alone. 
Results are presented as the 
means ± SEM of 5 rats per 
group. *) Significantly 
different from Eu rats 
(p<0.05). #) Significantly 
different from CTRL rats 
(p<0.05). CTRL 
Discussion 
This study focussed on the extrathyroidal effects of PHAHs on thyroid hormone turnover using 
thyroid hormone-substituted Tx rats (Tx+T3, Tx+T4) male Sprague-Dawley rats as a model. 
In this model, Tx rats were continuously infused with replacement doses of T3 or T4 using 
osmotic minipumps. Plasma T4, T3, and TSH were restored to levels approximately equal to 
those observed in Eu rats after 3 and 7 days of hormone replacement, suggesting that a near-
euthyroid state was achieved. However, on day 10, i.e. 3 days after corn oil administration, 
plasma T4 and T3 levels showed a significant decrease and plasma TSH a significant increase 
in the control Tx+T3 and Tx+T4 rats. This may be due to 1) increased body weight gain in the 
hormone-replaced Tx rats and, thus, decreased T3 and T4 infusion rates per 100 g bw, 2) 
increased peripheral thyroid hormone metabolism in the hormone-replaced Tx rats (Christenson 
et al., 1995), and/or 3) the administration of a rather large volume of corn oil, acting as a depot 
for the T3 and T4 released from the minipumps. 
Tissue thyroid state was assessed by measuring hepatic malic enzyme and Dl 
activities, which are under positive control of thyroid hormone (Oppenheimer et al, 1977; 
Kaplan, 1986), as well as brain D2 activity, which is down-regulated by thyroid hormone, in 
particular T4 (Leonard et al., 1984). Hepatic malic enzyme activity was very low in Tx rats, 
indicating functional hypothyroidism. In Tx+T3 and Tx+T4 rats, malic enzyme activity was 
partially restored back to Eu levels. Smaller, insignificant changes were observed for hepatic 
Dl activity, suggesting that malic enzyme activity is a more sensitive parameter for hepatic 
thyroid state. Brain D2 activity was highly elevated in the Tx group, whereas T4, but not T3, 
replacement resulted in a decrease in D2 activity back to Eu values. 
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As thyroidal secretion of T4 and T3 in the hormone-replaced rats is negligible, these 
rats are a suitable model for the study of the extrathyroidal effects of xenobiotics on thyroid 
hormone status and metabolism. T4 and FT4 levels were reduced to a greater extent by TCDD 
in Tx+T4 rats than in Eu rats, indicating that the TCDD-induced plasma T4 reduction is mainly 
due to an extrathyroidal mechanism. This is in agreement with findings reported by Barter and 
Klaassen (1992a) in Tx+T3/T4 rats after treatment with Aroclor, a PCB mixture. No effect of 
TCDD was found on plasma T3 levels in Eu rats, which is in agreement with other studies 
(Potter era/., 1983; Gorski and Rozman, 1987; Henry and Gasiewicz, 1987; Jones era/., 1987; 
Beetstra et al, 1991), although plasma T3 has also been reported to decrease (Pzadernik and 
Rozman, 1985; Rozman et ah, 1985a) or increase (Potter et al, 1986; Bastomsky, 1977) after 
TCDD treatment. In contrast to Eu rats, Tx+T3 rats showed a marked decrease in plasma T3 
after treatment with TCDD in this study, which may be explained by a TCDD-induced increase 
in the clearance of plasma T3. The variable effects of TCDD on plasma T3 in Eu rats reported 
in the different studies may be explained by the varying extents of the inhibition of hepatic Dl 
activity, the decrease in plasma T4 substrate levels, and the increase in plasma TSH and, hence, 
the stimulation of thyroidal T3 secretion. No significant effects of TCDD were observed on 
plasma TSH levels regardless of thyroid state, which has also been shown previously (Henry 
and Gasiewicz, 1987). It is not known why the TCDD-induced decrease in plasma T4 and FT4 
levels does not provoke an increase in TSH secretion. One explanation is a possible damaging 
effect of TCDD and PCBs on the hypothalamus and/or pituitary (Collins and Capen, 1980a; 
Gorski et al., 1988; Byrne et al., 1987; Liu et al., 1995). However, chronic administration of 
TCDD has been shown to increase plasma TSH, which may even be associated with 
development of thyroid tumors in rats (Sewall et al., 1995). 
T4 is glucuronidated in rat liver by at least 2 different UGT isozymes: bilirubin UGT 
and phenol UGT. Phenol UGT activity is inhibited in vitro in the presence of Brij 56, whereas 
bilirubin UGT activity is stimulated in vitro by this detergent (Visser et al, 1993a/b). T4 UGT 
activity was measured in this study in the absence of Brij 56 and, thus, largely reflect 
glucuronidation of T4 by phenol UGT. The results showed that TCDD treatment induced an 
approximately 5-fold increase in T4 UGT activity in Eu, Tx, and Tx+T3 or Tx+T4 rats. These 
results are in agreement with previous studies, showing that hepatic phenol UGT activity is 
potently induced by 3-methylcholanthrene-like inducers, such as TCDD and PCBs (Beetstra 
etal, 1991;DeSandroe/a/., 1992; Barter and Klaassen, 1992a/b; Visser etal, 1993a), which 
probably represents an increase in UGT gene expression (Mtinzel et al, 1994). This marked 
increase in hepatic T4 UGT activity is most likely responsible for the reduction of plasma T4 
and FT4 levels, as suggested previously (Beetstra et al., 1991; Barter and Klaassen, 1992a). 
This is further supported by the significant negative correlation between T4 UGT and plasma 
T4 levels found in this study (not shown) and in a previous study (Liu et al., 1995) employing 
different hepatic enzyme inducers. However, TCDD treatment does not decrease residual serum 
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T4 levels in Tx and Tx+T3 rats. In this respect it should be realized that glucuronidation is not 
an irreversible pathway of T4 disposal, as T4 glucuronide is hydrolyzed in the intestine and 
at least part of the liberated T4 is resorbed (enterohepatic cycle) (Visser, 1994a). A possible 
explanation for the lack of a TCDD-induced decrease in serum T4 in the Tx and Tx+T3 rats 
is a more efficient recovery of biliary-excreted T4 glucuronide in these animals. 
Perhaps the most remarkable result of our study is the decrease in plasma T3 levels 
after TCDD treatment of Tx+T3 rats. As mentioned above, this may be explained by a TCDD-
induced increase in plasma T3 clearance. In contrast to the strong increase in T4 UGT activity, 
TCDD produced only a small and insignificant increase in hepatic T3 UGT activity. Even if 
the approximately 30% increase in liver weight is taken into account, TCDD induces only about 
a 50% increase in hepatic T3 UGT capacity in contrast to a more than 5-fold increase in T4 
UGT capacity. The TCDD-induced increase in plasma T3 clearance may, therefore, be due to 
an increase in alternative pathways of T3 metabolism. 
TCDD did not affect hepatic Dl activity in this study, although in Tx rats an 
insignificant decrease was observed. In other studies TCDD treatment resulted in a significant 
decrease in liver Dl activity in rats (Visser et al., 1993a; Lans, 1995). Such a decrease in Dl 
activity has also been found after TCDD treatment of Tx and Tx+T3 rats (Eltom et al., 1992). 
A possible explanation for this discrepancy is the difference in dose and duration of TCDD 
exposure between the different studies. If it occurs, the decrease in hepatic Dl activity may be 
an indirect effect mediated by a TCDD-induced decrease in thyroid hormone bioactivity 
(Kaplan, 1986). In our study the lowest Dl activity was observed in TCDD-treated Tx rats 
which also had the lowest serum T3 levels. However, direct inhibition of Dl activity by TCDD-
like compounds in vitro has also been reported (Rickenbacher et al., 1989). 
In this study no statistically significant effects of TCDD were found on brain D2 
activity in Eu rats, although in Tx, Tx+T3, and Tx+T4 rats TCDD increased D2 activity to 122-
286% of controls. Increased brain D2 activity after treatment of rats with TCDD or PCB 
mixture has been demonstrated by Lans (1995) and Morse et al. (1996). This increase in brain 
D2 activity suggests a physiological response to decreased plasma T4 levels to maintain 
constant T3 levels in the brain (Silva and Matthews, 1984). A possible explanation for the 
relatively small TCDD-induced increases in brain D2 activity in the present study is the 
relatively small decrease in plasma T4 in comparison with the findings of Lans (1995), who 
used a higher dose of TCDD and a longer exposure time. 
Another important finding of the present study is the increased hepatic malic enzyme 
activity observed after TCDD treatment in all groups, except Tx rats. Kelling et al. (1987) and 
Roth et al. (1988) also reported on an increase in malic enzyme activity after treatment with 
TCDD, but also only in the presence of thyroid hormone. Thyroid hormone is, therefore, a 
permissive factor for the induction of malic enzyme by TCDD. Since malic enzyme is also 
controlled by the peroxisome proliferator-activated receptor (PPAR) (Castelein et al., 1994), 
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it appears therefore that malic enzyme expression is regulated by multiple nuclear receptors, 
including the T3 receptor, PPAR, and the Ah receptor. Both the Ah receptor and PPAR mediate 
the induction of different hepatic C YP isoenzymes by their ligands. The induction of malic 
enzyme by both receptor-ligand systems may serve the purpose of providing the necessary 
NADPH required for the induced CYP activities (Kelling et al, 1987). 
In conclusion, T4 or T3 was infused by osmotic minipumps into Tx rats restoring 
plasma T3 and T4 to near-euthyroid levels; this provided a model in which the peripheral 
effects of TCDD on thyroid hormone turnover can be investigated without confounding effects 
on thyroid function. TCDD induced greater decreases in plasma T4 levels in Tx+T4 rats than 
in Eu rats, indicating that these changes are caused by an extrathyroidal mechanism in which 
increased hepatic T4 glucuronidation by induction of phenol UGT activity plays an important 
role. 
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MODULATING EFFECTS OF THYROID STATE ON THE 
INDUCTION OF BIOTRANSFORMATION ENZYMES BY 2,3,7,8-
TETRACHLORODIBENZO-p-DIOXIN 
Abstract 
In this study we investigated to what extent the induction of detoxification enzymes by TCDD 
is modulated by concomitant TCDD-induced changes in thyroid state. Euthyroid (Eu) male 
Sprague-Dawley rats, surgically thyroidectomized (Tx) rats and Tx rats receiving substitution 
doses of 3,3',5-triiodothyronine (Tx+T3) or thyroxine (Tx+T4) by osmotic minipumps were 
treated with a single ip injection of 10 ug TCDD/kg body weight or with vehicle (corn oil). 
Three days after TCDD administration, rats were sacrificed, and blood and livers were collected 
for analysis. Total hepatic cytochrome P450 content was increased by =50% by TCDD in all 
groups but was not affected by thyroid state. In Eu rats, TCDD increased C YP1A1 /1A2 activity 
90-fold, CYP1A1 protein content 52-fold, and CYP1A1 mRNA levels =5.8-fold. Similar 
findings were obtained in Tx, Tx+T3 and Tx+T4 rats except that TCDD-induced CYP1 Al 
activity was significantly decreased in Tx rats. NADPH cytochrome P450 reductase activity 
was not affected by TCDD but was decreased in Tx rats, which may explain the diminished 
TCDD-induced CYP1 Al activity in Tx rats. Hepaticp-nitrophenol UGT activity was induced 
=4-fold by TCDD in Eu rats. Similar basal and TCDD-induced activities were observed in 
Tx+T3 and Tx+T4 rats, but TCDD-induced activities were significantly lower in Tx rats. 
TCDD did not have a significant effect on overall GST activity or hepatic GST 2-2, 3-3 or 4-4 
protein levels but produced a marked increase in GST 1-1 protein levels. Thyroid state did not 
affect basal or TCDD-induced GST activity or subunit pattern. Iodothyronine sulfotransferase 
activity was not affected by TCDD treatment and was slightly but not significantly lower in 
Tx rats than in Eu, Tx+T3, and Tx+T4 rats. These results suggest that the changes in thyroid 
hormone levels associated with TCDD treatment have little modulating effects on the induction 
of hepatic detoxification enzymes in Sprague-Dawley rats exposed to this compound. 
based on A.Gerlienke Schuur, Paul J. Tacken, TheoJ. Visser, and Abraham Bronwer (1998). 
Modulating effects of thyroid state on the induction of biotransformation enzymes by 2,3,7,8-
tetrachlorodibenzo-p-dioxin, ETAP 5, 7-16. 
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Introduction 
TCDD is the most toxic PHAH known and prototypical for the effects induced by this class 
of compounds. TCDD induces a variety of toxic responses in animals and humans, including 
chloracne, immunotoxicity, teratogenicity, liver lesions, and carcinogenicity (Poland and 
Knutson, 1982). A well-known biochemical effect of TCDD and related compounds is the 
induction of both phase I biotransformation enzymes, especially C YP1A isozymes (Safe, 1986), 
and phase II conjugation enzymes, such as UGTs (Owens, 1977) and GSTs (Kirsch et al, 
1975). 
It is also well known that PHAHs may alter thyroid hormone metabolism in rodents 
(for review, see Brouwer et al, 1998). A single dose of TCDD was found to strongly increase 
biliary excretion of T4 glucuronide in rats (Bastomsky, 1977). Other reports have also shown 
marked decreases in plasma T4 and free T4 levels and induction of hepatic T4 UGT activity 
after TCDD administration to rats (Visser et al, 1993a; Van Birgelen et al., 1995). 
Thyroid state may affect a variety of metabolic processes in most mammalian tissues, 
including the hepatic metabolism of drugs. Rumbaugh et al. (1978) reported on a dose-
dependent stimulation of hepatic mixed-function oxidases by thyroid hormones in rats. Skett 
and Weir (1982) demonstrated sex- and substrate-dependent effects of thyroidectomy and 
thyroid hormone replacement on drug metabolism. More recent studies suggest that thyroid 
hormone may act as a natural suppressor of the transcription of the CYP2B1, CYP2B2, 
CYP1A2 and CYP2A1 genes (Yamazoe et al, 1989; Murayama et al, 1991; Arlotto and 
Parkinson, 1989). In contrast, Eltom et al. (1992) found lower CYP1A activities in 
thyroidectomized (Tx) rats than in Tx rats treated with substitution doses of thyroid hormone. 
Moreover, thyroidectomy was found to partially protect rats against the lethal effects of 100 
ug TCDD/kg body wt per day in a 45-day exposure study (Rozman et al., 1984; 1985a). 
We have tested the hypothesis that the decrease in plasma T4 levels by PHAHs 
represents an adaptation mechanism, modulating the activities of biotransformation enzymes 
and, perhaps, protecting against the toxic effects induced by these compounds. This was done 
by studying the effects of TCDD in euthyroid (Eu) rats, Tx rats, Tx rats substituted with T4 
(Tx+T4) and Tx rats substituted with T3 (Tx+T3). Thyroid state parameters and thyroid 
hormone metabolism determined in this experimental model are reported elsewhere (Schuur 
et al, 1997; Chapter 2). Here, we describe the possible effects of thyroid state on basal and 
TCDD-induced expression of biotransformation enzymes in the liver, i.e. CYP1A1/1A2 
activity, p-nitrophenol (PNP) UGT activities, GST activity, and iodothyronine SULT activity. 
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Materials and methods 
Chemicals. 
TCDD, >99% pure, was obtained from Promochem (Wesel, Germany); T4, T3, uridine-
diphosphoglucuronic acid (UDPGA), 3'-phosphoadenosine-5'-phosphosulfate (PAPS), Brij 56, 
PNP, cytochrome c and bovine serum albumin (BSA) from Sigma Chemicals Co. (St. Louis, 
MO, USA); resorufin (RR) from Janssen Chimica (Tilburg, the Netherlands); BioRad protein 
reagent from BioRad Laboratories (Richmond, CA, USA); NADPH and glutathione (GSH) 
from Boehringer Mannheim GmbH (Mannheim, Germany); Trizol and sodium dodecyl sulfate 
(SDS) from Gibco BRL (Breda, the Netherlands); 3,3'-diiodothyronine (T2) and 3-
iodothyronine (Tl) from Henning Berlin GmbH (Berlin, Germany); and l-chloro-2,4-
dinitrobenzene (CDNB) from Aldrich Chemie (Bornem, Belgium). [125I]T2 was produced by 
radioiodination of Tl as described before (Visser et al, 1978). All other chemicals were of 
analytical grade. 
Animals and treatment. 
Male Sprague-Dawley rats, surgically thyroidectomized (Tx) or sham-operated by the supplier 
at 4 weeks of age, were purchased from Harlan/CPB (Zeist, the Netherlands). The rats were 
obtained at 6 weeks of age and allowed to acclimatize for 2 weeks before the experiment. They 
were maintained at 50% humidity and 21 °C on bedding in plastic cages with a 12-h light/12-h 
dark cycle. Rat chow (Hope Farms, Woerden, the Netherlands) and tap water with 0.5% CaCl2 
were supplied ad libitum. Model 2002 Alzet minipumps (Charles River Wiga, Sulzfeld, 
Germany), delivering 1 u.g T4/100 g body wt per day (Tx+T4 rats, n=15) or 0.4 u.g T3/100 g 
body wt per day (Tx+T3 rats, n=15) in 0.1 M NaOH in 0.9% saline, were implanted ip at day 
0 under ether anaesthesia. Five sham-operated rats, 15 non-operated Eu rats, and 15 Tx rats 
received pumps with solvent only. Water and food consumption were recorded daily, and body 
weight was recorded twice a week. On day 7, following osmotic minipump implantation, 5 rats 
of each group (Eu, Tx, Tx+T3 and Tx+T4) were given an ip injection of 10 u.g TCDD/ kg body 
wt in corn oil (5 ml/ kg). Of each group, 5 control and 5 pair-fed control rats were given an ip 
injection with corn oil only. On the day before pump implantation (day -1), day 3, day 7 and 
day 10, blood (~ 1 ml) was collected by orbital puncture in heparinized tubes and stored on ice 
until separation of plasma. On day 10 all rats were sacrificed under ether anaesthesia. Livers 
were perfused with saline, dissected, weighed and frozen in three portions. Tissue was stored 
at -80 °C until analysis. All procedures were approved by the Animal Welfare Committee of 
the Agricultural University Wageningen. 
Tissue preparation 
Livers were homogenized on ice in three volumes ice-cold 0.1 M Tris-HCl buffer, pH 7.5, 
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containing 0.25 M sucrose, using a Potter tube and the homogenate was centrifuged for 30 min 
at 9,000xg and 0-4 °C. The resulting supernatant was centrifuged for 90 min at 105,000xg and 
0-4 °C, and the microsomal pellet was resuspended in ice-cold 0.1 M phosphate buffer, pH 
7.5. Microsomes and cytosol were stored in aliquots at -80 °C until further analysis. Protein 
levels of tissue fractions were determined using BioRad Protein reagent (Bradford, 1976) and 
BSA as a standard. Another part of the liver was used for RNA-isolation using Trizol reagent 
according to the suppliers protocol. 
Enzyme assays 
Total cytochrome P450. Cytochrome P450 content in liver microsomes was estimated from 
the carbon monoxide-reduced difference spectrum in 0.1 M potassium phosphate (pH 7.4) 
containing 1 mg/ml hepatic microsomal protein (Omura and Sato, 1964). 
NADPH cytochrome c reductase. The reduction of cytochrome c was followed spectrophoto-
metrically at 550 nm for 1 min at room temperature. The incubation mixture contained 40 uM 
cytochrome c, 100 uM NADPH and 12.5 ug/ml microsomes in 0.3 M phosphate buffer (pH 
7.7). Results were calculated using an extinction coefficient of 21 mM"'*cm"' (Vermilion and 
Coon, 1978). 
Ethoxyresorufin O-deethylase. EROD activity was measured according to the method of Burke 
et al. (1977) adapted for use with 96 wells plates and a fluorospectrophotometric plate reader 
(Cytofluor 2350, Millipore, Etten-Leur, the Netherlands). Reaction mixtures contained 0.4 uM 
7-ethoxyresorufin (ER), 0.1 mM NADPH, 1 mg/ml BSA and 2.5-100 ug/ml microsomal protein 
in 200 ul 0.1 M Tris-HCl, pH 7.8. After preincubation for 2 min at 37CC, reactions were started 
by the addition of NADPH and after 5 min at 37°C they were stopped by adding 50 ul 1 M 
NaOH. The formation of the product resorufin (RR) was detected fluorimetrically (excitation 
530 nm, emission 590 nm) and compared with a calibration curve obtained using 0-150 nM 
RR in 0.08 M Tris-HCl, 0.8 mg BSA/ml and 0.8 M NaOH. Incubations were carried out in 
duplicate, and results were corrected for blanks without NADPH. 
CYPI Al protein levels. A cytochrome P450 LAI ELISA system from Amersham (Amersham, 
UK) was used to determine CYP1 Al protein levels. The kit was used exactly according to the 
protocol of the supplier. 
CYP1A1 mRNA analysis. Mouse P450 1 Al (ATCC-no. 63006) and human GAPDH (ATCC-no. 
57234) cDNA probes were obtained from ATCC (Rockville, MD). Serial dilutions of total 
RNA (0.176-22.5 ug) were dot-blotted using a mini-blot apparatus (Minifold, Schleicher and 
Schuell, Den Bosch, the Netherlands) on Hybond-N+ nitrocellulose membrane (Amersham, 
UK). Hybridization was carried out at 65 °C in 0.5 M sodium phosphate (pH 7.2), 7% SDS and 
1 mM EDTA using random-primed 32P-labelled probes. Membranes were washed at 65°C 
successively with 2x SSC/0.1% SDS, lxSSC/0.1% SDS and 0.3xSSC/0.1% SDS (lx SSC= 
150 mM NaCl, 15 mM sodium citrate, pH 7.0). MRNA signals were quantified using a 
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Phosphor Imager (Molecular Dynamics, Sunnyvale, CA), and CYP1A1 mRNA was 
standardized relative to GAPDH mRNA. 
PNP UDP-glucuronyltransferase. PNP UGT activity was measured by incubation of 1 mM 
PNP for 15 min at 37°C with 0.25 mg microsomal protein/ml, 5 mM UDPGA in 100 mM Tris-
HC1 (pH 7.4), 5 mM MgCl2 and 0.005% Brij 56 (Bock et al., 1973; Beetstra et al, 1991). 
Glutathione S-transferase. GST activity was measured according to Habig et al. (1974) adapted 
for use with 96 wells plates and a spectrophotometric plate reader (Thermo Max Microplate 
Reader, Molecular Devices Corp, Menlo Park, CA) as described by Van Iersel et al. (1996). 
Reaction mixtures contained 1 mM GSH, 1 mM CDNB and 1 mg cytosolic protein/ml in 250 
ul 0.1 M potassium phosphate buffer (pH 6.5) and 2 mM EDTA. After preincubation for 2 min 
at 25 CC, the reaction was started by the addition of CDNB, and conjugate formation was 
followed for 1 min at 25 °C at 340 nm. Separation and quantitation of GST subunits were done 
as described by Bogaards et al. (1989). 
lodothyronine sulfotransferase. SULT activity was determined by incubation of 1 uM T2 and 
= 80,000 cpm [l25I]T2 for 30 min at 37°C with 50 uM PAPS and 25 ug rat liver cytosol 
protein/ml in 200 ul 75 mM phosphate (pH 7.2) and 1.5 mM EDTA (Visser et al., 1996a). The 
reaction was stopped on ice by adding 750 ul 0.1 M HC1, and T2 sulfate formation was 
determined by Sephadex LH-20 chromatography (Rutgers et al., 1989). 
Statistics. 
Data are presented as means ± SEM. Treatment-related effects were first evaluated with a one-
way analysis of variance followed by a least significant difference test (p<0.05) to find 
significant differences between the treatment groups. The statistical software package 
SPSS/PC+™ (SPSS Inc, Chicago) was used. 
Results 
Since the various parameters determined did not differ between the pair-fed and ad libitum fed 
groups, only the data of the TCDD-treated rats and the pair-fed controls given corn oil alone 
are presented. The effects of thyroidectomy and thyroid hormone replacement on plasma 
thyroid parameters (T4, T3 and TSH), and tissue thyroid state parameters (hepatic type I 
deiodinase and malic enzyme activities and brain type II deiodinase activity) are presented 
elsewhere (Schuur et al, 1997; Chapter 2). TCDD had no effect on body weight and food and 
water intake (Schuur et al, 1997; Chapter 2). 
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Figure 3.1 Effects of 
TCDD treatment on hepatic 
cytochrome P450 content 
(A) and NADPH 
cytochrome c reductase 
activity (B) in Eu, Tx, 
Tx+T3, and Tx+T4 rats. 
Results are presented as 
means ± SEM of 5 rats. *) 
Significantly different 
(p<0.05) from Eu rats. #) 
Significantly different 
(p<0.05) from corn oil-
treated rats. 
Cytochrome P450 
The effects of TCDD and thyroid state on total hepatic CYP450 content are shown in Figure 
3.1 A. TCDD exposure significantly increased the amount of CYP450 by 30-110% in the 
different groups. No significant effects of thyroidectomy and thyroid hormone replacement were 
observed on basal as well as TCDD-induced CYP450 levels. 
The NADPH cytochrome P450 reductase activity (Figure 3.IB) was measured using 
cytochrome c as an electron acceptor. Thyroidectomy significantly decreased the cytochrome 
c reductase activity by almost 50% but replacement with T3 or T4 did not restore this activity 
back to Eu control levels. TCDD exposure did not affect cytochrome c reductase activity in 
the different groups, although an insignificant increase was observed in Tx+T3 rats. 
Cytochrome P4501A1 
Basal CYP1A1/1A2 activity, measured in the EROD assay, was not significantly different 
between Eu, Tx, Tx+T3 and Tx+T4 rats (Figure 3.2A). TCDD induced EROD activity 65- to 
160-fold in the different groups. TCDD-induced EROD activity was similar in Eu, Tx+T3 and 
Tx+T4 rats but significantly lower in Tx rats. 
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rats. Results are presented 
as means ± SEM of 5 rats. 
*) Significantly different 
(p<0.05) from Eu rats. #) 
Significantly different 
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CYP1A1 protein levels were measured by a specific ELISA (Figure 3.2B). No significant 
effects of thyroidectomy or thyroid hormone replacement were found on basal levels. TCDD 
caused a 31- to 52-fold induction of CYP1A1 protein levels in the different groups. TCDD-
induced CYP1 Al protein levels were not significantly affected by thyroid state. 
CYP1A1 mRNA levels were also measured in this study (Figure 3.2C). TCDD 
treatment resulted in a 4.4- to 7.3-fold increase in CYP1A1 mRNA levels in the different 
groups. Neither thyroidectomy nor thyroid hormone replacement significantly affected basal 
or TCDD-induced CYP1 Al mRNA levels. 
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Figure 3.3 Effects of 
TCDD treatment on hepatic 
PNP UGT activity in Eu, 
Tx, Tx+T3 or Tx+T4 rats. 
Results are presented as 
means ± SEM of 5 rats. *) 
Significantly different 
(p<0.05) from Eu rats. #) 
Significantly different 
(p<0.05) from corn oil-
treated rats. 
UDP-glucuronyltransferase activities 
Hepatic UGT activities were measured using PNP as a substrate (Figure 3.3). PNP is a model 
substrate for one of the two UGT isoenzymes which also catalyze glucuronidation of T4 
(Schuur et ai, 1997; Chapter 2). PNP UGT activity was induced 3.7- to 4.6-fold by TCDD 
treatment in the different groups. TCDD-induced, but not basal, PNP UGT activity was 
significantly lower in Tx rats than Eu rats. There was no significant difference in basal or 
TCDD-induced PNP UGT activities between Eu, Tx+T3 and Tx+T4 rats. 
Glutathione S-transferase 
GST activity was measured using CDNB as a substrate (Figure 3.4A). Thyroidectomy, thyroid 
hormone replacement, and TCDD treatment were all without significant effects on GST 
activity, although there was a slight increase in GST activity after TCDD treatment in Tx, 
Tx+T3 and Tx+T4 rats. TCDD induced a marked increase in GST protein subunit 1-1 levels 
in all groups, although the difference was not significant in Tx+T4 rats (Figure 3.4B-E). TCDD 
did not produce significant changes in the amount of GST protein subunits 2-2, 3-3 or 4-4 in 
the different groups. Thyroidectomy and thyroid hormone replacement were not associated with 
significant differences in basal or TCDD-induced GST protein subunit levels. 
lodothyronine sulfotransferase 
Thyroid state had no significant effect on iodothyronine ST activity, although a small, 
insignificant decrease was observed in Tx rats (Figure 3.5). TCDD treatment did not affect 
iodothyronine ST activity in any group. 
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A. 
Figure 3.4 Effects of 
TCDD treatment on hepatic 
GST activity (A) and GST 
protein subunit levels (B-E) 
in Eu, Tx, Tx+T3 or Tx+T4 
rats. GST subunit levels are 
expressed as percentage of 
that the corn oil-treated Eu 
rats. Results are presented 
as means ± SEM of 5 rats. 
#) Significantly different 
(p<0.05) from corn oil-
treated rats. 
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Figure 3.5 Effects of 
TCDD treatment on hepatic 
T2 ST activity in Eu, Tx, 
Tx+T3 or Tx+T4 rats. T2 
ST activity is expressed as 
percentage of that in the 
corn oil-treated Eu rats. 
Results are presented as 
means ± SEM of 5 rats. 
Discussion 
In this study, we tested the hypothesis that the induction of biotransformation enzymes by 
PHAHs is modulated by concomitant changes in plasma thyroid hormone levels. This 
hypothesis is based on the observations that many PHAHs interfere with .the metabolism of 
thyroid hormone, usually resulting in strongly reduced plasma T4 levels, and that thyroid 
hormone affects many metabolic pathways, including the activities of biotransformation 
enzymes. The hypothesis was tested by comparing the effects of TCDD on different hepatic 
phase I and phase II biotransformation enzymes in Eu rats, in Tx rats, and in Tx rats infused 
with replacement doses of T4 or T3. The plasma thyroid hormone levels and tissue 
iodothyronine deiodinase activities in these animals are described elsewhere (Schuur et al., 
1997; Chapter 2), showing that the hypothyroid state of the Tx rats is normalized by 
substitution with T4 or T3. 
The major conclusion of the present study is that there is little influence of thyroid state 
on induction of biotransformation enzymes by TCDD in male Sprague-Dawley rats. This 
applies to total cytochrome P450 levels, CYP1A1 protein levels and expression, GST activity 
and protein levels as well as iodothyronine ST activity. The only indications for a significant 
interaction between thyroid state and TCDD treatment were the decreased TCDD-induced PNP 
UGT and CYP1A1 activities in Tx rats as compared to Eu control rats. In addition, basal 
NADPH cytochrome c reductase activity and, although not significantly, basal iodothyronine 
ST activity were somewhat reduced in Tx rats. 
The finding that basal and TCDD-induced total hepatic cytochrome P450 content were 
not affected in Tx rats is in agreement with other studies (Rozman et al, 1985b; Henry and 
Gasiewicz, 1986; Eltom et al., 1992). However, other reports have shown an increase in basal 
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P450 levels after thyroidectomy and a decrease after treatment with T3 or T4 (Rumbaugh et 
al, 1978; Leakey etal, 1982; Muller etal, 1983a;Goudonnetefa/., 1990). The discrepancies 
between these findings may be related to possible differences in severity and duration of the 
hypo- and hyperthyroid states of the animals investigated. 
NADPH cytochrome c reductase activity is a measure for the NADPH cytochrome P450 
reductase activity (Ram and Waxman, 1992). The lower reductase activities we found in Tx 
versus Eu rats are in agreement with earlier reports that hypophysectomy and methimazole-
induced hypothyroidism result in decreased NADPH cytochrome P450 reductase activities and 
protein levels in rats (Kato and Takahashi, 1968; Waxman et al, 1989; Ram and Waxman, 
1992). Surprisingly, the decreased reductase activity in Tx rats was not restored by T3 or T4 
substitution, perhaps because this requires longer periods of replacement. 
TCDD was found to induce CYP1 Al activity in all rats. However, in Tx rats the degree 
of induction was significantly (=30%) lower than in Eu rats, which was reversed by substitution 
of Tx rats with either T3 or T4. This suggests a permissive effect of thyroid hormone on TCDD-
induced CYP1 Al activity, in agreement with earlier reports (Eltom et al, 1992; Henry and 
Gasiewicz, 1986). However, although hyperthyroidism may lead to increased basal CYP1 Al 
activities (Muller et al, 1983a), it has also been reported to impair TCDD induction of this 
isoenzyme (Eltom et al, 1992). In contrast, Rozman et al. (1985b) found no effect of 
thyroidectomy on induction of EROD by a lethal TCDD dose (100 ug/kg). Roth et al. (1988) 
showed that the effects of thyroidectomy on the induction of EROD activity indeed depends 
on the TCDD dose; low doses of TCDD produced smaller effects in Tx than in normal rats, 
and the opposite was found at higher TCDD doses. However, at the TCDD dose used in our 
experiment (10 |xg/kg) they found a higher EROD induction in Tx than in control rats. This 
discrepancy may be explained by differences in duration of TCDD exposure. 
The decreased TCDD-induced CYP1 Al/1 A2 activity we found in Tx versus Eu rats 
was not associated with decreased C YP1A1 protein or mRNA levels, suggesting that this effect 
was not exerted at the level of CYP1A1 gene expression. A possible explanation for the 
diminished TCDD-induced CYP1A1/1A2 activity in Tx rats is the decreased NADPH 
cytochrome P450 reductase activity that was observed in these animals. This is supported by 
the study of Waxman et al. (1989) who reported that cytochrome P450-catalyzed 
hydroxylations are stimulated by supplementation of microsomal incubations with NADPH 
cytochrome P450 reductase, suggesting that the latter is rate-limiting. 
The possible modulation by thyroid state of the induction of UGT isoenzymes by TCDD 
was studied using PNP as a substrate for one of the UGTs involved in the glucuronidation of 
T4 (Visser etal, 1993a; 1996b). PNP UGT activity was strongly induced by TCDD treatment 
in agreement with previous studies using TCDD and related compounds (Beetstra et al, 1991; 
Saito et al, 1991; Visser et al., 1993a; Van Birgelen et al, 1995). We found that thyroidectomy 
suppressed TCDD-induced PNP UGT activity, which was restored by substitution of Tx rats 
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with T3 or T4. These findings are in agreement with previous studies showing that basal and 
TCDD-induced phenol UGT activities are decreased in Tx rats and increased in T3-treated rats 
(Graham and Skett, 1987; Pennington et al, 1988; Moscioni and Gartner, 1983; Chowdhury 
et al., 1983; Goudonnet et al, 1990; Masmoudi et al, 1996). Therefore, PNP UGT activity 
appears to be positively regulated by thyroid hormone. 
TCDD treatment induced a small increase in GST activity and a marked increase in GST 
subunit 1 -1 levels in agreement with findings reported by others (Pimental et al., 1993). Neither 
basal nor TCDD-induced GST activity and subunit levels were affected by thyroid hormone 
state in our study. Williams et al. (1986) reported on an increase in GST activity with CDNB 
or DCNB as substrate and a decrease with l,2-epoxy-3-(p-nitrophenoxy)propane as substrate 
in mice made hypothyroid by treatment with propylthiouracil. These effects were reversed by 
treatment of the hypothyroid mice with T3. Beckett et al. (1988) found a decrease in GST 
activity with CDNB as substrate after treatment of rats with T3 or T4 for 4 weeks, which was 
associated with decreases in GST subunit 1-1,2-2 and 3-3 levels. 
In the present study, hepatic iodothyronine ST activity was assayed utilizing T2 as the 
preferred substrate (Visser et al, 1996a). We observed a decrease in iodothyronine ST activity 
in Tx versus Eu rats, which was restored by infusion of replacement doses of T4 or T3. These 
findings are in agreement with the decrease in hepatic T3 ST activity in Tx rats and its reversal 
by T3 substitution reported before by Gong et al. (1992). TCDD treatment had no effect on 
T2 ST activity. It has previously been reported that treatment of rats with 3-methylcholanthrene 
results in a decreased hepatic expression of hydroxysteroid ST (Runge-Morris and Wilusz, 
1994), but it is unlikely that this isoenzyme is involved in the sulfation of iodothyronines. 
In conclusion, we found little support for the hypothesis that the induction of 
biotransformation enzymes by TCDD is modulated by the marked changes in thyroid hormone 
levels that are associated with TCDD treatment. The variable responses of the basal and TCDD-
induced activities of these enzymes to changes in thyroid state observed in our study and those 
published by others may be due to differences in strain and sex of the animals, the severity and 
duration of the hypo- and hyperthyroid states induced as well as the duration and dose of TCDD 
treatment. 
The most obvious indications for an interaction between thyroid state and TCDD 
treatment were the decreased TCDD-induced CYP1 Al/1 A2 and PNP UGT activities in Tx rats. 
It remains unknown, however, if the marked decrease in plasma T4 level associated with TCDD 
treatment is a limiting factor in the induction of these biotransformation enzymes. In this 
respect it should be realized that the plasma level of the bioactive hormone T3 shows a much 
smaller decrease in response to TCDD treatment than the plasma level of the prohormone T4. 
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CHAPTER 4 
EFFECT OF THYROID STATE ON POLYCHLOROBIPHENYL-
INDUCED CYTOCHROME P450 1A AND 2B ISOZYME 
EXPRESSION 
Abstract 
Earlier reports have suggested a potential modulating effect of thyroid state on cytochrome 
P450 expression. PCBs induce a decrease in plasma T4 and are potent inducers of CYP1A and 
2B isozymes. In this study we investigated the potential interaction between thyroid hormone 
and PCBs in the regulation of CYP1A1 and CYP2B expression. Hypothyroid (surgically 
thyroidectomized, Tx) male Sprague-Dawley rats, euthyroid (Eu) rats, and rats made 
hyperthyroid by infusing 10 ug T3/100 g BW/day (Eu+T3) were treated with a single ip 
injection of 75 mg 2,2',4,4',5,5'-hexachlorobiphenyl (PCB 153)/kg BW, 100 ug 3,3',4,4',5-
pentachlorobiphenyl (PCB 126)/kg BW or with vehicle (corn oil). Four days after PCB 
administration, rats were sacrificed, and blood and livers were collected for analysis. 
The thyroid state of the rats was confirmed by measurement of plasma T4, T3 and TSH 
and of functional parameters such as hepatic type I deiodinase activity, malic enzyme activity 
and a-glycerolphosphate dehydrogenase activity. Total hepatic cytochrome P450 content was 
increased by about 50% by PCB treatment in all groups, but was not affected by thyroid state. 
NADPH cytochrome P450 reductase activity was decreased in Tx rats and increased in Eu+T3 
rats, while PCB treatment had no effect. PCB 126 specifically induced T4 UGT activity, 
measured in the absence of detergent, and CYP1A activity, protein and mRNA levels, whereas 
PCB 153 induced T4 UGT activity, measured in the presence of the detergent Brij 56, and 
CYP2B activity, protein and mRNA levels. Thyroid state did not significantly affect T4 UGT 
activity or CYP1A and CYP2B activities, protein or mRNA levels. 
In conclusion, hepatic NADPH cytochrome P450 reductase activity is dependent on 
thyroid state, whereas both total cytochrome P450 as well as CYP1 Al and CYP2B are not or 
only marginally affected. The results from this study are different from earlier reports 
suggesting a modulating effect of thyroid state on CYP1A and CYP2B. In our hands, the PCB-
induced decrease in T4 was not enough to create an effect on the activity of the 
biotransformation enzymes tested. 
basedonA.GerlienkeSchuur, MarylseC. Vis, MiraA.M. Wenker, Abraham Brouwer, andTheo 
J. Visser (1998). Effects of thyroid state on polychlorobiphenyl-induced induction of 
cytochrome P450 IA and 2B isozyme expression, submitted. 
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Introduction 
PCBs and PCDDs are potent inducers of biotransformation enzymes in the liver. PCB 
congeners can be divided into three distinct groups, based on their induction of specific 
isozymes of the cytochrome P450 system. The first group consists of the non-ortho coplanar 
PCBs which induce CYP1 Al/2, i.e. a 3MC- or dioxin-type of induction. Secondly, the di-ortho 
substituted PCBs which, like PB, induce CYP2B1/2. The final group consists of the mono-ortho 
coplanar PCBs which induce both CYP1A and CYP2B isozymes (Safe, 1994). 
PCBs and PCDDs are also potent thyroid state-modulating environmental toxicants (for 
review see Brouwer et al, 1998). PCDDs and PCBs cause a decrease in plasma total and free 
T4 levels in rats, mice and marmoset monkeys (for TCDD:Bastomsky, 1977; Potter et al., 1983; 
1986;PazdernikandRozman, 1985; Henry and Gasiewicz, 1986; 1987; Joneses/., 1987;Roth 
etal, 1988; Pohjanvirtae/a/., 1989; Lans, 1995; for Aroclor: Bastomsky, 1974; Byrne etal, 
1987; Gray et al, 1993; Brouwer, 1989; Beetstra et al., 1991). This decrease in plasma T4 
levels is accomplished by at least three different mechanisms. Firstly, PCBs and PCDDs induce 
hepatic UGT towards T4 which results in an increased excretion of T4 glucuronide (Bastomsky, 
1974; Beetstra, 1991). Secondly, PCBs and PCDDs directly inhibit thyroid hormone secretion 
(Gupta et al, 1973; Rozman et al, 1986; Collins and Capen, 1980b; Sepkovic and Byrne, 
1984). Thirdly, T4 binding to plasma transthyretin (TTR) is competitively inhibited by 
hydroxylated metabolites of different PCDDs and PCBs (Brouwer and van den Berg, 1986; 
Lans etal, 1993; 1994). 
However, it is still unclear whether this decrease in plasma thyroid hormone levels after 
treatment with PCBs and PCDDs should be considered as a toxicological effect, or an adaptive 
response of the animal to a toxic stressor. It has been reported that thyroidectomy has a partially 
protective effect on TCDD-induced toxicity (Pazdernik and Rozman, 1985; Rozman et al, 
1984). Alteration of thyroid hormone levels may also have a modulating effect on the induction 
of biotransformation enzymes. Eltom et al. (1992) found a suppressive effect of Tx on TCDD-
induced CYP1 Al activity, measured as EROD activity, in rat liver. However, Rozman et al. 
(1985b) found no effect of Tx on EROD activity after TCDD treatment. We have previously 
also investigated the hypothesis that thyroid hormones modulate the induction of 
biotransformation enzymes (Schuur et al, 1997; 1998a; Chapter 2 and 3). We found that 
induction of EROD activity by TCDD was slightly decreased in Tx vs normal rats. Yet, no 
effect of Tx was found on CYP1A1 protein or mRNA levels. 
This lack of a clear effect of thyroid hormones on CYP1A1 activity differs from other 
reports on the endocrine regulation of different cytochrome P450 isozymes. Arlotto and 
Parkinson (1989) found a suppressive effect of thyroid hormones on hepatic CYP2A1 mRNA 
and protein levels. Murayama et al. (1991) also found lower levels of hepatic CYP2B1/2 
mRNA and protein in hyperthyroid rats. Ram and Waxman (1991) established that thyroid 
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hormones can differentially regulate the expression of three male-specific, growth hormone-
regulated hepatic P450s. C YP3 A2 was shown to be under negative control of T4 and C YP2C11 
under positive control, while CYP2A2 was not appreciably affected by thyroid state. 
Here we report on further studies of the interaction between thyroid hormone and PCBs 
in the regulation of CYP1A1 and CYP2B expression. 2,2',4,4',5,5'-Hexachlorobiphenyl (PCB 
153) was chosen as a CYP2B inducer and 3,3',4,4',5-pentachlorobiphenyl (PCB 126) as a 
CYP1 Al inducer. The experiment involved both Tx rats and rats made hyperthyroid by T3 
infusion using osmotic minipumps. The thyroid state of the rats was confirmed by measurement 
of plasma T4, T3, and TSH levels and of functional parameters such as type I deiodinase (Dl) 
activity, a-glycerolphosphate dehydrogenase (a-GPD) activity and malic enzyme activity in 
liver. 
Materials and methods 
Chemicals. 
PCB 153 and PCB 126 were obtained from Schmidt BV (Amsterdam, The Netherlands); T4, 
T3, rT3, DTT, UDPGA, Brij 56, PTU, 2-iodophenyl-3-nitrophenyl-5-phenyltetrazolium 
chloride (INT) and BSA from Sigma Chemicals Co. (St. Louis, MO, USA); malic acid and 
resorufin (RR) from Janssen Chimica (Tilburg, The Netherlands); NADPH from Boehringer 
Mannheim GmbH (Mannheim, Germany); Trizol and sodium dodecyl sulfate (SDS) from 
Gibco BRL (Breda, The Netherlands) and BioRad protein reagent from Bio-Rad Laboratories 
(Richmond, CA, USA). [125I]T4, [125I]T3 and [,25I]rT3 were obtained from Amersham 
(Buckinghamshire, UK); they were purified on Sephadex LH-20 (Pharmacia, Woerden, The 
Netherlands) before each assay. All other chemicals were of analytical grade. 
Animals and treatment. 
Male Sprague-Dawley rats, surgically thyroidectomized or sham-operated by the supplier at 
4 weeks of age, were purchased from Iffa Credo (L'Arbresle Cedex, France). The rats were 
obtained at 6 weeks of age; they were allowed to acclimatize for 2 weeks and were maintained 
at 50% humidity and 21°C on bedding in plastic cages with a 12 h light-12 h dark cycle. Rat 
chow (Hope Farms, Woerden, The Netherlands) and tap water with 0.5% CaCl2 were supplied 
ad libitum. Model 2002 Alzet minipumps (Charles River Wiga, Sulzfeld, Germany) were 
implanted intraperitoneally (ip) in sham-operated, euthyroid (Eu) rats at 8 weeks of age (day 
0) under ether anaesthesia, delivering 10 ug T3/100 g BW per day in 0.1 N NaOH in 0.9% NaCl 
(Eu+T3 group; n=15). All 15 Tx and 15 other Eu rats received pumps with solvent only. Body 
weight was recorded twice a week. On day 6 following osmotic minipump implantation, 5 rats 
of each group (Tx, Eu and Eu+T3) were given an ip injection of 100 ug PCB 126 or 75 mg PCB 
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153 in corn oil/kg BW or with corn oil alone (controls; 5 ml/kg BW). 
On the day before the PCB injection (day 5) and on day 10, blood (= 1 ml) was collected 
by orbital puncture in heparinized tubes and stored on ice until plasma was prepared by 
centrifiigation. All rats were sacrificed under ether anaesthesia on day 10. Livers were perfused 
with saline, isolated, weighed and frozen in 3 portions on dry ice. Kidneys, thymus and brains 
were isolated, weighed and frozen on dry ice. All tissues were stored at -80°C and plasma at 
-20 °C until analysis. All procedures were approved by the Animal Welfare Committee of the 
Agricultural University Wageningen. 
Tissue preparation. 
Livers and brains were homogenized and centrifuged as described before (Schuur et al, 1997; 
1998a; Chapter 2 and 3). Mitochondria, cytosol and microsomes were prepared by differential 
centrifugation and stored at -80°C. Protein levels of tissue fractions were determined using the 
Bio-Rad protein reagent (Bradford, 1976) and BSA as a standard. Another part of the liver was 
used for RNA isolation using Trizol reagent according to the suppliers protocol. 
Thyroid hormone analysis. 
Plasma TT4, FT4 and TT3 were analysed in duplicate using the Amerlite chemiluminescence 
kits (Amersham, Little Chalfont, UK) according to the protocol of the supplier with the 
following modifications: the TT4 and TT3 assay buffers were diluted five times with 
demineralized water; the standard curve for TT4 ranged from 0 to 120 nmol/1. TSH was 
determined by PJA with the materials and protocols of the National Institute of Diabetes and 
Digestive and Kidney Diseases (NIDDK), using TSH RP-2 as a standard. 
Enzyme assays. 
Type I iodothyronine deiodinase (Dl). Hepatic Dl activity was determined as previously 
described (Mol and Visser, 1985). Shortly, microsomes (20 ug protein/ml) were incubated for 
30 min at 37°C with 1 uM rT3 and =100,000 cpm [,25I]rT3 in 0.1 M phosphate buffer, pH 7.2, 
2 mM EDTA and 5 mM DTT. The reaction was stopped on ice by the addition of 750 ul 0.1 
M HC1. The reaction mixtures were centrifuged and radioiodide was analyzed in the supernatant 
by Sephadex LH-20 chromatography as described before (Rutgers et al, 1989). 
UDP-glucuronyltransferase (UGTs). Hepatic T4 UGT activity was determined essentially 
according to Beetstra et al. (1991). Microsomes (1 mg/ml) were incubated for 30 min at 37°C 
with 1 uM T4 (50,000 cpm [125I]T4), 3.75 mM MgCl2,0.1 mM PTU in the presence or absence 
(blank) of 5 mM UDPGA in 200 ul 75 mM Tris-HCl, pH 7.8 (Rutgers et al, 1989). Reactions 
were stopped by the addition of 0.2 ml ice-cold methanol. After centrifugation, 0.2 ml 
supernatant was mixed with 0.75 ml 0.1 M HC1 and analyzed for glucuronide formation by 
chromatography on Sephadex LH-20 minicolumns (Beetstra et al, 1991). T4 UGT was 
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determined in the absence and in the presence of the detergent 0.05% Brij 56 (Visser et al, 
1993b). 
Malic enzyme. Malic enzyme activity in liver cytosol was determined according to Hsu and 
Lardy (1967) by following the formation of NADPH spectrophotometrically for 10 min. at 340 
nm using a 96-wells plate spectrophotometer (Thermo Max Microplate Reader, Molecular 
Devices, Menlo Park, CA, USA). Incubation mixtures contained 16 mM MnCl2, 1.13 mM 
NADP, 0.1 mM malic acid, 0.33 mg cytosolic protein/ml in 0.13 M triethanolamine buffer (pH 
7.4). 
a-Glycerolphosphate dehydrogenase. ocGPD activity in liver mitochondria was measured 
according to Garrib and McMurray (1984) with a continuous spectrophotometrical method 
monitoring the reduction of INT. The incubation mixture contained 0.25 mM INT, 0.8 mM 
potassium cyanide, 30 ul of a saturated menadione solution in 0.2% BSA, 24 mM L,D-glycerol 
phosphate and 0.2-1 mg protein/ml of mitochondrial pellet in a total volume of 250 ul in 0.25 
M potassium phosphate buffer (pH 7.5). The absorption of INT at 490 nm was measured every 
10 sec for 10 min. An extinction coefficient of 11.5 nM"'*cm"' was used. 
Total cytochrome P450. Cytochrome P450 content in liver microsomes was estimated from 
the CO-reduced difference spectrum in 0.1 M potassium phosphate (pH 7.4) containing 1 mg 
microsomal protein/ml (Omura and Sato, 1964). 
NADPH cytochrome c reductase. The reduction of cytochrome c was followed 
spectrophotometrically at 550 nm for 1 min at room temperature. The incubation mixture 
contained 40 uM cytochrome c, 100 uM NADPH and 12.5 ug microsomal protein/ml in 0.3 
M phosphate buffer (pH 7.7). Results were calculated using an extinction coefficient of 21 mM" 
'•cm'1 (Vermilion and Coon, 1978). 
Ethoxyresorufin andpentoxyresorufin O-deethylase. EROD was measured according to the 
method of Burke et al. (1977) adapted for use with 96 wells plates and a 
fluorospectrophotometric plate reader (Cytofluor 2350, Millipore, Etten-Leur, The Netherlands) 
(Schuur et al., 1998a; Chapter 3). PROD was measured following the same procedure as for 
EROD with a final concentration of 2 uM pentoxyresorufin (PR) and 25-100 |ig microsomal 
protein/ml. 
CYP1A1 and CYP2B protein levels. Cytochrome P4501A1 and 2B1/2 ELISA systems from 
Amersham were used to determine CYP1A1 or 2B1/2 protein levels according to the protocol 
of the supplier. 
CYP1A1 or CYP2B mRNA analysis. Mouse CYP1 Al (ATCC-no. 63006) and human GAPDH 
(ATCC-no. 57234) cDNA probes were obtained from ATCC (Rockville,MD, USA). Rat 
CYP2B cDNA probe was a generous gift from Dr. M. Adesnik (Kumar et al., 1983). Serial 
dilutions of total RNA (0.176-22.5 ug) were dot-blotted using a mini-blot apparatus (Minifold, 
Schleicher and Schuell, Den Bosch, The Netherlands) on Hybond-N+ nitrocellulose membrane 
(Amersham). Hybridization was carried out overnight at 65 °C in 0.5 M sodium phosphate (pH 
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7.2), 7% SDS and 1 mM EDTA using random-primed 32P-labelled probes. Membranes were 
washed for 30 min at 65°C with successively 2xSSC/0.1% SDS, lxSSC/0.1% SDS and 
0.3xSSC/0.1% SDS (lxSSC = 150 mM NaCl, 15 mM sodium citrate, pH 7.0). Messenger RNA 
signals were quantified using a Phosphor Imager (Molecular Dynamics, Sunnyvale, CA), and 
CYP1 Al or CYP2B mRNA was standardized relative to GAPDH mRNA. 
Statistics. 
The data were first tested on normality and homogeneity of variances with respectively the Chi-
square test and the Bartlett test. The data were log-transformed to obtain normality and 
homogeneity. The log-transformed data were evaluated with a 2-way ANOVA with the thyroid 
state (Tx, Eu and Eu+T3) and the PCB treatment (vehicle and 75 mg PCB 153/kg BW or 
vehicle and 100 ug PCB 126/kg BW) as the two factors. Treatment-related effects were further 
determined using ANOVA with a least significant difference test (p<0.05) to find significant 
differences between the treatment groups. PO.05 was considered significant. All analyses were 
performed with the statistical software package SAS. Data are presented as the mean ± SEM. 
Results 
Body weights of Tx rats were 74% of Eu controls prior to osmotic minipump implantation (day 
0) and 72% of both Eu and Eu+T3 rats at the end of the experiment (day 10). Liver and thymus 
weights were not significantly different between the various treatment groups on day 10 (data 
not shown). 
Plasma thyroid hormone levels 
Plasma concentrations of TT4, FT4, TT3 and TSH in corn oil-treated control rats on day 5 (one 
day prior to PCB treatment) and day 10 (end of the experiment) after osmotic minipump 
implantation are presented in Table 4.1. Eu rats had higher levels of TT4 on day 10 than on 
day 5, but TSH, TT3 and FT4 levels remained fairly constant over the 6 day period in Eu rats. 
Tx rats showed a significant (62%) decrease in plasma TT3 levels as compared to Eu 
rats on day 10 but not on day 5. TT4 and FT4 plasma levels in Tx rats were significantly 
decreased to = 15%ofEuratsonday 5 and 10. Plasma TSH concentrations were increased =10 
fold in Tx rats compared with Eu rats, also on both days. 
Treatment of Eu rats with T3 caused =4 fold increase in plasma TT3 concentrations 
on day 5, compared with Eu rats. Plasma TT3 levels in Eu+T3 rats were lower on day 10 than 
on day 5, and approached the levels in Eu rats. TT4 and FT4 plasma levels were strongly 
decreased in Eu+T3 rats to = 10% of Eu levels on day 5, and to =35% of Eu levels on day 10. 
TSH levels in Eu+T3 rats were significantly lower, = 6-fold on day 5 and ~ 2-fold on day 10 
than in Eu rats. 
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Table 4.1 Plasma thyroid hormone levels in Tx, Eu, and Eu+T3 rats. 
TT3 
(nmol/1) 
TT4 
(nmol/1) 
FT4 
(pmol/1) 
TSH 
(ng/1) 
Tx 
day 5 
1.13 
±0.08 
6.72 a 
±1.00 
4.96 ac 
±0.52 
25.41 a 
±4.80 
day 10 
0.44 ac 
±0.02 
8.76 a 
±1.47 
3.19 a 
±0.53 
24.68 a 
±2.65 
Eu 
day 5 
1.14 
±0.08 
35.20 
±3.28 
21.65 
±1.96 
3.07 
±0.67 
day 10 
0.86 
±0.04 
48.83 
±1.75 
20.15 
±1.34 
2.60 
±0.65 
Eu+T3 
day 5 
4.10 ab 
±0.70 
2.64 a 
±0.24 
2.32 a 
±0.38 
0.48 a 
±0.14 
day 10 
0.93 
±0.02 
13.24 a 
±4.67 
5.44 a 
±1.78 
1.24 a 
±0.45 
Note. Euthyroid male Sprague-Dawley rats were infused with T3 (10 ug/lOOg BW/day) via 
an osmotic minipump from day 0 on (Eu +T3). Thyroidectomized (Tx) and euthyroid (Eu) male 
Sprague-Dawley rats received a minipump with solvent only. On day 6 these rats were given 
an injection with corn oil (as a control). Blood was taken on day 5 and on day 10, the final day 
of the experiment. Data are presented as mean ± SEM (n=5 for all groups, except Eu n=4). a) 
denotes a significant difference (p<0.05) with the Eu group, b) a significant difference (p<0.05) 
with the Tx group, and c) a significant difference (p<0.05) with the Eu+T3 group. 
The effects of PCB 153 or PCB 126 on plasma thyroid hormone levels are presented in Table 
4.2. No effect of either the di-ortho PCB 153 or the coplanar PCB 126 treatment was found 
on plasma TT3 concentrations on day 10 in any of the groups. 
In Tx rats, plasma TT4 levels were not significantly lower after PCB 153 treatment to 
53% of corn oil-treated Tx rats. In PCB 126 treated Tx and Eu rats, plasma TT4 concentrations 
were also lower, to 64% and 75% of corn oil treated rats, respectively. Little or no change in 
plasma TT4 was observed in the PCB 153 or PCB 126 treated other groups. 
Plasma FT4 levels were changed in a similar manner as TT4 levels after PCB treatment. 
PCB 153 caused a not-significant decrease in plasma FT4 levels in Tx rats (to 51 % of corn oil 
Tx rats), no obvious effect in Eu rats and not-significant higher levels in Eu+T3 rats (to 166% 
of corn oil treated Eu+T3 rats). FT4 concentrations were somewhat lower in all groups after 
PCB 126 treatment compared with corn oil-treated rats, but this was only significant in Tx rats 
(to 66% of corn oil-treated Tx rats). 
Plasma TSH concentrations were not significantly changed by PCB treatment in any 
of the groups. 
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Table 4.2 Plasma thyroid hormone levels in Tx, Eu, and Eu+T3 rats after treatment with PCB 
153andPCB 126. 
Tx 
Eu 
Eu+T3 
Corn oil 
PCB 153 
PCB 126 
Corn oil 
PCB 153 
PCB 126 
Corn oil 
PCB 153 
PCB 126 
TT3 
(nmol/1) 
0.44 ±0.02 ac 
0.34 ±0.06 ac 
0.54 ±0.09 ac 
0.86 ± 0.04 
0.91 ± 0.06 
0.90 ± 0.03 
0.93 ± 0.02 
0.90 ±0.06 
1.00 ±0.09 
TT4 
(nmol/1) 
8.76 ±1.47 a 
4.64 ±0.34 a 
5.64 ±0.58 a 
48.83 ±1.75 
43.50 ±1.34 
36.46 ± 1.93 d 
13.24 ±4.67 a 
19.94 ± 4.64ab 
11.32 ±5.63 a 
FT4 
(pmol/1) 
3.19 ±0.53 a 
1.63 ±0.15 a 
2.10 ±0.19 a 
20.15 ±1.34 
18.28 ±1.03 
17.52 ±1.35 
5.44 ±1.78 a 
9.02 ± 2.25 ab 
5.33 ±2.37 a 
TSH 
(ng/1) 
24.68±2.65 a 
21.60±2.44 a 
19.38±2.98 a 
2.60± 0.66 
3.30±0.53 
4.15±0.36 
1.24±0.45 a 
1.38±0.34 a 
1.17±0.45 a 
Note. Thyroidectomized (Tx), euthyroid (Eu), and Eu rats infused with T3 (10 ug/100 g 
BW/day; Eu +T3) from day 0 were treated with 75 mg PCB 153/kg BW, 100 ug PCB 126/kg 
BW, or with the vehicle corn oil on day 6. The experiment was terminated on day 10. Data are 
presented as mean ± SEM (n=5 for all groups, except Eu n=4). a) denotes a significant 
difference (p<0.05) with the Eu group, b) a significant difference (p<0.05) with the Tx group, 
c) a significant difference (p<0.05) with the Eu+T3 group, d) denotes a significant difference 
(p<0.05) with the corn oil treated rats in the same group. 
Thyroid hormone metabolism 
Figure 4.1 shows thyroid state-dependent enzyme activities in livers isolated at day 10 after 
the implantation of the osmotic minipumps, i.e. 4 days after PCB treatment. Hepatic Dl activity 
was lower in Tx rats compared with Eu rats, in particular following PCB treatment. In Eu+T3 
rats, a 2-fold elevation of Dl activity was observed compared with Eu rats, although the 
difference was smaller after PCB 153 treatment and not significant after PCB 126 treatment. 
PCB treatment had no significant effect on Dl activity. 
Hepatic mitochondrial ocGPD activity was decreased in all Tx rats to =30% of that in 
Eu rats. In Eu+T3 rats, ccGPD activity was =2.6-fold higher than in Eu rats. No effect was 
observed on aGPD activity by PCB 126 and PCB 153 in all groups. 
Thyroidectomy caused a decrease in hepatic malic enzyme activity to =30% of that in 
Eu rats. Malic enzyme activity was increased =2.4-fold in Eu+T3 rats compared with Eu rats. 
No significant effects were found on malic enzyme activity by PCBs in any group. 
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A. 
Figure 4.1 Functional 
thyroid hormone status 
parameters in Tx, Eu and 
Eu+T3 rats Hepatic type I 
deiodinase activity (A), a-
glycerol phosphate 
dehydrogenase (oc-GPD), 
(B) and malic enzyme (C) 
were measured on day 10 
a f t e r m i n i p u m p 
implantation, i.e. at 4 days 
after treatment with corn 
oil, PCB 153 orPCB 126. 
Results are presented as 
mean ± SEM (for all groups 
n=5, only Eu corn oil group 
n=4). a) denotes a 
significant difference 
(p<0.05) with the 
corresponding Eu group. 
B. 
corn oil 
Eu+T3 
PCB 126 
T4 UGT activities were measured in the absence or presence of Brij 56 (Figure 4.2). No 
significant effects of thyroid state on T4 UGT activities were found, although a downward trend 
was observed from Tx to Eu+T3 rats. PCB 126 treatment, but not PCB 153 treatment, caused 
a significant increase in T4 UGT activities measured in the absence of Brij 56 in all groups. 
In contrast, T4 UGT activities measured in the presence of Brij 56 were increased significantly 
by PCB 153 treatment, but not by PCB 126 treatment, in all groups. 
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corn oil 
Figure 4.2 Hepatic T4 
UGT activities in Tx, Eu 
and Eu+T3 rats,measured 
in the absence (A) or 
presence of Brij 56 (B), on 
day 10 after minipump 
implantation, ie at 4 days 
after treatment with corn 
oil, PCB 153orPCB 126. 
Results are presented as 
mean ± SEM (for all groups 
n=5, only Eu corn oil group 
n=4). d) denotes a 
significant difference 
(p<0.05) with the corn oil 
treated rats in the same 
group. 
Effects on cytochrome F'450 parameters 
Effects of thyroid state on basal and PCB-induced cytochrome P450 parameters are presented 
in Table 4.3 and Figures 4.3,4.4, and 4.5. 
Total amounts of cytochrome P450 were not significantly different between Tx, Eu and 
Eu+T3 rats (Figure 4.3A). Total cytochrome P450 levels were increased significantly after 
treatment with PCB 153 and PCB 126 irrespective of thyroid state. The increase was over 2-
fold with PCB 153 and about 1.5-fold with PCB 126. NADPH cytochrome P450 reductase was 
measured by following the reduction of cytochrome c (Figure 4.3B). NADPH cytochrome c 
reductase was significantly decreased in Tx rats and significantly increased in Eu+T3 rats 
compared to Eu rats. NADPH cytochrome c reductase activity was not significantly affected 
by PCB treatment. 
CYP1A1 activity was determined as EROD activity (Figure 4.4A). Basal and PCB-
induced CYP1 Al activity was not influenced by the thyroid state. There was also no effect of 
thyroid state on CYP1 Al protein (Figure 4.4B) and mRNA (Figure 4.4C) levels. PCB 126 
58 
Effects of thyroid state on the induction of CYP1A and CYP2B 
Figure 4.3 Total hepatic 
cytochrome P450 (A) and 
NADPH cytochrome c 
reductase activity (B) in Tx, 
Eu and Eu+T3 rats, 
measured on day 10,4 days 
after exposure to corn oil, 
PCB 153 or PCB 126. 
Results are presented as 
mean ± SEM (for all groups 
n=5, only Eu corn oil group 
n=4). a) denotes a 
significant difference 
( p < 0 . 0 5 ) w i t h 
corresponding Eu group, b) 
a significant difference 
( p < 0 . 05 ) w i t h 
corresponding Tx group, d) 
a significant difference 
(p<0.05) with corn oil 
treated rats of the same 
group and f) a significant 
difference (p<0.05) with 
PCB 126 treatment group. 
corn oil 
induced the EROD activity 200-fold in all groups compared with corresponding corn oil-treated 
controls. 
CYP1 Al protein amounts were also highly induced by PCB 126 in all thyroid state 
groups. The fold induction of CYP1 Al protein levels by PCB 126 was about 22 times in Tx, 
37 times in Eu and 20 times in Eu+T3 rats. PCB 126 treatment induced CYP1 Al mRNA levels 
about 6-fold in all groups. PCB 153 did not affect CYP1 Al activity, protein or mRNA levels 
(Figure 4.4). 
CYP2B activity was determined as PROD activity. Basal as well as PCB-induced PROD 
activity, CYP2B protein and mRNA levels were not significantly affected by thyroid state 
(Figure 4.5A-C and Table 4.3). PCB 153 treatment caused an induction of PROD activity in 
all groups, although the fold induction depended on the thyroid state. In Tx rats PROD was 
induced 9 fold, in Eu rats 13 fold, and in Eu+T3 rats 26 fold. CYP2B1/2 protein levels were 
also increased by PCB 153 in all groups. The fold induction was 10 in Tx rats, 13 in Eu rats 
and 9 in Eu+T3 rats. CYP2B1/2 mRNA levels were also significantly induced by PCB 153 in 
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all groups, i.e. 31-fold in Tx, 19-fold in Eu, and 12-fold in Eu+T3 rats. PCB 126 also caused 
an increase in PROD activity. The induction varied between 7 and 14 fold compared with the 
corn oil-treated controls. CYP2B1/2 protein and mRNA levels were not changed by PCB 126 
treatment in any of the groups (Figure 4.4C). 
£ 6 
B. 
C. 
Eu+T3 
«>0.00 
corn oil 
Figure 4.4 CYP1A1 
parameters in Tx, Eu and 
Eu+T3 rats. Liver 
microsomal EROD activity 
(A), CYP1 Al protein levels 
(B) and CYP1A1 mRNA 
levels (C) were measured 
on day 10, 4 days after 
treatment with corn oil, 
PCB 153 or PCB 126. 
Results are presented as 
mean ± SEM (for all groups 
n=5, only Eu corn oil group 
n=4). d) denotes a 
significant difference 
( p < 0 . 0 5 ) w i t h 
corresponding corn oil 
treated group. 
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A. 
Figure 4.5 CYP2B1/2 
parameters in Tx, Eu and 
Eu+T3 rats Liver 
microsomal PROD activity 
(A), CYP2B1/2 protein 
levels (B) and CYP2B1/2 
mRNA levels (C) were 
measured on day 10,4 days 
after treatment with corn 
oil, PCB 153 or PCB 126. 
Results are presented as 
mean ± SEM (for all groups 
n=5, only Eu corn oil group 
n=4). b) denotes a 
significant difference 
(p<0.05) with Tx group, d) 
a significant difference 
(p<005) with corresponding 
corn oil treated group. 
B. 
C. 
Eu+T3 
PCB 126 
The effects of thyroid state and PCB treatment on all cytochrome P450 parameters are 
summarized in Table 4.3, computed by a two-way ANOVA, with PCB treatment and thyroid 
state as factors. 
It is shown that PCB 126 treatment caused a significant increase in total cytochrome 
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Effects of thyroid state on the induction of CYP1A and CYP2B 
It is shown that PCB 126 treatment caused a significant increase in total cytochrome P450 
content, EROD activity, CYP1 Al protein and mRNA levels. PCB 153 significantly increased 
total cytochrome P450 content, PROD activity, C YP2B protein and mRNA levels and NADPH 
cytochrome c reductase activity. Thyroid state only caused a significant change in NADPH 
cytochrome c reductase activity. 
Discussion 
The main objective of the present study was to investigate the possible role of thyroid state on 
PCB-induced cytochrome P450 1A1 and 2B isozymes expression in liver. The study was 
carried out in rats made hypothyroid by thyroidectomy, in euthyroid rats, and in rats made 
hyperthyroid by minipump infusion of excess T3. Tx rats had decreased plasma TT3, TT4 and 
FT4 concentrations, increased TSH levels, as well as lowered hepatic thyroid state sensitive 
parameters (eg Dl, malic enzyme and aGPD activities), indicating that they were functionally 
hypothyroid. Treatment of Eu rats with T3 showed increased plasma TT3 and decreased TSH 
levels, although this was less clear on day 10 than on day 5. However, increased hepatic Dl, 
malic enzyme and aGPD activities were clear signs of a functional hyperthyroidism. This was 
accompanied by strongly reduced TT4 and FT4 levels, as a consequence of suppressed TSH 
secretion. 
T4 is glucuronidated in rat liver by at least two different UGT isozymes: bilirubin UGT 
and phenol UGT. Phenol UGT activity is inhibited in vitro in the presence of Brij 56, whereas 
bilirubin UGT activity is stimulated in vitro by this detergent (Visser et al., 1993a/b). T4 UGT 
activity in the absence of detergent (the phenol type) was induced after treatment with PCB 
126, while PCB 153 treatment caused an induction of T4 UGT activity in the presence of Brij 
(the bilirubin type). This is in agreement with other reports showing an induction of phenol 
UGT activity by 3MC inducers such as PCBs and TCDD and an induction of bilirubin UGT 
activity by PB inducers such as di-ortho PCBs (Moscioni and Gartner, 1983; Beetstra et al., 
1991; Saito et al., 1991; Barter and Klaassen, 1992a; De Sandro et al., 1992). In this study, 
thyroid state had no effect on basal and PCB-induced UGT activities. In earlier reports, 
thyroidectomy led to a slight increase in bilirubin UGT activity in rats and treatment with T3 
resulted in a decrease in this activity (Chowdhury et al., 1983; Moscioni and Gartner, 1983; 
Pennington et al., 1988; Visser et al., 1996b). In contrast, thyroidectomy had a suppressive 
effect on phenol UGT activity, while treatment with T3 or T4 resulted in a restoration of UGT 
activity up to Eu or even higher levels (Chowdhury et al, 1983; Moscioni and Gartner, 1983; 
Graham and Skett, 1987; Pennington etal, 1988;Goudonnete?a/., 1990; Visser et al, 1996b; 
Masmoudi et al, 1996). 
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No significant effect of thyroid state was observed on basal or PCB-induced total 
cytochrome P450 levels. Other investigations have reported conflicting effects of thyroid state 
on cytochrome P450 levels in rat liver. Thyroidectomy was found to increase (Rumbaugh et 
al, 1978; Goudonnet et al, 1990) or to have no effect (Kato and Takahashi, 1968; Rozman 
et al, 1985b; Henry and Gasiewicz, 1987; Eltom et al, 1992; Schuur et al, 1998a), whereas 
T3 treatment was reported to cause an increase (Miiller et al, 1983a) or a decrease in total 
cytochrome P450 levels (Rumbaugh et al, 1978; Leakey et al, 1982; Miiller et al, 1983b; 
Goudonnet et al, 1990; Rosenberg et al, 1995). The opposite effects of T3 on basal 
cytochrome P450 levels in the two studies by Miiller et al. (1983a/b) were suggested to be due 
to different doses and administration routes or different ages of the animals. 
In this study, NADPH cytochrome P450 reductase activities were diminished in Tx rats 
and elevated in Eu+T3 rats compared with Eu rats. This is in agreement with previous reports 
(Kato and Takahashi, 1968; Rumbaugh et al, 1978; Leakeys al, 1982; Rozman etal, 1985b; 
Waxman et al, 1989; Ram and Waxman, 1992; Schuur et al, 1998a). PCB 153 slightly 
increased NADPH cytochrome P450 reductase activities in all thyroid state groups in our 
experiment. PCB 153 is regarded as a PB-type microsomal enzyme inducer, and PCB treatment 
has also been shown to stimulate NADPH cytochrome P450 reductase activity (Shephard et 
al, 1982). The dioxin-like PCB congener, PCB 126, had no effect on NADPH cytochrome 
P450 reductase activities. This is in accordance with Rozman et al (1985b) who found no effect 
ofTCDD. 
In this study, no effect of thyroid state was observed on basal and PCB-induced EROD 
activity, CYP1 Al protein levels nor on CYP1 Al mRNA levels. This is in contrast with our 
hypothesis and with other reports. In our previous study a decrease in EROD activity was found 
in Tx rats (Schuur et al, 1998a). Eltom et al (1992) found a decrease in basal and TCDD-
induced EROD activity after thyroidectomy, which was reversed by treatment with T3. 
Rumbaugh et al. (1978) also found a decrease in benzo(a)pyrene hydroxylase activity, which 
is also catalyzed by CYP1A1, in Tx rats which was reversed by treatment with T4. Roth et al 
(1988) showed that the modulation of TCDD-induced EROD activity by thyroidectomy 
depended on the TCDD dose. Rozman et al. (1985b) found no effects of thyroidectomy and 
T3 or T4 treatment on basal and TCDD-induced EROD activity. However, benzo(a)pyrene 
hydroxylase activity was significantly decreased in control but not in TCDD-induced Tx rats, 
while this effect was reversed by T3 treatment but not by T4 treatment. 
The differences between the results obtained in the various studies could probably be 
explained by differences in the dose and duration ofTCDD treatment and the thyroid state. 
CYP2B activity, CYP2B protein and mRNA levels were induced after treatment with 
PCB 153 in all rats. PCB 126 also induced PROD activity, but not CYP2B protein or mRNA 
levels. This PCB 126-induced PROD activity reflects induction of CYP1A as pentoxyresorufin 
is also moderately metabolized by CYP1A (Burke et al, 1994). 
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In our study, PROD activity showed an upward tendency from the hypothyroid to the 
hypothyroid state, although this was only significant for the Eu+T3 vs Tx group after PCB 153 
treatment. Thyroid state had no significant effect on CYP2B1/2 protein or mRNA levels. These 
small effects of thyroid state on CYP2B in this study are in conflict with results published 
earlier. Rosenberg et al. (1995) found a decrease in CYP2B1 (to 20%) and CYP2B2 (to 10%) 
protein levels after T3 treatment of Tx male Sprague-Dawley rats. Murayama et al. (1991) 
found 14 times higher basal CYP2B1 plus CYP2B2 levels after thyroidectomy or 6-propyl-2-
thiouracil (PTU) treatment of male Sprague-Dawley rats, which was reversed by T3 treatment. 
After treatment with PB, hypothyroid rats showed only a 10% increase in CYP2B levels. Also 
in hypophysectomized male rats, administration of T3 or growth hormone (GH) reversed a 10-
50 fold increase in CYP2B1 and CYP2B2 levels (Yamazoe et al, 1989). Yamazoe and his 
group suggest that both CYP2Bs are regulated by GH and thyroid hormone, with CYP2B2 
being more responsive for T3 and CYP2B1 more responsive to GH (Murayama et al, 1991). 
There is not a simple explanation for the discrepancy in effect of thyroid hormones on 
constitutive as well as induced CYP2B levels between our study and earlier reports. The fact 
that we used PCB 153 instead of PB is an unlikely cause of this difference. Two reports have 
suggested a common mechanism for the induction of CYP2B by di-ortho substituted PCBs and 
PB (Connor et al., 1995; Ikegwuonu et al, 1996). Another possible explanation is the 
difference in rat strains used. Larsen et al. (1994) reported on differences in basal and PB-
induced CYP2B protein levels between 3 strains; Wistar Furth inbred rats, Wistar Kyoto rats 
and F344 rats. Those differences were greater in female rats than in male rats. These variations 
between the strains largely disappeared after hypophysectomy, whereas they were enhanced 
by feeding intact rats a carbohydrate-rich diet. Larsen and Jefcoate (1995) also reported that 
methimazole (MMI)-induced hypothyroidism was as effective as hypophysectomy in elevating 
PB-induced CYP2B1 and CYP2B2 levels, whereas basal CYP2B2 levels were not elevated 
by MMI treatment. However, rats of the same strain and sex (male Sprague-Dawley rats) were 
used by Yamazoe's group (Yamazoe et al, 1987; Yamazoe et al, 1989; Murayama et al, 
1991), Rosenberg et al. (1995) and in our study. Thus, the differences in modulation of CYP2B 
by thyroid hormone are not likely explained by strain differences, although the Sprague-Dawley 
strain is an outbred strain. Finally, it is not excluded that the discrepancy between the present 
study and other reports is due to differences in the degree of hypo- and hyperthyroid states of 
the experimental animals. 
In conclusion, hepatic NADPH cytochrome P450 reductase activity is dependent on 
thyroid state. However, in our hands, basal and PCB-induced total cytochrome P450 as well 
as CYP1 Al and CYP2B levels are not or only marginally affected by thyroid state. Therefore, 
the PCB-induced decrease in plasma T4 is of no importance in regulating the expression of 
biotransformation enzymes induced by toxic PCBs. 
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CHAPTER 5 
IN VITRO INHIBITION OF THYROID HORMONE SULFATION 
BY HYDROXYLATED METABOLITES OF 
POLYHALOGENATED AROMATIC HYDROCARBONS 
Abstract 
Earlier studies in our laboratory showed that hydroxylated metabolites of PCBs, PCDDs and 
PCDFs competitively inhibit T4 binding toTTR and Dl activity. In this study we investigated 
the possible inhibitory effects of hydroxylated metabolites of PHAHs on iodothyronine 
sulfotransferase activity. Rat liver cytosol was used as a source of sulfotransferase enzyme in 
an in vitro assay with 125I-labelled T2 as a model substrate. Increasing amounts of hydroxylated 
PCBs, PCDDs or PCDFs, or extracts from incubation mixtures of PHAHs with induced liver 
microsomes were added as potential inhibitors of T2 sulfotransferase activity. Hydroxylated 
metabolites of PCBs, PCDDs and PCDFs were found to be potent inhibitors of T2 
sulfotransferase activity in vitro with IC50 values in the low micromolar range (0.2-3.8 uM). 
The most potent inhibitor of T2 sulfotransferase activity within our experiments was the PCB 
metabolite 3-hydroxy-2,3',4,4',5-pentachlorobiphenyl with an IC50 value of 0.2 uM. A hydroxyl 
group in the para or meta position appeared to be an important structural requirement for T2 
sulfotransferase inhibition by PCB metabolites. Ortho hydroxy PCBs were much less potent 
and none of the parent PHAHs was capable of inhibiting T2 sulfotransferase activity. In 
addition, the formation of T2 sulfotransferase-inhibiting metabolites of individual brominated 
diphenyl ethers and nitrofen as well as from some commercial PHAH mixtures (e.g. Bromkal, 
Clophen A50 and Aroclor 1254) was also demonstrated. 
These results indicate that hydroxylated PHAHs are potent inhibitors of thyroid 
hormone sulfation. Since thyroid hormone sulfation may play an important role in regulating 
free hormone levels in the fetus, and PCB metabolites are known to accumulate in fetal tissues 
after maternal exposure to PCBs, these observations may have implications for fetal thyroid 
hormone homeostasis and development. 
based on A. Gerlienke Schuur, Fransje F. Legger, Marieke E. van Meeteren, Marielle J.H. 
Moonen, Ingeborg van Leeuwen-Bol, Ake Bergman, Theo J. Visser, and Abraham Brouwer 
(1998). In vitro inhibition of thyroid hormone sulfation by hydroxylated metabolites of 
halogenated aromatic hydrocarbons. Chemical Research in Toxicology, 11, 1075-1081. 
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Introduction 
PCBs, PCDDs and PCDFs are persistent environmental pollutants that induce a broad spectrum 
of toxic effects in mammals (Safe, 1990). One aspect of the toxicity of these compounds is their 
effect on thyroid hormone levels and metabolism. TCDD and PCBs are known to affect the 
thyroid hormone system on at least at three different levels: 1) thyroid gland, 2) plasma 
transport, and 3) hepatic metabolism (for review; Brouwer et al, 1998). Exposure to TCDD 
or PCBs resulted in increased glucuronidation and biliary clearance of thyroxine (T4) and, thus 
decreased serum T4 levels in laboratory mammals (Potter et al, 1986; Roth et al, 1988; 
Beetstra et al, 1991). In addition, it has been shown that hydroxylated metabolites of PCBs, 
PCDDs and PCDFs competitively inhibit T4 binding to TTR, but not to TBG, both plasma 
thyroid hormone transport proteins (Lans et al, 1993; 1994). The same hydroxylated 
compounds were also demonstrated to inhibit Dl involved in the conversion of T4 to the active 
hormone T3 or to the inactive metabolite rT3 (Adams et al, 1990; Lans, 1995). 
Sulfotransferase isoenzymes catalyzing the sulfation of thyroid hormone are also 
possible targets for hydroxylated polyhalogenated aromatic hydrocarbons (PHAH-OHs), based 
on the earlier observation that PCP is a potent inhibitor of phenol sulfotransferase activity 
(Meerman etal, 1983). Sulfation is an important inactivation pathway for thyroid hormones. 
Iodothyronine sulfates have been demonstrated to be better substrates for hepatic Dl than the 
non-sulfated iodothyronines (Visser, 1994a/b). Thyroid hormones have been shown to be 
sulfated by several rat and human phenol sulfotransferases (Young et al, 1988; Gong et al, 
1992). Phenol sulfotransferases constitute one of two known sulfotransferase families, the other 
being the hydroxysteroid sulfotransferase family. Highest phenol sulfotransferase activity is 
found in the liver (Matsui and Homma, 1994). 
The major objective of this study was to investigate the possible inhibition of 
iodothyronine sulfotransferase activity by hydroxylated metabolites of PCBs, PCDDs and 
PCDFs. In addition, the iodothyronine sulfotransferase inhibitory potential of some individual 
PHAHs and mixtures of PHAHs was tested after metabolic conversion. For this purpose 
microsomes obtained from rats treated with phenobarbital (cytochrome P4502B) or B-
naphthoflavone (a cytochrome P4501A inducer) were used. A second aim of this study was 
to obtain more information about structural requirements of hydroxylated PCBs for inhibition 
of thyroid hormone sulfation. In our in vitro sulfation assay, we used 3,3'-T2 as a model 
substrate for T3, the active form of thyroid hormone. T2 has been shown to be the best substrate 
of all iodothyronines tested (Visser et al, 1996a). The PHAH-OHs tested in this study have 
been identified as major metabolites in blood samples from environmentally or experimentally 
exposed mammals. 
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Materials 
The structures of the PCB-, PCDD- and PCDF-metabolites tested are shown in Figure 5.1. They 
include: A) 2-OH-3,3',4,4'-tetrachlorobiphenyl (TCB), B) 4-OH-3,3',4',5-TCB, C) 5-OH-
3,3',4,4'-TCB, D) 6-OH-3,3',4,4'-TCB, E) 4,4'-(OH)2-3,3',5,5'-TCB, F) 4-OH-2',3,3',4',5-
pentachlorobiphenl (PeCB), G) 4-OH-3,3',4',5,5'-PeCB, H) 4-OH-2',3,4',5,5'-PeCB, I) 4-OH-
2,3,3',4',5-PeCB, J) 4-OH-3,3',4'-trichlorobiphenyl (TriCB), K) 4-OH-2',3,3,,4',5,5'-
hexachlorobiphenyl (HCB), L) 2-OH-2',3,3',4,4'-PeCB, M) 3-OH-2',3',4,4',5-PeCB and N) 3-
OH-2,3',4,4',5-PeCB. They were synthesized according to the method described elsewhere 
(Klasson- Wehler et al., 1990; Bergman et al., 1995) and were at least 98% pure. 4-OH-3,3',5,5'-
TCB (O) and 5-OH-3,3',4,4',5'-PeCB (P) were a generous gift from Dr. H. Kuroki, Daiichi 
College of Pharmaceutical Sciences (Fukuoka 815, Japan). 3,3'-(OH)2-4,4'-dichlorobiphenyl 
(DCB) (Q) was a generous gift from Dr. S.H. Safe, Texas A&M University (Texas, USA). 
The hydroxylated polychlorinated dibenzofurans (PCDF-OHs) used in the present 
study were: a) 8-OH-2,3,4-trichlorodibenzofuran (TriCDF), b) 2-OH-7,8-dichlorodibenzofuran 
(DCDF), c) 3-OH-2,6,7,8-tetrachlorodibenzofuran (TCDF), d) 3-OH-2,4,7,8-TCDF, e) 2-OH-
1,3,7,8-TCDF, f) l-OH-2,4,7,8-TCDF, g) 3-OH-2,4,7,8,9-pentachlorodibenzofuran (PCDF), 
h) 4-OH-l,3,6,7-TCDF (see Figure 5.1 for corresponding structures). PCDF-OHs a to c were 
a generous gift from Dr. S.H. Safe, and PCDF-OHs d to h were a generous gift from Dr. H. 
Kuroki. 
The hydroxylated polychlorinated dibenzo-/?-dioxins (PCDD-OHs) used in the present 
study were: i) 8-OH-2,3-dichlorodibenzo-/?-dioxin(DCDD), j) 7-OH-2,3,8-trichlorodibenzo-/7-
dioxin (TriCDD) and k) 2-OH-l,3,7,8-tetrachlorodibenzo-/>-dioxin (TCDD) (see Figure 5.1 for 
structures). All PCDD-OHs were obtained from Dr. S.H. Safe. 
Other hydroxylated compounds (for structures see Figure 5.2) tested in the present 
study were 2-OH-2',4,4'-trichlorodiphenylether (2-OH-TriCDE), obtained from Ultra Science 
(N. Kingstown, RI), and pentachlorophenol (PCP), bisphenol A (4,4'-isopropylidenediphenol), 
3,3',5,5'-tetrachlorobisphenol A and 3,3',5,5'-tetrabromobisphenol A, which were all obtained 
from Aldrich Chemical Co. (Bornem, Belgium). In addition, the parent PCB congeners 3,3',4,4'-
TeCB (PCB 77) and 3,3',4,4',5-PeCB (PCB 126), which were obtained from Promochem 
(Wesel, Germany) were also tested. 
The following compounds (for structures, see Figure 5.2) were tested for T2 
sulfotransferase inhibition after metabolic activation by incubation with liver microsomes and 
NADPH: Nitrofen (2,4-dichloro-4'-nitrodiphenylether, a generous gift from Prof. D. Tibboel, 
Sophia Children's Hospital Rotterdam, the Netherlands), 3,3',4,4'-tetrachlorodiphenyl ether 
(TCDE), 2,2',4,4'-brominated diphenyl ether (PBDE) mixture, Bromkal 70-5-DE (obtained from 
Chemische Fabrik Kalk, Germany) and three pure PBDE congener's 2,2',4,4'-
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 c,-/ W iH a 
Figure 5.1 Structures of the hydroxylated PCBs, PCDFs and PCDDs used as possible 
inhibitors in the T2 sulfotransferase activity assay. Names corresponding to the alphabetic 
indicators are given in the Materials and methods section. 
tetrabromodiphenyl ether (TBDE), 2,2',4,4',5-pentabromodiphenyl ether (PeBDE), and 
2,2',4,4',5,5'-hexabromodiphenyl ether (HBDE), which were synthesized according to the 
method described by Orn et al. (1996). TCDE, Aroclor 1254 (obtained from Ultra Science (N. 
Kingstown, RI)), a technical mixture of PCBs. Phenobarbital (PB) was obtained from Fluka 
Chemie (Buchs, Switzerland), p-naphthoflavone (NF) was obtained from Janssen Chimica 
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Figure 5.2 Structures of 
other halogenated aromatic 
compounds used as 
possible inhibitors in the T2 
sulfotransferase activity 
assay. 
a / ~ 
HO-V^ 
HoT" 
c,>= 
~io^~\ 
nitrofen 
= / l \ = / 
C H 3 
bisphenol A 
s%rt 
=/ i \ = / 
CH3 \ ; i 
N 0 2 
OH 
OH 
3,3',5,5'-tetrachlorobisphenol A 
B r ' C H 3 
3,3',5.5--tetrabromobisphenol A 
OH CI 
ci
-\=rA=/" 
2,-hydroxyl-2,4,4--trichlorodiphenylether 
-0*^0° Br =^/^  
3.3',4,4'-tetrachlorodiphenylether 
:i CI 
2,2',4,4'-tetrachlorodiphenylether 
Br Br 
2.2',4,4'-letrabromodipheny1ether 
Br Br 
2,2',4,4',5-pentabromodiphenylether 
Br B r N 
Br B r 
2.2',4,4',5,5'-hexabromodiphenylether 
(Tilburg, The Netherlands). 3,3'-Diiodothyronine (T2) and 3-iodothyronine (Tl) were obtained 
from Henning (Berlin, Germany). 3,[3'-125I]T2 was produced by radioiodination of Tl as 
described before (Visser et al, 1978). NADPH was obtained from Boehringer (Mannheim, 
Germany). Sephadex LH20 was purchased from Pharmacia (Woerden, The Netherlands). 3'-
phosphoadenosine-5'-phosphosulfate (PAPS) was purchased from Sigma Chemicals Co. (St. 
Louis, MO, USA). All other chemicals were of analytical grade. 
Cytosolic and microsomal preparations. 
Male Wistar rats (about 250 g of body weight) were treated with NF (3 daily ip injections of 
30 mg/kg body weight dissolved in corn oil) or PB (0.1 % w/v in the drinking water for 7 days). 
Rats were sacrificed under ether anesthesia, one day after the last NF treatment, and the livers 
were removed. The livers of three rats per treatment group were pooled. Livers were 
homogenized on ice in 3 volumes of ice-cold 0.1 M Tris-HCl buffer, pH 7.5 containing 0.25 
M sucrose, using a Potter-Elvehjem tube. The homogenate was centrifuged for 30 min at 
9,000xg and 0-4°C. The resulting supernatant was collected and centrifuged for 90 min at 
105,000xg and 0-4°C. The microsomal pellet was suspended in 0.1 M potassium phosphate 
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buffer, pH 7.5, and stored at -80°C until use. 
A cytosolic preparation from the liver of a non-treated 8 week old male Wistar rat was 
used as a source of sulfotransferase activity. Protein levels were determined with the Bio-Rad 
assay, using BSA as a standard (Bradford, 1976). 
Metabolism ofPHAHs by induced hepatic microsomes. 
Incubations were carried out in glass tubes at 37°C in a shaking water bath in a final volume 
of 1 ml 0.1 M Tris-HCl buffer, pH 7.5, as described before (Morse et al, 1995) with 
modifications. A mixture containing 1 mg/ml microsomal proteins and 10 uM PHAH was 
vortexed for 1 minute and pre-incubated for 2 minutes at 37°C. The reaction was initiated by 
adding NADPH in a final concentration of 1 mM. The incubation was continued for 15 min 
at 37°C. Reactions were stopped by the addition of 2 ml of ice-cold methanol. After 
centrifugation (1200xg, 5 min), the supernatants were extracted 2 times with 2 ml of diisopropyl 
ether by vortexing for 30 s and the diisopropyl ether fractions were collected following 
centrifugation at lOOOxg for 3 min. Control incubations were done without NADPH or without 
PHAH. The pooled diisopropyl ether extracts were dried under nitrogen, dissolved in 30 ul 
DMSO and stored until analysis. 
Liver cytosolic T2 sulfotransferase activity assay. 
T2 sulfotransferase activity was determined using radiolabeled T2 as substrate. In short, rat 
liver cytosol (25 ug/ml final protein concentration) was incubated with 1 uM T2 and 80,000 
cpm [l25I]T2, 50 uM PAPS in 75 mM Tris-HCl, 1.5 mM EDTA (pH 7.2) in a total volume of 
200 ul. Incubations were carried out for 30 min at 37°C. The reaction was stopped on ice by 
adding 750 ul of 0.1 M HC1. The T2 sulfate formed was analyzed by Sephadex LH-20 
chromatography as described by Rutgers et al. (Rutgers et al, 1989). 
Stock solutions of the various hydroxylated PCBs, PCDDs and PCDFs as well as the 
extracts of the in vitro metabolism experiments were made up in DMSO. PHAH-OHs were 
diluted in 75 mM Tris-HCl, 1.5 mM EDTA (pH 7.2) and added in a concentration series from 
0.01 to 10 uM. Extracts were diluted in buffer and added to the T2 sulfotransferase assay 
mixture, such that the concentration of formed metabolites could be maximally 1.7 uM. The 
maximum percentage of DMSO in the assay mixture did not exceed 0.5 %. Inhibition curves 
are presented as T2 sulfotransferase activity (as percentage of uninhibited control; means ± SD 
of duplicates) versus the log concentration of inhibitor. The concentrations causing 50% 
inhibition of control activity (IC50) were obtained from the inhibition curves in at least two 
experiments. 
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Results 
Hydroxylated PCBs, PCDDs and PCDFs 
The inhibition of T2 sulfation by four different hydroxy metabolites of the parent compound 
3,3',4,4'-TCB is presented as an example in Figure 5.3. A clear dose-dependent almost complete 
inhibition of T2 sulfotransferase activity was observed by 4-OH-3,3',4',5-TCB (B), 5-OH-
3,3',4,4'-TCB (C) and 6-OH-3,3',4,4'-TCB (D) with IC50 values of 1.4, 3.8 and 6.9 uM 
respectively. No inhibition of T2 sulfotransferase activity was found for the parent compound 
3,3',4,4-TCB as well as its ortho hydroxy metabolite 2-OH-3,3',4,4'-TCB (A). 
^ 1 2 0 
Figure 5.3 Inhibition of 
T2 sulfotransferase activity 
by 3,3',4,4'-TeCB and it 
metabolites using rat liver 
cytosol. T2 sulfotransferase 
activity is presented as 
percentage of control. Data 
are given as the mean. 
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In addition to the metabolites of 3,3',4,4'-TCB, a series of other hydroxylated organohalogens 
was tested for their inhibition of T2 sulfotransferase activity (Table 5.1). All of the hydroxylated 
PCBs, except for the ortho hydroxy substituted 2-OH-3,3',4,4'-TCB (A) and 2-OH-2',3,3',4,4'-
PeCB (L), inhibited T2 sulfotransferase activity with IC50 values in the low micromolar range. 
The most potent inhibitors of T2 sulfotransferase activity with IC50 values between 0.2 and 
1.0 uM were the meta and para hydroxy-substituted 3-OH-2,3',4,4',5-PeCB (N), 4-OH-
2,3,3',4',5-PeCB(I),4-OH-2',3,3',4',5-PeCB(F),andthedi-hydroxy-metabolites3,3'-(OH)2-4,4'-
DiCB (Q) and 4,4'-(OH)2-3,3',5,5'-TeCB (E). The other PCB-OHs had IC50 values ranging 
from 1.3-6.9 uM. The tested hydroxylated PCDDs and PCDFs were also capable of inhibiting 
T2 sulfotransferase activity except for l-OH-2,4,7,8-TeCDF (f). They had IC50 values in the 
same concentration range as the PCB-OHs, i.e. from 0.2 to 3.0 uM. 
From these data, we can obtain some information about the structural requirements 
of PHAH-OHs for inhibition of T2 sulfotransferase. Firstly, hydroxylation of the PHAHs is 
an essential requirement since both parent PCBs 3,3',4,4'-TCB (Figure 5.3) and 3,3',4,4',5-PeCB 
(data not shown) were incapable of inhibiting T2 sulfotransferase activity. Substitution of the 
OH group in the meta and para positions appeared to be necessary, while ortho-hydroxy 
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Table 5.1 In vitro inhibition of T2 sulfotransferase activity by the tested hydroxylated PCBs, 
PCDFs and PCDDs using rat liver cytosol. 
Compound IC50 (uM) 
A. 2-OH-3,3',4,4'-tetrachlorobiphenyl >10.0 
B. 4-OH-3,3',4',5-tetrachlorobiphenyl 1.4 ±1.0 
C. 5-OH-3,3',4,4'-tetrachlorobiphenyl 3.8 ±1.6 
D. 6-OH-3,3',4,4'-tetrachlorobiphenyl 6.9 ±0.8 
E. 4,4'-(OH)2-3,3',5,5'-tetrachlorobiphenyl 0.8 ±0.23 
F. 4-OH-2\3,3',4',5-pentachlorobiphenyl 0.6 ±0.03 
G. 4-OH-3,3',4',5,5'-pentachlorobiphenyl 3.0 ±1.0 
H. 4-OH-2\3,4',5,5'-pentachlorobiphenyl 1.3 ±0.25 
I. 4-OH-2,3,3',4',5-pentachlorobiphenyl 0.6 ±0.08 
J. 4-OH-3,3',4'-trichlorobiphenyl 2.8 ±0.25 
K. 4-OH-2',3,3',4',5,5'-hexachlorobiphenyl 2.1 ±0.40 
L. 2-OH-2',3,3',4,4'-pentachlorobiphenyl >5 
M. S-OH^S'^'^-pentachlorobiphenyl 3.3 ±0.75 
N. 3-OH-2,3',4,4',5-pentachlorobiphenyl 0.2 ±0.02 
O. 4-OH-3,3',5,5'-tetrachlorobiphenyl 2.8 ±1.30 
P. 5-OH-3,3',4,4',5'-pentachlorobiphenyl 2.4 ±0.05 
Q. 3,3'-(OH)2-4,4'-dichlorobiphenyl 0.5 ±0.02 
a. 8-OH-2,3,4-trichlorodibenzofuran 2.1 
b. 2-OH-7,8-dichlorodibenzofuran 1.3 
c. 3-OH-2,6,7,8-tetrachlorodibenzoruran 1.8±0.05 
d. 3-OH-2,4,7,8-tetrachlorodibenzofuran 1.9 ±0.00 
e. 2-OH-l,3,7,8-tetrachlorodibenzoruran 0.9 ±0.06 
f. l-OH-2,4,7,8-tetrachlorodibenzofuran >10 
g. 3-OH-2,4,7,8,9-pentachlorodibenzoruran 2.2±0.35 
h. 4-OH-l,3,6,7-tetrachlorodibenzofuran 0.2 ±0.07 
i. 8-OH-2,3-dichlorodibenzo-p-dioxin 3.0 ±0.03 
j . 7-OH-2,3,8-trichlorodibenzo-p-dioxin 1.4 ±0.57 
k. 2-OH-l,3,7,8-tetrachlorodibenzo-p-dioxin 1.2 ±0.08 
Note. Structural formulas of congeners as represented in Figure 5.1. IC50 values are the 
micromolar concentrations of inhibitor resulting in inhibition of T2 sulfotransferase activity 
to 50% of control (no inhibitor). 
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substituted PCBs did not inhibit T2 sulfotransferase activity. The number of halogen atoms 
on the phenolic ring did not seem to be a determining factor for T2 sulfotransferase inhibition 
potency e.g., 3,3'-(OH)2-4,4'-DiCB (Q) with one chlorine atom on each phenolic ring was as 
potent an inhibitor as 3-OH-2,3',4,4',5-PeCB (N) with 3 chlorine atoms on the phenolic ring. 
The planarity of the molecule does not seem to play a major role either, since the rigid planar 
structures of the PCDD-OHs and PCDF-OHs had a similar T2 sulfotransferase inhibitory 
potency as the hydroxylated PCBs, where there is freedom of axial rotation of the aromatic 
rings along the central C-C axis. Chlorine substitution on the non-hydroxylated phenyl ring 
slightly affected the inhibition potency, as is apparent when comparing compounds with the 
same chlorine substitution pattern on the phenolic-ring but with a different chlorine substitution 
pattern on the other ring, namely: 4-OH-3,3',4',5-TCB (A), 4-OH-2',3,3',4',5-PeCB (F), 4-OH-
3,3',4',5,5'-PeCB (G), 4-OH-2',3,4',5,5'-PeCB (H), 4-OH-2',3,3',4',5,5'-HeCB (K), and 4-OH-
3,3',5,5'-TCB (O). 
Related hydroxylated halogenated compounds 
Some other hydroxylated halogenated compounds, related to the group of hydroxylated PCBs, 
PCDDs and PCDFs, were also tested for their inhibition of T2 sulfation (Table 5.2). The well-
known phenol sulfotransferase inhibitor PCP was by far the most potent inhibitor of T2 
sulfotransferase activity with an IC50 value of 0.005 uM. The plasticizer bisphenol A did not 
inhibit T2 sulfation. However, the halogenated bisphenol A compounds were potent inhibitors 
of T2 sulfotransferase activity with IC50 values of 1.5 uM for 3,3',5,5'-tetrachlorobisphenol 
and 4.3 uM for 3,3',5,5'-tetrabromobisphenol. The only commercially available hydroxylated 
metabolite of a halogenated diphenyl ether (2-OH-2',4,4'-TriCDE) was tested and had an IC50 
value of 3.1 uM. 
Table 5.2 In vitro inhibition of T2 sulfotransferase activity by different hydroxylated 
compounds using rat liver cytosol. 
Compound 
bisphenol A 
3,3',5,5'-tetrachlorobisphenol 
3,3',5,5'-tetrabromobisphenol 
2'-OH-2,4,4'-trichlorodiphenylether 
pentachlorophenol 
Note. Structures of these compounds are shown in Figure 5.2. IC50 values are the micromolar 
concentrations of inhibitor resulting in inhibition of T2 sulfotransferase activity to 50% of 
control (no inhibitor). 
IC50 (uM) 
>10.0 
1.5 ±0.5 
4.3 ±1.1 
3.1 ±0.7 
0.005 ±0.0003 
79 
Chapter 5 
T2 sulfotransferase inhibition following metabolism ofPHAHs 
Some individual PHAH congeners as well as PHAH mixtures were tested after incubation with 
cytochrome P450s for their possible inhibition of T2 sulfotransferase activity (Table 5.3). 
Control incubations without NADPH or without PHAH did not produce T2 sulfotransferase 
inhibiting compounds. Incubation of NF-microsomes (CYPlA-enriched) with 2,2',4,4',5-
PeBDE or 2,2',4,4'-TeCDE in the presence of NADPH resulted in the formation of T2 
sulfotransferase-inhibiting metabolites. Incubation of these compounds with PB-microsomes 
(mostly CYP2B-enriched) also resulted in T2 sulfotransferase inhibiting metabolites. CYP2B 
but not CYP1 A-enriched microsomes catalyzed the formation of T2 sulfotransferase-inhibiting 
metabolites from the parent compounds nitrofen, 2,2',4,4'-TeBDE and 3,3'A4'-TeCDE in the 
presence of NADPH. Incubation of the PCB mixtures Aroclor 1254 and Clophen A50 but not 
the PBDE mixture Bromkal with either PB- or NF microsomes also resulted in production of 
metabolites that inhibited T2 sulfotransferase activity. 
Table 5.3 In vitro inhibition of T2 sulfotransferase activity, using rat liver cytosol, of various 
PHAH compounds after incubation with liver microsomes enriched with CYP1A or CYP2B 
and NADPH. 
Compound 
nitrofen 
Aroclor 1254 
Clophen A50 
bromkal 
2,2',4,4'-tetrabromodiphenylether 
2,2',4,4',5-pentabromodiphenylether 
2,2',4,4',5,5'-hexabromodiphenylether 
2,2',4,4'-tetrachlorodiphenylether 
3,3',4,4'-tetrachlorodiphenylether 
Note. Structures of these compounds are shown in Figure 5.2. Results are presented as 
qualitative data: -: no inhibition of T2-SULT activity; +: inhibition between 20 -60%; ++: more 
than 60% inhibition in comparison with control incubations (without NADPH or without 
compound). 
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Discussion 
The results from this study clearly indicate that the sulfotransferase isozyme(s) catalyzing 
thyroid hormone sulfation is (are) also a target protein for inhibition of binding by hydroxylated 
PHAHs. PCB-OHs, PCDD-OHs, PCDF-OHs as well as other hydroxylated halogenated 
compounds were shown to be potent inhibitors of in vitro T2 sulfation using rat liver cytosol 
as enzyme source. In addition, a number of individual PHAH congeners as well as mixtures 
of PHAHs could be converted in vitro into T2 sulfation-inhibiting substances by incubation 
with both CYP1A and CYP2B enriched microsomes and NADPH. 
To compare the inhibiting potency of the various chemicals, IC50 values were calculated. The 
most potent PCB-OH with respect to inhibition of T2 sulfation was the metabolite 3-OH-
2,3',4,4',5-PeCB (N) with an IC50 value of 0.2 uM. The IC50 values of all other PHAH-OHs 
inhibiting T2 sulfotransferase activity were in the low micromolar range, within a relatively 
small range of 0.2 and 6.9 uM. The most potent chemical tested in this study was PCP (with 
an IC50 value of 0.005 uM), which is a well-known phenol sulfotransferase inhibitor, in vitro 
(Duffel and Jakoby, 1981) as well as in vivo (Meerman et al, 1983). 
With the results obtained in this study, it is possible to make some statements about 
structural requirements for the PHAH-OHs that inhibit T2 sulfation in vitro. The first and very 
important structural requirement for the inhibition of T2 sulfation is the presence of a hydroxy 1 
group. As shown in Figure 5.3, the parent compound 3,3',4,4'-TeCB itself did not cause any 
inhibition of T2 sulfotransferase activity, while all OH-metabolites of 3,3',4,4'-TeCB were 
inhibitors. Similar conclusions were reported by Eaton et al. (1996) for inhibition by flavonoids 
of phenol sulfotransferase activity, measured withp-nitrophenol, minoxidil or acetaminophen 
as a substrate. The 7-hydroxyl substituent seemed to be the most important structural feature 
of flavonoids for inhibition of phenol sulfotransferase activity. Other natural phenolic 
compounds and food additives were also found to be potent inhibitors of phenol 
sulfotransferase activity (Gibb et al, 1987; Bamforth et al, 1993). 
A second structural aspect which appeared to have a major impact on the T2 
sulfotransferase inhibition potency of the tested PHAH-OHs, is the position of the OH-group 
in PHAH-OHs. This study indicates that for PCB-OHs a hydroxyl group in the para or meta 
position is necessary; ortho hydroxylated PCBs caused no T2 sulfation inhibition in the tested 
concentration range. However, the only commercially available, ortho hydroxylated chlorinated 
diphenyl ether (2-OH-2',4,4'-TriCDE) inhibited T2 sulfotransferase activity with an IC50 value 
of 3.1 uM. The affinity of this compound for the sulfotransferase active site may be explained 
by its diphenyl ether structure. For PCDF-OHs, it is possible to conclude that an OH-group in 
position 1 is not favorable for T2 sulfation inhibition. Secondly, an OH-group in position 4 
resulted in the lowest IC50 value found, 0.2 uM. 
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Another structural property that has an influence on the T2 sulfotransferase inhibition 
is the halogen substitution pattern. This applies especially to the bisphenol A derivatives, where 
it was shown that they were inhibitors of T2 sulfation only when substituted with bromines or 
chlorines. However, for PCDD-OHs a chlorine atom adjacent to the OH groups is not required 
for T2 sulfation inhibition, as is shown by the potent inhibitor 8-OH-2,3-DiCDD (i). It was also 
demonstrated that PCB-OHs with a similar chlorine substitution pattern on the hydroxylated 
phenyl ring but with a different chlorine substitution pattern on the other phenyl ring had 
slightly different IC50 values. 
As a last structural property, it can be stated that the planarity of the molecule does 
not seem to play a major role since rigid planar structures of the PCDD-OHs and PCDF-OHs 
have similar T2 sulfotransferase inhibitory potencies as the hydroxylated PCBs. 
Some other chemicals were also tested for their possible inhibition on T2 sulfotransferase 
activity after incubation with NADPH and microsomes enriched with CYP1A or CYP2B. 
Mammals are not exposed to individual congeners but to mixtures of PHAHs, which can 
possibly be hydroxylated by hepatic cytochrome P450 isozymes. It was demonstrated that the 
PCB mixtures Aroclor 1254 and Clophen A50 caused T2 sulfotransferase activity inhibition 
after incubation with NADPH and liver microsomes enriched with CYP1A or CYP2B after 
in vivo NF or PB treatment, respectively. Obtaining quantitative information about the potency 
of these compounds is not possible, but our results strongly suggest that hydroxylated 
metabolites of other PHAHs such as nitrofen and brominated diphenyl ethers are able to inhibit 
T2 sulfotransferase activity in vitro. 
The inhibition potency of T2 sulfotransferase activity by PHAH-OHs may be compared with 
their potency to interfere with other thyroid hormone-binding proteins such as TTR and Dl. 
In general, inhibition of T2 sulfotransferase activity by PHAH-OH is less potent than inhibition 
of T4 binding to TTR, which is characterized by IC50 values in the low nanomolar range (Lans 
et al, 1993; 1994). Secondly, the range of IC50 values for T4-TTR competition is much 
broader for the various PCB metabolites, i.e. 6-1000 nM. It is remarkable how small the range 
of IC50 values is for T2 sulfotransferase inhibition. Yet, the structural requirements for both 
inhibitions are very similar, both prefer an OH-group on the para or meta position. 
Similar IC50 values are observed for the inhibition of Dl activity and T2 
sulfotransferase activity by PCB-OHs. IC50 values for Dl inhibition by the various PCB-OHs 
were also in the micromolar range (Adams et al., 1990; Lans, 1995). A remarkable difference, 
however, is that dihydroxylated PCB-OHs are more potent inhibitors of Dl activity than of T2 
sulfotransferase activity. 
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The results on T2 sulfotransferase inhibition by hydroxylated PHAHs as reported here, were 
all obtained by in vitro methods, using hepatic cytosol as source of sulfotransferase(s) and liver 
microsomes as source of CYP1A or CYP2B. It is still a question whether the sulfotransferase 
inhibitory effects of PHAH-OHs would also occur in vivo. For that to happen, sufficient 
amounts of PHAH-OHs should be able to reach the intracellularly located sulfotransferase 
proteins. Relatively high levels of para-hydroxylated PCB metabolites from penta-, hexa- and 
hepta-chlorinated biphenyls have been found in the plasma of rats exposed to Aroclor 1254 
and in environmentally exposed humans and marine mammals (Bergman et al, 1994). Other 
metabolites (2-OH-2',3,3',4,4'-PeCB (L) and4-OH-2',3,3',4,,5-PeCB (F)) were identified in mice 
following exposure to 2,3,3',4,4'-PeCB (PCB 105; Klasson-Wehler ef a/., 1990). Exposure of 
rats to Aroclor 1254 resulted in the presence of considerable amounts of several hydroxy PCB 
metabolites in blood, including the 4-OH-2',3,3',4',5-PeCB (F, Klasson-Wehler et al, 1992). 
Furthermore, 4-OH-3,3',4',5,5'-PeCB (G) has been detected after in vivo exposure to 3,3',4,4',5-
PeCB (PCB 126; Koga et al, 1990). There was also a significant accumulation of 4-OH-
2,3,3',4',5-PeCB (I) in the plasma of late gestational fetuses from pregnant rats exposed to 25 
mg/kg Aroclor 1254 for 7 days (concentrations up to 4.6 uM). In addition, relatively large 
amounts of this metabolite were found in the fetal, but not weanling rat brain (Morse et al, 
1996). Two of the major hydroxy metabolites of 2,3,7,8-TCDD (compounds j and k) were 
identified in mammalian species (Mason and Safe, 1986; Ramsey et al, 1982). Summarizing 
the reports above, PCB and PCDD metabolites are found in blood of animals treated with the 
parent compound but also in free living mammals. Concentrations of some of the mentioned 
metabolites may be up in micromolar range, especially in fetal plasma and tissues. These 
metabolites were shown in the present study to be potent T2 sulfotransferase inhibitors with 
IC50 values also in the micromolar range. 
In this study, only male rat liver cytosol was used in the in vitro T2 sulfotransferase 
assay. It is known that iodothyronine sulfotransferase activity is higher in male than in female 
rat liver cytosol (Kaptein et al, 1997). Iodothyronines are sulfated in rats by at least two 
isozymes, i.e. rat SULT1B1 and rat SULT1C1 (Sakakibara et al, 1995; Fujita et al, 1997; 
Visser et al, 1998a). Whereas hepatic expression of SULT1B1 is independent of sex, 
SULT1C1 is only expressed in male but not in female rat liver (Nagata et al, 1993; Araki et 
al, 1997). Therefore, the sulfation of T2 analyzed in the present study represents the activity 
of both SULT1B1 and SULT1C1. However, similar results were obtained in experiments 
utilizing female rat liver cytosol, where T2 sulfation is only catalyzed by SULT1B1 (Schuur 
etal 1998b; Chapter 6). 
In the healthy adult, sulfation results in the irreversible inactivation of thyroid 
hormone, since sulfation strongly facilitates the inner ring deiodination of T4 and T3 by Dl 
(Visser, 1994b). T3S is barely detectable in serum of healthy human adults (<0.1 nM) but is 
much higher in fetuses of different stages (Chopra et al, 1992; Santini et al., 1993). It has been 
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suggested that sulfation of iodothyronines is an important pathway when D1 activity is low, 
such as in non-thyroidal illness and during fetal development (Santini et al, 1992a). This is 
supported by Huang et al. (1996), who reported on similar time courses in serum T3 levels and 
hepatic T3 sulfatase activity in the fetal rat, suggesting that sulfation-desulfation of T3 plays 
a role in the regulation of thyroid hormone metabolism in developing mammals. Based on these 
findings, the hypothesis is postulated that prenatal exposure of mammals to PHAHs, resulting 
in the accumulation of hydroxylated PHAHs in the fetal compartment, causes an inhibition of 
thyroid hormone sulfation with potential thyroid hormone-disrupting consequences. 
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CHAPTER 6 
IN VITRO INHIBITION OF THYROID HORMONE SULFATION 
BY POLYCHLOROBIPHENYLOLS: ISOZYME SPECIFICITY 
AND INHIBITION KINETICS 
Abstract 
It was recently demonstrated by our laboratory that hydroxylated metabolites of polychlorinated 
biphenyls (PCB-OHs) are inhibitors of thyroid hormone sulfation. In this study, a more detailed 
investigation on sulfotransferase isozyme specificity and the kinetics of inhibition was 
performed. Thyroid hormone sulfation was determined using 3,3'-T2 as a substrate, and various 
sources of sulfotransferase enzyme were used, e.g. female and male rat liver cytosol, male brain 
cytosol and cytosolic preparations of V79 cells transfected with rat SULT1C1, human 
SULT1 Al and human SULT1A3. 
The inhibition pattern and IC50 values were very similar for male and female rat liver 
and rSULTlCl and hSULTlAl. PCB-OHs were not able to inhibit the T2 sulfotranferase 
activity using hSULTl A3. Metabolite 3-hydroxy-2,3',4,4',5-pentachlorobiphenyl did not inhibit 
T2 sulfotransferase activity in male brain cytosol, while it was a very potent inhibitor in male 
and female rat liver cytosol. IC50 values for the tested PCB-OHs were not different with either 
T2 or T3 as substrate, supporting the hypothesis that T2 is the preferred iodothyronine substrate 
for the sulfotransferases catalyzing the sulfation of the active hormone T3. The Lineweaver-
Burk plot obtained with rat liver cytosol and T2 suggested that the nature of the T2 sulfation 
inhibition by 4-hydroxy-2',3,3',4',5-pentachlorobiphenyl is competitive. Finally, it was 
demonstrated that tested hydroxylated polychlorinated dibenzo-/>-dioxins and biphenyls were, 
albeit poorly, sulfated by sulfotransferases as measured by the production of 35S-labeled 
metabolites. 
based on A. Gerlienke Schuur, Ingeborg van Leeuwen-Bol, Willeke M. C. Jong, Ake Bergman, 
Michael WH. Coughtrie, Abraham Brouwer, and Theo J. Visser (1998). In vitro inhibition of 
thyroid hormone sulfation bypolychlorobiphenylols: isozyme specificity and inhibition kinetics. 
Toxicological Sciences, in press. 
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Introduction 
Sulfation is one of the major conjugation reactions for drugs and environmental chemicals as 
well as for endogenous compounds. Sulfate conjugation is catalyzed by multiple forms of 
sulfotransferases present in cytosol, which transfer a sulfuryl group from 3'-phosphoadenosine 
5'-phosphosulfate (PAPS) to hydroxyl and amino groups of numerous substrates (Mulder and 
Jakoby, 1990). Recently, accumulating evidence indicates that sulfotransferases exist as a 
multigene family, each possessing distinct but closely related catalytic properties. 
Sulfotransferases may be classified into phenol (Family 1) and hydroxysteroid (Family 2) 
sulfotransferase families based on amino acid sequence identity and catalytic function 
(reviewed in Falany, 1991; Matsui and Homma, 1994; Falany, 1997; Weinshilboum et al, 
1997). 
Thyroid hormones belong to the endogenous substrates of the phenol sulfotransferases 
as firstly characterized by Sekura et al. (1981). Thyroid hormones are sulfated by at least four 
different human isozymes (Young et al, 1988; Visser, 1994b; Visser et al., 1998a; Fujita et 
al, 1997); two forms of a phenol-preferring sulfotransferase (P-PST; SULT1A1 and 
SULT1A2), a monoamine-preferring phenol sulfotransferase (M-PST; SULT1 A3) and SULT 
1B1. In rat, iodothyronine sulfation was only demonstrated for SULT 1B1 (Sakakibara etal, 
1995) and SULT1C1 but not for SULT1A1 (Visser et al., 1996a; 1998b). Iodothyronine 
sulfation rates in rat liver cytosol were in the order 3,3'-T2 » T3 = rT3 > T4 (Visser et al., 
1996a; 1998b). Inhibition profiles of well-known sulfotransferase inhibitors (Rein et al., 1982) 
may distinguish between the different isozymes. It was shown that T3 sulfation in rat liver 
cytosol was inhibited by low concentrations of 2,6-dichloro-4-nitrophenol (DCNP; IC50= 5.5 
uM) and PCP (IC50= 0.065 [M) (Gong et al., 1992), suggesting that T3 sulfation was catalyzed 
by a P-PST like-isozyme. We have shown previously (Schuur et al, 1998b; Chapter 5) that 
hydroxylated metabolites of polychlorinated biphenyls (PCB-OHs), polychlorinated dibenzo-p-
dioxins (PCDD-OHs) and polychlorinated dibenzofurans (PCDF-OHs) are also able to inhibit 
thyroid hormone sulfation in vitro, using T2 as a substrate. 
In this study, the inhibition kinetics and the isozyme specificity of iodothyronine 
sulfotransferase inhibition by PCB-OHs were investigated in more detail. Firstly, different 
sulfotransferase enzyme sources were used: male and female rat liver cytosol, male rat brain 
cytosol and cytosol from V79 cells transfected with rat SULT1C1 (Nagata et al, 1993; Glatt 
et al, 1996), with a variant of human SULT1 Al (Jones et al, 1995) or with human SULT1 A3 
(Jones et al, 1995). Secondly, T2 and T3 were compared as substrates in the sulfotransferase 
assay, to validate the used of T2 as a model substrate for the active hormone T3. Thirdly, T2 
sulfotransferase inhibition kinetics of 4-hydroxy-2,3,3',4',5-pentachlorobiphenyl were 
investigated using rat liver cytosol. Fourthly, we investigated if PCB-OHs or PCDD-OHs were 
sulfated themselves by rat liver cytosol. 
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Materials and methods 
Materials 
The following hydroxylated polychlorinated biphenyls (PCB-OHs) were tested (see Figure 6.1 
for structures): A) 2-hydroxy-2',3,3',4,4'-pentachlorobiphenyl (2-OH-2',3,3',4,4'-PeCB), B) 4-
OH-2',3,4',5,5'-PeCB, C) 4-OH-2,3,3',4,,5-PeCB and D) 3-OH-2,3',4,4',5-PeCB. They were 
obtained by demethylation of the corresponding methoxy-PCBs synthesized according to the 
method described by Klasson-Wehler et al. (1990). They were at least 98% pure and their 
structural identification was performed using mass spectrometry as reported by Bergman et al. 
(1995). The following PCDD-OHs were used: a) 8-OH-2,3-dichlorodibenzo-/?-dioxin (8-OH-
2,3-DCDD), b) 7-OH-2,3,8-trichlorodibenzo-p-dioxin (7-OH-2,3,8-TriCDD) and c) 2-OH-
1,3,7,8-tetrachlorodibenzo-p-dioxin (2-OH-l,3,7,8-TCDD) (structures not shown). They were 
a generous gift of Dr. S.H. Safe, Texas A&M University (Texas, USA). The PCDD-OHs were 
synthesized according to Mason and Safe (1986) and their structural identity was checked as 
reported by Safe and Safe (1984). 
OH ^ H 
T2 ^-CH-CH;/ V o -4 VoH 
B. 
Figure 6.1 Structures of 
the hydroxylated PCBs 
used as inhibitors in the T2 
sulfotransferase activity 
assays. For structural Q# 
formulas see Materials and 
methods. 
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Pentachlorophenol (PCP) and /?-hydroxybiphenyl were obtained from Aldrich (Bornem, 
Belgium). Bovine serum albumin (BSA), 3'-phosphoadenosine-5'-phosphosulfate (PAPS) and 
3,3',5-triiodothyronine (T3) were purchased from Sigma (Zwijndrecht, The Netherlands). 3,3'-
diiodothyronine (T2) and 3-iodothyronine (Tl) were obtained from Henning (Berlin, Germany). 
125I-labeled T2 was produced by radioiodination of Tl as described before (Visser et al., 1978). 
125I-labeled T3 was obtained from Orange Medical (Tilburg, The Netherlands). [35S]PAPS was 
obtained from Du Pont-NEN (Den Bosch, The Netherlands). Sephadex LH-20 was purchased 
from Pharmacia (Woerden, The Netherlands). Dimethylsulfoxide (DMSO) was obtained from 
Acros Chimica (Den Bosch, The Netherlands). 
Cytosolic preparations 
Cytosol was prepared from the liver and brain of an 8 weeks old untreated male and from the 
liver of a 32 weeks old female Wistar rat. Tissue was homogenized on ice in 3 volumes ice-cold 
0.1 M Tris-HCl buffer, pH 7.5, containing 0.25 M sucrose, using a Potter tube. The homogenate 
was centrifuged for 30 min at 9,000xg and 4°C. The resulting supernatant was centrifuged for 
90 min at 105,000xg and 4°C. The high-speed supernatant was stored at-80°C until analysis. 
Cytosol was also prepared from cultured V79 cells stably expressing specific 
sulfotransferase isozymes, e.g. rat SULT1C1 (Nagata et al, 1993; Glatt et al, 1996), a variant 
of human SULT1 Al (Jones et al., 1995), and human SULT1 A3 (Jones et al., 1995). These cells 
were cultured in DMEM (Gibco Life Technologies, Breda, The Netherlands) supplemented 
with 10% FCS (Sigma) in a 37°C, 5% C02 humidified air environment. Confluent cell layers 
were washed in PBS, scraped from the bottom in 0.1 M Tris-HCl, 2 mM EDTA buffer (pH 7.2), 
homogenized and centrifuged for 90 min at 105,000xg and 4CC. The resulting supernatant 
(cytosol) was stored at -80°C until analysis. 
Protein levels were determined with the Bio-Rad assay (Bio-Rad Laboratories, 
Munich, Germany), using BSA as a standard (Bradford, 1976). 
Iodothyronine sulfotransferase assay 
Iodothyronine sulfotransferase activity was determined as described previously (Visser et al, 
1996a; Schuur et al, 1997; Chapter 2) using radiolabeled [1251]T2 or [125I]T3 as substrate. In 
short, cytosol was incubated with 1 uM T2 or T3 and 80,000 cpm [125I]T2 or [125I]T3, 50 uM 
PAPS in 75 mM Tris-HCl and 1.5 mM EDTA (pH 7.2) in a total volume of 200 ul. The protein 
concentrations at which the different enzyme preparations were tested varied between 25 ug/ml 
(female and male liver and male brain cytosol) and 50-200 ug/ml for the V79 cytosolic 
preparations. Incubations were carried out for 30 min at 37CC. The reaction was stopped on 
ice by adding 750 ul 0.1 M HC1. The T2 (or T3) sulfate formed was analyzed by Sephadex LH-
20 chromatography as described by Rutgers et al. (1989). 
Stock solutions of the hydroxylated PCBs were prepared in DMSO, further diluted 
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in buffer and added in the concentration range of 0.01 to 10 uM to the T2 sulfotransferase 
incubation mixture, such that the DMSO concentration did not exceed 0.5% (v/v). Inhibition 
curves are presented as T2 sulfotransferase activity (% of control) versus the log concentration 
of inhibitor (nM). The concentrations of inhibitor causing 50% inhibition (IC50) were estimated 
from the inhibition curves obtained in at least two experiments. 
The kinetics of inhibition of T2 sulfotransferase by PCB-OHs were investigated by 
incubation of male rat liver cytosol (25 ng protein/ml) with 0.1-10 uM radiolabeled T2 in the 
absence or presence of 0.5,1 and 2 uM 4-OH-2,3,3',4',5-PeCB. The results were analysed by 
Lineweaver-Burk analysis. 
Sulfation of PCB-OHs and PCDD-OHs 
A concentration series of 0.05-10 uM of PCB-OHs or PCDD-OHs were incubated with male 
rat liver cytosolic (25 ug protein/ml) and 0.1 uM [35S]-PAPS in a total volume of 150 ul 10 
mM potassium phosphate buffer (pH 7.4). A modified assay (Foldes and Meek, 1973; Pacifici 
et al., 1991) was used and optimized using/7-hydroxybiphenyl as substrate. Other substrates 
tested were: the PCB-metabolites A, B, C and D (Figure 6.1) as well as the PCDD metabolites 
8-OH-2,3-DiCDD, 7-OH-2,3,8-TriCDD and 2-OH-l,3,7,8-TeCDD and PCP. The reaction 
mixture was incubated for 30 min at 37°C. [35S]PAPS and protein were precipitated with 200 
ul each of 0.1 M barium acetate, 0.1 M barium hydroxide and 0.1 M zinc sulfate. After 
vortexing and centrifugation, 500 ul of the supernatant together with 4 ml scintillation liquid 
(Ultima Gold, Packard, Groningen, The Netherlands) was counted in a liquid scintillation 
counter (Tri-Carb 1600, Packard). The amount of sulfated product was calculated after 
correction for the radioactivity recovered from blank reaction mixtures containing the solvent 
DMSO but no substrate. 
Results 
Source and isozyme specificity 
Hydroxylated PCBs were previously reported to markedly reduce T2 sulfotransferase activity 
in male rat liver cytosol (Schuur et al., 1998b; Chapter 5). Inhibition of iodothyronine 
sulfotransferase activity by PCB-OHs was extended to other sources of enzyme, including 
female rat liver, male rat brain and V79 cells transfected with human SULT1A1, human 
SULT1 A3 and rat SULT1C1. 
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Figure 6.2 Dose-
dependent inhibition of T2 
sulfotransferase activity (% 
of control) by 3-OH-
2,3',4,4',5-PeCB (D) using 
different enzyme sources. 
The enzyme sources used 
were male rat liver cytosol, 
male rat brain cytosol and 
cytosol obtained from V79 
cells containing human 
SULT1A1. The control T2 
sulfotransferase activity 
was 324.2, 44.9 and 80.3 
pmol T2 sulfate formed/mg 
protein*min respectively. 
Data are presented as mean 
% of control ± SD, 
obtained from one 
experiment and performed 
in duplicate. 
IC50 values of PCB-OHs for T2 sulfotransferase activity are summarized in Table 6.1. Even 
at 10 uM, the ortho hydroxylated metabolite 2-OH-2',3,3',4,4'-PeCB (A) was unable to inhibit 
T2 sulfation by any of the enzymes tested . The meta and para hydroxylated metabolites (B, 
C and D) inhibited all sulfotransferase activities except that of human SULT1 A3. IC50 values 
for metabolites B, C and D were slightly higher with female rat liver cytosol than with male 
rat liver cytosol, although the order of potency remained the same. The meta hydroxylated 3-
OH-2,3',4,4',5-PeCB (D) did not inhibit T2 sulfotransferase activity in male brain cytosol, even 
though it was the most potent inhibitor using male or female rat liver cytosol (also demonstrated 
in Figure 6.2). Both para hydroxylated compounds B and C had similar IC50 values in male 
brain and liver cytosol (Table 6.1). 
The recombinant sulfotransferases were also used to obtain more information about 
isozyme specificity of sulfotransferase inhibition by PCB-OHs. Rat SULT1C1 isozyme (Table 
6.1 and Figure 6.2) showed almost the same pattern for T2 sulfotransferase inhibition by PCB-
OHs as rat liver cytosol. Human SULT1 A3, on the other hand, was not inhibited at all by any 
of the PCB metabolites. Human SULT1A1 behaves very similar to rat SULT1C1 which 
suggests a close resemblance between their substrate specificities. 
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Substrate dependence of sulfotransferase inhibition by PCB-OHs 
In the above experiments, T2 was tested as the preferred substrate for iodothyronine 
sulfotransferases but T3 is the physiologically relevant, active thyroid hormone. Therefore, we 
have tested the validity of T2 sulfotransferase data for T3 sulfation. As shown in Table 6.1 and 
Figure 6.3 (example), the IC50 values for T3 sulfotransferase inhibition by PCB-OHs were in 
the same range as the IC50 values using T2 as a substrate. Both order and potency of 
sulfotransferase inhibition by PCB-OHs were very similar using either T3 or T2 as a substrate, 
supporting the idea that T2 is a good model substrate for T3 in sulfotransferase inhibition 
studies. 
Figure 6.3 Comparison of 
a dose-response curve of 
sulfotransferase inhibition 
by 3-OH-2,3',4,4',5-PeCB 
(D) using T2 or T3 as 
substrates and male rat liver 
cytosol. Data are presented 
as mean % of control ± SD, 
obtained from one 
experiment and performed 
in duplicate. 
100 1000 
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T2 sulfotransferase inhibition kinetics by PCB-OHs 
The mode of inhibition of T2 sulfotransferase activity was investigated using male rat liver 
cytosol, a range of [125I]T2/T2 substrate concentrations and increasing 4-OH-2,3,3',4',5-PeCB 
concentrations. As shown in Figure 6.4A, the substrate concentration-dependent increase in 
sulfotransferase activity in the absence of inhibitor followed Michaelis-Menten kinetics, with 
a maximum sulfation rate being reached at 5 uM of T2. The sulfotransferase activities were 
reduced at all T2 concentrations by 4-OH-2,3,3',4',5-PeCB in a dose-dependent manner. 
Double-reciprocal conversion of the data from Figure 6.4A into Lineweaver-Burk plots is 
shown in Figure 6.4B. The apparent Km and Vmax values are 1.3 uM and 0.6 nmol/mg*min. 
The slope and x-axis intercept of the linear Lineweaver-Burk plots were much more affected 
in the presence of inhibitor than the y-axis intercept, suggesting that the mode of inhibition was 
largely competitive. The calculated apparent Ki for 4-OH-2,3,3',4',5-PeCB is 0.09 uM. 
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Figure 6.4 Kinetics of sulfotransferase inhibition by 4-OH-2,3,3',4',5-PeCB metabolite 
(C). Rat liver cytosol was used as enzyme source and T2 as substrate. 
A. T2 sulfotransferase activity versus T2 concentration. 
B. Lineweaver-Burk plot. 
Are hydroxylated PCB inhbitors also potential substrates for sulfotransferases? 
The PCB-OH inhibitors used in this study and some PCDD-OHs were also tested as possible 
substrates for sulfotransferases In Table 6.2, the amount of sulfated products formed in 20 
minutes, is presented. These data indicate that the tested PCB metabolites were poorly sulfated, 
the best one being metabolite D. The tested PCDD-OHs as well as PCP were somewhat better 
substrates, although the activities were still very low. 
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Table 6.2 Sulfation of PCB-OHs and PCDD-OHs measured with [35S]-PAPS using rat liver 
cytosol. 
PHAH metabolite pmol sulfated product/ mg protein/20 min 
2-OH-2',3,3',4,4'-PeCB (A) 17 ± 11 
4-OH-2',3,4',5,5'-PeCB (B) 55 ± 9 
4-OH-2,3,3',4',5-PeCB (C) 44 ± 26 
3-OH-2,3',4,4',5-PeCB (D) 109 ± 9 
8-OH-2,3-DCDD 235 ± 54 
7-OH-2,3,8-TriCDD 390 ± 32 
2-OH-l,3,7,8-TCDD 127 ±13 
PCP 127 ± 27 
Note. Data are obtained from 2-3 different experiments, using 0.1 \iM PAPS and 25 |ig 
cytosolic protein/ml. The maximum enzyme rate is given. 
Discussion 
It was shown previously that T2 sulfation in rat liver cytosol is inhibited by hydroxylated PCBs 
(Schuur et al., 1998b; Chapter 5). In the present study, the kinetics, isozyme and substrate 
specificity of iodothyronine sulfotransferase activity inhibition by PCB-OHs were investigated 
in more detail. 
Phenol sulfotransferase isozyme specificity 
To facilitate comparison of the different enzyme sources for sulfotransferase, IC50 values were 
calculated for the four tested PCB-OHs with different sulfotransferase enzyme sources. IC50 
values of the PCB-OHs for the recombinant sulfotransferase isozymes human SULT1 Al and 
rat SULT1C1 were quite similar and followed the same order as with male rat liver cytosol. 
However, T2 sulfation by SULT1 A3 was not inhibited at all by the tested PCB-OHs. 
Other known sulfation inhibitors such as DCNP and PCP were also found to inhibit 
human P-PST (SULT1A1) but not M-PST (SULT1A3) (Rein et al, 1982; Campbell et al, 
1987). In this study, we tested the variant of SULT1A1 cloned by Jones et al. (1995), which 
is 99% identical with the SULT1A1 cloned by Falany' s group (Wilborn et al., 1993; Ganguly 
et al., 1995). However, the apparent Km value of the SULT1 Al variant (Jones et al., 1995) 
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for T2 was about 10-fold higher compared with the variant cloned by Ganguly et al. (1995) 
(Visser et al, 1998a). Further studies are required to investigated the role of other human 
isozymes such as SULT1A2, the recently cloned SULT1B1 (Fujita et al, 1997; Wang etal, 
1998) and SULT1C1 (Her et al, 1997). 
For rat, it was demonstrated in vitro that thyroid hormones are sulfated by rat 
SULT1C1 and SULT1B1 (Sakakibara et al, 1995), but not by rat SULT1A1 (Visser et al, 
1996a; 1998b). The rat isozyme SULT1C1 may be responsible for the inhibition of T2 
sulfotransferase activity by PCB-OHs in male rat liver cytosol. However, SULT1C1 is a male-
dominant sulfotransferase and is expressed at very low levels in female liver (Nagata et al, 
1993; Liu and Klaassen, 1996), and in this study female rat liver cytosol showed similar IC50 
values for PCB-OHs as male rat liver cytosol, rat SULT1C1 and human SULT1A1. SULT1B1 
is equally expressed in female and male rat liver (Yamazoe et al, 1994; Sakakibara et al, 
1995), and is probably responsible for T2 sulfation in female liver cytosol. SULT1B1 could, 
thus, be the main target for inhibition by PCB-OHs in female liver. Our results, therefore, 
suggest similar substrate specificities for rat SULT1B1 and SULT1C1. 
T2 sulfotransferase activity in male rat brain cytosol was not inhibited at all by the 
meta-hydroxylated metabolite D, even though it was the most potent inhibitor using rat liver 
cytosol. A possible cause of this difference could be a variation in isozyme pattern between 
rat liver and brain. Dunn and Klaassen (1996) demonstrated SULT1C1 expression only in rat 
liver, kidney and spleen, but not in rat brain. Apparently, the iodothyronine sulfotransferase(s) 
in rat brain is not identical with rat SULT1B1 or SULT1C1. However, it is not excluded that 
the lack of inhibition of T2 sulfation in rat brain by compound D is due to sequestration of the 
inhibitor by non-specific binding to other proteins in brain cytosol. 
In conclusion, we suggest that human SULT1 Al and rat SULT1C1 are involved in 
the inhibition of T2 sulfation by PCB-OHs, as well as a sulfotransferase isozyme responsible 
for T2 sulfation in female liver cytosol, probably rat SULT1B1. However, it is necessary to 
obtain more information about the various isozymes involved in iodothyronine sulfation in 
humans as well as in rats. Only then is it possible to investigate more specifically which of these 
isozymes are sensitive to inhibition by PCB-OHs. 
Substrate specificity 
In this study, T2 was used as a model substrate in the in vitro inhibition studies. In vivo 
however, T3 is the most important and active form of thyroid hormone. The IC50 values as 
well as the ranking order of sulfotransferase activity inhibition by the tested PCB-OHs were 
almost the same for the substrates T2 and T3. Overall, we conclude that T2 sulfation is a 
suitable model substrate to assess the potency of T3 sulfation inhibitors. 
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Type of inhibition 
In this study, kinetic analysis suggested a competitive mode of inhibition of T2 sulfation by 
PCB-OHs. On the basis of the close structural resemblance between PCB-OHs and 
iodothyronines, it is not unexpected to observe competitive inhibition. Other thyroid hormone-
binding proteins such as type I deiodinase and transthyretin are also competitively inhibited 
by hydroxylated PCBs (Adams et al, 1990; Rickenbacher et al, 1989; Lans et al, 1994; Lans, 
1995). 
An explanation for the inconclusive results of the kinetic analysis may be the 
involvement of multiple sulfotransferases in the sulfation of T2 in cytosol which may be 
inhibited differently. To get more decisive results, single purified isozymes should be tested 
for the inhibition kinetics of T2 sulfation by PCB-OHs. Another explanation is that the inhibitor 
PCB-OH is a substrate for sulfotransferase itself, and may, therefore, be sulfated itself, thereby 
lowering its concentration. 
Different types of inhibition of phenol sulfotransferase activity have been reported 
for different inhibitors in rat and human tissues. For instance, vanillin, a substrate for phenol 
sulfotransferase, showed a partial non-competitive or mixed-type inhibition in rat liver cytosol 
and phenol, p-nitrophenol or dopamine as substrates (Cruickshank and Sansom, 1993). In 
human liver cytosol, the flavonoid quercetin was also found to be a non-competitive inhibitor 
of p-nitrophenol, acetaminophen and minoxidil sulfation (Walle et al, 1995; Eaton et al, 
1996). Another well-known inhibitor, DCNP, demonstrated in rat liver cytosol competitive 
inhibition vs substrates (Seah and Wong, 1994). However, in human brain cytosol (Whittemore 
et al., 1986) and human liver cytosol or partially purified P-PST (Walle et al., 1995), DNCP 
was demonstrated to be a non-competitive inhibitor of phenol sulfation. Furthermore, the 
inhibitor PCP was found to be a competitive inhibitor vs the substrate (Duffel and Jakoby, 
1981). Inhibitors are mostly alternative substrates, as we also demonstrated for PCB-OHs and 
PCDD-OHs (this study; Schuur et al, 1998b; Chapter 5). It should also be mentioned that 
phenol sulfotransferases are subject to substrate inhibition, which results in complex inhibition 
mechanisms (Binder and Duffel, 1988). 
Relevance 
The potential for inhibition of thyroid hormone sulfation by PCB-OHs in vivo is difficult to 
ascertain. DCNP has been shown to inhibit iodothryonine sulfation in vivo (De Herder et al., 
1988). PCBs are known neurotoxicants exerting effects on fetal development (Brouwer et al, 
1995). It was demonstrated before that PCB-OHs accumulate up to low micromolar 
concentrations in fetal tissues after exposure of pregnant rats to Aroclor 1254, a PCB mixture 
(Morse et al, 1996). 
Sulfation is an important step in the irreversible inactivation of thyroid hormone, since 
iodothyronine sulfates are rapidly degraded by the type I iodothyronine deiodinase (Dl). It has 
96 
Inhibition of thyroid hormone sulfation by PCB-OHs 
been suggested that sulfation of iodothyronines is an important reversible pathway of thyroid 
hormone inactivation when Dl is low, such as in non-thyroidal illness and during fetal 
development (Visser et al., 1994b). Santini et al. (1992a) postulated that T3 sulfation has an 
important function during fetal development since it allows recovery of active T3 from T3 
sulfate by action of sulfatases in tissues at the time when hormone action is required. Taken 
together, it is important to investigate the possible in vivo inhibition of the thyroid hormone 
sulfation by PCB metabolites during fetal development. 
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CHAPTER 7 
EFFECTS OF PENTACHLOROPHENOL AND HYDROXYLATED 
POLYCHLORINATED BIPHENYLS ON THYROID HORMONE 
CONJUGATION IN A RAT AND HUMAN HEPATOMA CELL 
LINE 
Abstract 
It was previously demonstrated in our laboratory that hydroxylated metabolites of 
polychlorinated biphenyls (PCB-OHs) inhibit the sulfation of iodothyronines in rat liver cytosol. 
In this study, the inhibition of 3,3'-diiodothyronine (T2) sulfation by pentachlorophenol (PCP) 
and PCB-OHs was investigated in hepatoma cell lines in relation to the cellular uptake of these 
compounds, providing a more appropriate model of the in vivo situation. The human HepG2 
hepatoma cell line was shown to conjugate T2 almost exclusively by sulfation, glucuronidation 
being negligible. The rat FaO hepatoma cell line on the other hand produced 37% T2 sulfate 
and 63% T2 glucuronide. It was demonstrated that PCP inhibited T2 sulfation in both cell lines, 
although it was 103 times less potent in cells than in rat liver cytosol. Remarkably, 10 uM PCP 
inhibited the sulfation and glucuronidation of T2 by FaO cells to the same extent. Micromolar 
concentrations of 4-hydroxy-3,3',4',5-tetrachlorobiphenyl or 4-hydroxy-2',3,3',4',5-pentachloro-
biphenyl hardly affected T2 conjugation in FaO cells, but both PCB-OHs reduced T2 sulfate 
formation in HepG2 cells. Inhibition of T2 sulfation was stronger using medium without FCS 
than medium with 5% FCS. This was due to a lower uptake of inhibitor by the cells in the 
presence of serum, as demonstrated using radiolabeled PCP. In conclusion, this study confirms 
the inhibition of T2 sulfation by PCP and PCB-OHs previously observed in rat liver cytosol 
in a rat and a human hepatoma cell line. Thus, it seems reasonable to assume that iodothyronine 
sulfation is also inhibited by PCB metabolites and PCP in vivo. 
based on A. Gerlienke Schuur, Ake Bergman, Abraham Brouwer, and Theo J. Visser (1998). 
Effects of pentachlorophenol and hydroxylated polychlorinated biphenyls on thyroid hormone 
conjugation in a rat and a human hepatoma cell line, submitted. 
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Introduction 
The main metabolic pathways for thyroid hormone are deiodination, glucuronidation and 
sulfation (Visser, 1990; 1994b). Sulfation has been viewed as an essential step in the 
metabolism of iodothyronines, increasing their water solubility and thus stimulating their 
excretion in bile and urine. Furthermore, 3,3',5-triiodothyronine (T3) sulfate does not bind to 
the T3 receptor and is thus unable to mimic thyroid hormone activity (Spaulding et al., 1992). 
Moreover, iodothyronine sulfates are rapidly degraded by inner ring deiodination by the type 
I deiodinase (Dl) (Often et al, 1983; Visser et al, 1984; Rutgers et al, 1989). It has been 
suggested that thyroid hormone sulfation is an important reversible inactivation step when Dl 
is low such as occurs in the fetal situation (Santini et al, 1992a/b). In the fetus, active T3 may 
be recovered from T3S through the action of sulfatases in tissues where hormone action is 
required. 
Environmental pollutants such as polychlorinated biphenyls (PCBs) are known to 
interfere with thyroid hormone metabolism through multiple mechanisms (for review: see 
Brouwer et al, 1998). One way of interference is through competive inhibition of thyroid 
hormone binding to its specific binding proteins, such as transthyretin and Dl, by hydroxylated 
metabolites of polychlorinated biphenyls (PCB-OHs) (Adams et al, 1989; Lans et al, 1993, 
1994). Recently, it was demonstrated that sulfotransferases are also targets for hydroxylated 
PCBs and related compounds (Schuur et al, 1998b; Chapter 5). Hydroxylated PCBs were 
found to inhibit iodothyronine sulfation in rat liver cytosol. This inhibition was mainly 
competitive in nature and sulfotransferase isozyme-specific, e.g. rat SULT1C1 and human 
SULT1A1, but not human SULT1A3, were inhibited by PCB-OHs (Schuur et al, 1998c; 
Chapter 6). 
In the present investigation, the inhibition of thyroid hormone sulfation by 
pentachlorophenol (PCP) and hydroxylated PCB metabolites was investigated using rat and 
human hepatoma cell lines. Such a study using intact cells is thought to be more representative 
of the in vivo situation. PCP and the model hydroxylated PCBs, 4-hydroxy-2',3,3',4',5-
pentachlorobiphenyl(PeCB-OH)and4-hydroxy-3,3',4',5-tetrachlorobiphenyl(TeCB-OH),were 
used to examine their potential impact on iodothyronine sulfation in the rat FaO hepatoma cell 
line and the human HepG2 hepatoma cell line, using 3,3'-diiodothyronine (T2) as a model 
substrate. [14C]PCP was used to estimate the cellular uptake of this phenol. 
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Materials and methods 
Materials 
4-Hydroxy-2',3,3',4,,5-pentachlorobiphenyl (PeCB-OH) and 4-hydroxy-3,3',4',5-
tetrachlorobiphenyl (TeCB-OH) were synthesized according to the method described elsewhere 
(Klasson-Wehler et al, 1990; Bergman et al, 1995). Pentachlorophenol (PCP) was obtained 
from Aldrich (Bornem, Belgium). [I4C]PCP, 6-propyl-2-thiouracil (PTU) and 3'-phospho-
adenosine-5'-phosphosulfate (PAPS) were obtained from Sigma (St. Louis, MO). 3,3'-
diiodothyronine (T2) and 3 -iodothyronine (T1) were obtained from Henning (Berlin, Germany). 
[I25I]T2 was produced by radioiodination of Tl as described before (Visser et al, 1978). 
Sephadex LH-20 was purchased from Pharmacia (Woerden, The Netherlands). DMSO was 
obtained from Acros Chimica (Den Bosch, The Netherlands). Phosphate-buffered saline (PBS) 
was obtained from Oxoid Ltd (Basingstoke, UK). Cell culture media were obtained from Gibco 
Life Technologies (Breda, The Netherlands). Fetal calf serum (FCS) was obtained from Sigma. 
Cell culture flasks and 6-well plates were obtained from Costar Europe Ltd (Badhoevedorp, 
The Netherlands). 
Cell culture 
HepG2 cells were obtained from ATCC (no HB 8065, Rockville, MD) and FaO cells from 
ECACC (no 89042701, Salisbury, UK). Both cell types were cultured in DMEM/F12 
supplemented with 10% FCS in a 37 °C, 5% C02 humidified air environment. For the 
experiments, confluent cell layers were obtained in 6-well plates, washed with PBS and 
incubated with 2 ml of medium which consisted of DMEM/F12 without phenol red, containing 
100 uM PTU, 1 uM T2 with =100,000 cpm [125I]T2. PTU is an inhibitor of Dl (Visser, 1990) 
and was added to inhibit the possible breakdown of the T2 sulfate formed. This medium was 
used without or with 5% FCS. The PCB-OHs and PCP were dissolved in DMSO and diluted 
in the medium with a maximal final DMSO concentration of 1%. The cells were incubated for 
4 h in an atmosphere of 37°C and 5% C02. To determine the amount of PCP present in the cells 
following exposure, [14C]PCP was added to the wells. In individual experiments each condition 
was tested in duplicate, and untreated controls (with maximally 1% DMSO) and blanks 
(medium without cells) were included. Each experiment was performed 2-5 times. 
T2 sulfotransferase activity 
Cells were washed with PBS, and scraped in 0.1 M Tris-HCl, 2 mM EDTA (pH 7.2). After 
centrifugation for 75 min at 105,000xg and 0-4°C, protein levels were determined with the Bio-
Rad assay (Bio-Rad Laboratories, Munich, Germany), using BSA as a standard (Bradford, 
1976). T2 sulfotransferase activity was measured as described by Kaptein et al. (1997). In short, 
cell cytosol (500 ug/ml final protein concentration) was incubated with 1 uM T2 and 80,000 
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cpm [,25I]T2, 50 uM PAPS in 75 mM Tris-HCl, 1.5 mM EDTA (pH 7.2) in a total volume of 
200 ul. Incubations were carried out for 30 min at 37°C. The reaction was stopped on ice by 
adding 750 ul of 0.1 M HC1. The T2 sulfate formed was analyzed by Sephadex LH-20 
chromatography as described by Rutgers et al. (1989). 
T2 conjugate analysis 
After 4 h of exposure, 0.5 ml culture medium was taken and 0.5 ml 1 M HC1 was added to the 
sample. The remainder of the medium was removed and cells were extracted in 0.5 ml 0.1 M 
NaOH and 0.5 ml 1 M HC1 was added. The acidified medium and cell samples were counted 
for 125I radioactivity using a Cobra AutoGamma counting system (Canberra-Packard, 
Groningen, The Netherlands). Conjugated [125I]T2 was isolated by Sephadex LH-20 
chromatography as described by Rutgers et al. (1989) and counted for radioactivity. 
In a separate experiment, the nature of the conjugated T2, i.e. the ratio between T2 
glucuronide (T2G) and T2 sulfate (T2S), was determined. For this purpose, medium and cell 
samples were analyzed by Sephadex LH-20 chromatography without and after treatment for 
1 h at 80°C with 1 M HC1. T2S is hydrolyzed during this treatment, while T2G is stable (Mol 
andVisser, 1985). 
Presence ofPCP in the cells 
After 4 h of exposure to [14C]PCP, 1 ml of medium was harvested and 4 ml of scintillation 
liquid (Ultima Gold, Packard) was added. The cells were extracted in 1 ml 0.1 M NaOH and 
4 ml of scintillation liquid was added. All samples were counted using a liquid scintillation 
counter (Tri-Carb 1600, Packard). 
Results 
Initially, we tested the sulfotransferase activity in the cytosol of the hepatoma cell lines using 
1 uM [125I]T2 as substrate and 50 uM 3'-phosphoadenosine-5'-phosphosulfate as cofactor. In 
the rat FaO hepatoma cell line this amounted to 286 pmol T2S formed/mg protein per 30 min 
and in the human HepG2 hepatoma cell line 702 pmol/mg protein per 30 min. 
Thereafter, we tested the ability of intact hepatoma cell lines to conjugate T2 to T2S 
and T2G. Figure 7.1 shows the total amounts (medium plus cells) of T2 conjugates as well as 
of T2S and T2G produced by FaO and HepG2 cells. In FaO cells (Figure 7.1 A), T2 conjugates 
consisted for 63% of T2G and 37% of T2S. Total T2 conjugation was reduced by =40% by 
addition of 10 uM PCP and by only -10% in the presence of 10 uM TeCB-OH. Similar effects 
of PCP and TeCB-OHwere found on T2S and T2G formation. In HepG2 cells (Figure 7.IB), 
total T2 conjugation was almost completely accounted for by sulfation. T2S formation was 
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Figure 7.1 Effect of 
pentachlorophenol (PCP) 
and 4-OH-3,3',4',5 
tetrachlorobiphenyl (TeCB-
OH) on T2 conjugation in 
intact hepatoma cells. Total 
T2 conjugation as well as 
T2 glucuronides and T2 
sulfates were measured in 
medium and cells of the rat 
hepatoma cell line FaO (A) 
and the human hepatoma 
cell line HepG2 (B) after in 
4 h of exposure to 10 |iM 
PCP or TeCB-OH in 
medium without 5% FCS. 
Results presented are from 
one experiment performed 
in duplicate. 
A. s 
B.
 = 
h- 500 
total T2G T2S 
X 
1 
i , HepG2 
• 
total 
CONTROL 
T2G 
YZA PCP 
T2S 
I TeCB-OH 
inhibited by =75% by 10 uM PCP and by =80% by 10 uM TeCB-OH. In addition, the amount 
of non- and conjugated T2 present in cells was not changed in the presence of PCP or PCB-
OHs, as is shown in Table 7.1. 
Dose-dependence ofT2 sulfation inhibition by PCP or PeCB-OH 
Inhibition studies were performed in intact cells coincubated with [125I]T2 and PCP or PeCB-
OH. The control value of total T2 conjugate formed in 4 h by FaO cells was about 0.5 nmol 
per well in medium with 5% FCS and 0.9 nmol per well in medium without FCS for most of 
the incubations. In untreated control HepG2 cells, the total amount of T2 conjugate formed in 
4 h was about 0.9 nmol per well in medium with 5% FCS and about 1.2 nmol per well in 
medium without FCS. Irrespective of the presence of serum, most T2 conjugate was found in 
the medium. For this reason, further data represent T2 conjugates determined in the medium. 
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Inhibition of iodothyronine sulfation by PCP and PCB-OH in hepatoma cells 
Figure 7.2 shows the results of one example experiment in which the effects of increasing 
concentrations of PCP and PeCB-OH on the conjugation of T2 in FaO cells are demonstrated. 
PCP decreased T2 conjugate formation in FaO cells incubated in medium without FCS by up 
to 80% (Figure 7.2A). Repeated experiments with FaO cells showed a high degree of variation, 
with IC50 values ranging between 0.5 and 8 uM. However, when medium with 5% FCS was 
used, formation of T2 conjugates in FaO cells was not reduced by up to 10 uM PCP. PeCB-OH 
caused a slight (20%) reduction of T2 conjugation by FaO cells in the absence of FCS but had 
no effect in the presence of 5% FCS (Figure 7.2B). 
Figure 7.2 Dose-
dependency of T2 
conjugate reduction by 
pentachlorophenol (PCP; 
A) and 4-OH-2',3,3',4',5-
pen tach lo rob ipheny l 
(PeCB-OH; B) exposure 
for 4 h in rat hepatoma FaO 
cells, in medium with or 
without 5% FCS. The 
percentage of formed T2 
conjugate in medium is 
expressed as percentage of 
DMSO control. Results 
presented are from one 
experiment performed in 
duplicate. PeCB-OH (uM) O 0% FCS • 5% FCS 
Figure 7.3 shows the results of one separate experiment in which the inhibitory effect of PCP 
and PeCB-OH on T2S formation by HepG2 cells are presented. PCP was found to clearly 
reduce the formation of T2S in HepG2 cells in a dose-dependent manner in the absence but 
not in the presence of 5% FCS (Figure 7.3A). IC50 values for the reduction of T2S formation 
by PCP varied between 0.8 and 3.9 uM in medium without FCS. PeCB-OH decreased T2S 
formation by HepG2 cells to the same extent as PCP (Figure 7.3B), with an IC50 value of 3.6 
105 
Chapter 7 
120 
I 100' 
c 
o 
if 80 
o 
3? 
*~ 60 
T3 
(U 
£ 40 
a 20 
H 
0 
• • 
-
• 
t 
• • 
———J 
B. f 
10 
PCP (uM) 
PeCB-OH (uM) 
O 0% FCS # 5% FCS 
Figure 7.3 Dose 
dependency of T2 
conjugate reduction by 
pentachlorophenol (PCP; 
A) and 4-OH-2',3,3',4',5-
pen tach lo rob ipheny l 
(PeCB-OH; B) exposure for 
4 h in human hepatoma 
HepG2 cells, in medium 
with or without 5% FCS. 
The percentage of formed 
T2 conjugate in medium is 
expressed as percentage of 
DMSO control. 
uM in the absence of FCS. However, in the presence of 5% FCS, no effect on T2S formation 
by PeCB-OH was observed up to 10 uM. 
[I4C]PCP cellular uptake 
The difference in reduction of T2 conjugation in cells exposed to inhibitors in medium without 
and with 5% FCS could be caused by a difference in the amount of the inhibitor taken up by 
the cells. To investigate this, [14C]PCP was used to determine the amount of inhibitor present 
in the cells after 4 h of exposure. In HepG2 cells, 8 and 22% of labelled PCP was present, in 
medium with and without FCS respectively. The percentages of PCP present in FaO cells 
accounted for 2.5 and 8% in medium with and without FCS respectively. Figure 7.4 shows the 
amount of PCP present in FaO or HepG2 cells after 4 h of exposure versus the added 
concentration of PCP in the medium. It was found that in the presence of 5% FCS the amount 
of PCP taken up in the cell was up to 70% lower than that in the absence of 5% FCS. 
Furthermore, the amount of PCP taken up in HepG2 cells was about 3 times higher compared 
to the uptake in FaO cells. 
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Figure 7.4 The uptake of 
PCP in the rat hepatoma 
cell line FaO (A) or the 
human hepatoma cell line 
HepG2 (B) in medium with 
or without 5% FCS. The 
amount of PCP (measured 
with l4C-PCP) present in 
the cells is plotted against 
the PCP concentration 
added in the medium. 
Results presented are from 
one experiment performed 
in duplicate. 
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Discussion 
Recently, it was shown that phenolic organohalogens, such as PCP and hydroxylated PCBs, 
were potent inhibitors of the iodothyronine sulfotransferase activity in rat liver cytosol (Schuur 
et al., 1998a; Chapter 5). The aim of the present study was to investigate the sulfotransferase 
inhibitory effect of PCP and PCB-OH in intact cells using the rat FaO hepatoma cell line and 
the human HepG2 hepatoma cell line. Although hepatoma cells are different from normal 
hepatocytes, studies using these cells were thought to be more representative of the in vivo 
situation than experiments using subcellular fractions. 
The T2 conjugates produced by FaO cells consisted for one-third of T2S and for two-
third of T2G. This is in agreement with another report demonstrating low or even undetectable 
2-naphthol sulfation but significant 1-naphthol glucuronidation in FaO cells (Utesch et al., 
1992). Addition of PCP or TeCB-OH to the culture medium of FaO cells produced a parallel 
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decrease in the production of T2S and T2G. 
Little or no formation of T2G was found in HepG2 cells, and T2 sulfation was =2-fold 
higher than in FaO cells. Other reports do not give consistent results on sulfation in HepG2 
cells. Dawson et al. (1985) found very little ethoxycoumarin sulfation. Van Stralen et al. (1993) 
reported that T3 is poorly sulfated in HepG2 cells, while De Jong et al. (1995) demonstrated 
that both T2 and Triac were sulfated in HepG2 cells, with only a small percentage of T2 being 
glucuronidated. Due to the sulfotransferase isozymes present, HepG2 cells may represent a 
good model for sulfate conjugation in normal human liver cells (Shwed et al., 1992). We found 
that PCP and PeCB-OH are equipotent inhibitors of T2 sulfation in HepG2 cells. 
We have shown that PCP has a similar potency in inhibiting T2 sulfation in HepG2 
and FaO cells, with IC50 values of =4 uM. Whereas PeCB-OH is equally potent in reducing 
T2S formation in HepG2 cells, PeCB-OH is a much weaker inhibitor in FaO cells. The IC50 
values for PCP in both FaO and HepG2 cells are much greater than the IC50 values of 5 nM 
and 2 nM for PCP inhibition of T2 sulfation in rat and human liver cytosol, respectively 
(Schuur et al., 1998b; Chapter 5; Visser et al., 1998a). The IC50 value for PeCB-OH in HepG2 
cells is much closer to its IC50 value of ~ 1 uM for inhibition of T2 sulfation by rat liver cytosol 
and human SULT1 Al (Schuur et al, 1998c; Chapter 6). Other groups also reported on the 
difference between in vitro assays using cytosolic preparations or cells. For example, the 
flavonoid quercetin and the well-known phenol sulfotransferase inhibitor DCNP were found 
to be much less potent inhibitors of PNP sulfation in HepG2 cells (with 10% FCS) than with 
cell-free phenol sulfotransferase solutions (Eaton et al., 1996). The difference may be caused 
by binding of the inhibitor to serum proteins, relative membrane impermeability and the 
conversion to inactive metabolites in cells. In addition, the composition of sulfotransferase 
isoenzymes may be different between tumor cells and normal tissue. 
We demonstrated that in medium with 5% FCS, IC50 values were higher for both 
inhibitors and both cell lines than in medium without FCS. This is probably explained by the 
lower availability of the inhibitor in the presence of serum due to protein (albumin) binding. 
It was indeed proven using radiolabeled PCP, that the amount of inhibitor present in the cell 
was higher after incubation without FCS than in the presence of 5% FCS. The amount of PCP 
taken up by HepG2 cells was higher than that taken up by FaO cells. This is in agreement with 
the more strongly reduced formation of T2S in HepG2 cells than in FaO cells. 
The potential for inhibition of thyroid hormone sulfation by PCB-OHs in vivo is 
difficult to estimate. Similar to PCP and DNCP (Mulder and Scholtens, 1977; Koster et al., 
1982; Meerman et al., 1983), PCB-OHs may also be active inhibitors of thyroid hormone 
sulfation in vivo. The effectiveness in vivo will depend on the bioavailability of the compounds. 
Quercetin has been shown to have no effect on the sulfation of harmol in the perfused rat liver 
(Shali et al., 1991), although quercetin was a potent inhibitor in human liver cytosol and in 
HepG2 cells (Walle et al., 1995; Eaton et al., 1996). Uptake and tissue distribution of PCB-OHs 
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may be similar to other phenolic halogenated compounds such as PCP and DNCP, due to 
similar physico-chemical properties. PCB-OHs were demonstrated before in human plasma, 
and in plasma and tissues of PCB-exposed animals (Bergman et al, 1994), and at even higher 
levels in rat fetuses of PCB-exposed mothers (Morse et al., 1996). 
The parallel reduction of T2 sulfation and glucuronidation in FaO cells by PCP is 
surprising, since sulfotransferases are generally regarded as high-affinity enzymes and UDP-
glucuronyltransferases as low-affinity enzymes. These findings suggest that a common step 
preceding sulfation and glucuronidation of T2 in FaO cells is inhibited, such as transport of 
T2 across the cell membrane. However, in the presence of PCP accumulation of non-conjugated 
T2 was observed in both FaO cells and HepG2 cells (not shown), suggesting direct inhibition 
of the conjugating enzymes and not inhibition of cellular uptake of T2. 
Further studies in our laboratory are aimed at determining in vivo effects of PCB-OH 
exposure on fetal thyroid hormone metabolism including sulfation and the potential 
toxicological impact for the developing animal. 
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CHAPTER 8 
EFFECT OF PRENATAL EXPOSURE TO 
PENTACHLOROPHENOL OR AROCLOR 1254 ON MATERNAL 
AND FETAL THYROID HORMONE METABOLISM, 
ESPECIALLY SULFATION, IN WISTAR RATS 
Abstract 
Polyhalogenated aromatic hydrocarbons (PHAHs) are known to interfere with several aspects 
of thyroid hormone metabolism. Recently, the inhibition of thyroid hormone sulfation by 
hydroxylated PHAH metabolites was demonstrated in vitro. The present study was undertaken 
to investigate whether PCB metabolites are also able to inhibit thyroid hormone sulfation in 
vivo. Pregnant Wistar rats were exposed to Aroclor 1254, to the well-known phenol 
sulfotransferase (SULT) inhibitor pentachlorophenol (PCP), or to corn oil (vehicle) from day 
10 of gestation (GD10) until GDI 8. Dams and fetuses were sacrificed on GD20, and maternal 
and fetal blood, liver and brain were collected. Thyroid hormone and thyroxine sulfate (T4S) 
levels were measured in serum; T4 UDP-glucuronyltransferase (UGT), type I deiodinase (Dl) 
and 3,3'-iodothyronine (3,3'-T2) SULT activities were analysed in liver; and type II deiodinase 
(D2) and 3,3'-T2 SULT activities were analysed in brain. 
Aroclor 1254 exposure resulted in decreased total T4 (TT4) and free T4 (FT4) levels 
in dams as well as fetuses. Treatment with PCP resulted in a decrease in serum TT4 but an 
increase in serum FT4 in dams and fetuses. The FT4/TT4 ratio was increased after both 
treatments. Fetal T4S levels were very low in contrast to previously reported high levels in fetal 
serum ofhuman and sheep. Treatment with PCP or Aroclor 1254 did not significantly change 
the T4S levels in both dams and fetuses. In maternal and fetal brain, 3,3'-T2 SULT activity was 
not affected after treatment with Aroclor 1254 or PCP. Maternal and fetal liver 3,3'-T2 SULT 
activity was not affected as well by Aroclor 1254. However, PCP caused an increase in 3,3'-T2 
SULT activity in maternal liver and a decrease in fetal liver. Further data showed an induction 
of hepatic T4 UGT activity in dams after treatment with Aroclor 1254, but not with PCP. Dl 
activity was low in fetal versus maternal liver, and was decreased in both dams and fetuses after 
treatment with Aroclor 1254 and PCP. Brain D2 activity was increased in both dams and fetuses 
after exposure to Aroclor 1254. 
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In conclusion, perinatal exposure to PCP resulted in placental transfer of PCP to fetal 
rat tissues. Thyroid hormone levels and metabolism were affected after PCP exposure. The 
effect of PCP and Aroclor 1254 on thyroid hormone sulfation was not clear, and will be 
dependent on the in situ balance between the concentrations of substrate thyroid hormone, the 
enzyme sulfotransferase and the competitive inhibitor PCP/PCB-OH. Administration of PCP 
or Aroclor 1254, overall did not result in a decrease in fetal serum T4S levels, perhaps because 
degradation of T4S by hepatic D1 is simultaneously decreased. Moreover, in fetal rats, sulfation 
seems to play a less important role in the metabolism of thyroid hormone than in fetal humans 
or sheep, considering the low T4S levels in fetal serum. 
based on A. Gerlienke Schuur, Peter H. Cenijn, Maria A. W. Faassen-Peters, Dennis C. Morse, 
Hans van Toor, Ake Bergman, Eva Klasson-Wehler, Peter J. van Bladeren, Theo J. Visser, and 
Abraham Brouwer (1998). Effect of prenatal exposure to pentachlorophenol or Aroclor 1254 
on maternal and fetal thyroid hormone metabolism, especially sulfation, in Wistar rat. 
submitted. 
Introduction 
PCBs and related compounds are known to interfere with thyroid hormone metabolism 
(Brouwer et al., 1998). Exposure of laboratory animals to PCBs results in increased hepatic 
UGT activity and, consequently, decreased serum TT4 levels (e.g. Beetstra et al., 1991). 
Hydroxylated metabolites of PCBs and related compounds compete with thyroid hormones 
for binding to different thyroid hormone-binding proteins such as TTR (Lans et al, 1993; 
1994), Dl (Adams et al, 1990; Lans, 1995) and phenol sulfotransferases. Inhibition of thyroid 
hormone sulfation in vitro was studied using 3,3'-T2 as a substrate and rat liver cytosol as 
enzyme source (Schuur et al, 1998b; Chapter 5). More recently, inhibition of 3,3'-T2 sulfation 
by 4-hydroxy-2',3,3',4',5-pentachlorobiphenyl (4-OH-PeCB) as well as by PCP was also 
demonstrated in a rat and a human hepatoma cell line (Schuur et al, 1998d; Chapter 7). 
In adult rats, thyroid hormone sulfation is considered an irreversible inactivation 
pathway. Not only does sulfation impair the binding of the active hormone T3 to the T3 
receptor, it also accelerates the inner ring deiodination of T3 and its precursor T4 by hepatic 
Dl to inactive 3,3'-T2 and rT3, respectively. It has been suggested that sulfation is a reversible 
inactivation pathway in the fetal situation, when D1 activity is low (Santini et al., 1992a; Visser 
et al, 1994b). In this respect, T3 sulfate (T3S) is regarded as a reservoir of inactive hormone 
from which active T3 may be recovered by action of sulfatases in tissues where hormone action 
is required. 
It has been demonstrated before that prenatal exposure to Aroclor 1254, a mixture of 
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PCBs, results in the accumulation of PCB metabolites in fetal tissues (Morse et al., 1996). The 
aim of this study is to investigate if thyroid hormone sulfation in the fetus is inhibited by these 
PCB metabolites. This hypothesis was tested by exposing pregnant Wistar rats to Aroclor 1254 
from day 10 to day 18 of gestation. The well-known in vitro and in vivo phenol SULT inhibitor 
PCP (Duffel and Jakoby, 1981; Meerman et al., 1983) was used in the same study as a positive 
control, although it has never been tested as SULT inhibitor in the fetal situation. Serum T4S 
and T3S levels were determined as well as iodothyronine SULT activities in fetal and maternal 
liver using 3,3'-T2 as the preferred substrate (Visser et al, 1998a). The possible effect of the 
inhibition of iodothyronine SULT activity on thyroid hormone levels was studied by 
measurement of fetal serum T4, T3 and rT3 concentrations. In addition, hepatic Dl and T4 
UGT activities, and brain D2 activities were determined in maternal and fetal tissues. Moreover, 
the amounts of PCP and 4-OH-PeCB were analysed in pooled maternal and fetal blood and 
tissues. 
Materials and methods 
Chemicals 
PCP (99% pure) was obtained from Riedel-de Haen AG (Seelze, Germany), and Aroclor 1254 
was kindly donated by Dr. M. Van den Berg (Ritox, University of Utrecht, Utrecht, The 
Netherlands). T4, T3, rT3, DTT, UDPGA, PTU, PAPS and bovine serum albumin (BSA) were 
obtained from Sigma Chemicals Co. (St. Louis, MO, USA); resorufin from Janssen Chimica 
(Tilburg, The Netherlands); NADPH from Boehringer Mannheim GmbH (Mannheim, 
Germany) and Bio-Rad protein reagent from Bio-Rad Laboratories (Richmond, Ca, USA). 
[125I]T4, [,25I]T3 and [l25I]rT3 were obtained from Amersham (Buckinghamshire, UK); they 
were purified on Sephadex LH-20 (Pharmacia, Woerden, The Netherlands) before each assay. 
3,3'-T2 and 3-iodothyronine (3-T1) were obtained from Henning (Berlin, Germany). I25I-
labelled 3,3'-T2 was produced by radioiodination of 3-T1 as described before (Visser et al., 
1978). All other chemicals were of analytical grade. 
Animals and treatment 
Wistar WU rats (14 weeks old) were purchased from Charles River (Sulzfeld, Germany). The 
rats were allowed to acclimatize for 2 weeks and were maintained at 50% humidity and 21°C 
on bedding in plastic cages with a 12-light/12-h dark cycle. Rat chow (Hope Farms, Woerden, 
The Netherlands) and tap water were supplied ad libitum. After the acclimatization period 
breeding was started by placing two females in a cage with one male overnight. The females 
were examined each morning by vaginal smear. When spermatozoa were found, the animal 
was housed separately, and this was termed day 0 of gestation (GDO). Animals were assigned 
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at random to the different treatment groups. Maternal body weight was monitored daily 
throughout gestation. On GD10 the pregnant rats were transferred to a macrolon cage with a 
grated steel support to facilitate the collection of PCB and PCP-contaminated feces. Pregnant 
females were untreated or received a daily oral dose of corn oil (vehicle), 25 mg Aroclor 1254 
or 30 mg PCP per kg body weight in corn oil (2 ml/kg body weight) from GD10 until GD18. 
On GD20, rats were sacrificed under ether anesthesia, and maternal blood was 
collected from the vena cava. Maternal brains and livers as well as fetuses were isolated and 
weighed. Fetal blood was collected by decapitation, and the fetal livers and brains were isolated, 
weighed and frozen on dry ice. Fetal blood was pooled per mother and serum was prepared for 
thyroid hormone analysis. Pooled fetal liver and brain tissues as well as maternal liver and brain 
tissues were stored at -80°C. Serum was stored at -20°C until analysis. All procedures were 
approved by the Animal Welfare Committee of the Agricultural University Wageningen. 
Tissue preparation 
Livers and brains were homogenized, and cytosol and microsomes were prepared as described 
before (Schuur et al., 1997; Chapter 2). Protein levels of tissue fractions were determined using 
the Bio-Rad protein reagent (Bradford, 1976) and BSA as a standard. 
Thyroid hormone analysis 
Serum TT4, TT3 and FT4 were analysed using the Amerlite chemiluminescence kits (Amerlite, 
Amersham, Buckinghamshire, UK) according to the protocol of the supplier with the following 
modifications: the TT4 and TT3 assay buffer were diluted five times with demineralized water; 
the standard curve for TT4 ranged from 0 to 120 nmol TT4/1. Serum rT3 was measured by 
specific RIA as described before (Eelkman Rooda et al, 1989). Plasma T4S and T3S were 
determined by specific RIAs using antisera kindly donated by Dr. Sing-Yung Wu (Veterans 
Affairs Medical Center, Long Beach, CA, USA) essentially as described by Wu et al. (1995). 
Analysis of PCP and 4-OH-PeCB in serum, liver and brain 
Serum from a PCP-treated dam and serum from an Aroclor 1254-treated dam and its fetuses 
were used for the analysis. In addition, 3 pooled samples of brain and liver tissues from all PCP 
treated dams and their fetuses were used for the analysis. The method used will be described 
in detail elsewhere (Hovander et al, 1998). In brief, serum samples (±5 g) were denaturated 
by HC1 and 2-propanol after which the compounds were extracted with hexane :methyl-tert-
butyl ether. The extract was separated into phenol and neutral compounds, by partitioning 
between KOH (0.5 M in 50% ethanol) and hexane. The phenolic compounds were derivatized 
with diazaomethane prior to a lipid removal step. The extract was dissolved in hexane and 
lipids were removed by partitioning with sulphuric acid. Analysis was performed by GC (ECD) 
(Bergman etal, 1994). 
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Enzyme assays 
Ethoxyresorufin O-deethylase (EROD) activity. EROD activity was measured according to the 
method of Burke et al. (1977) adapted for use with 96-well plates and a fluoro-
spectrophotometric plate reader (Cytofluor 2350, Millipore) (Schuur et al, 1998a; Chapter 3). 
T4 UGTactivity. Hepatic T4 UGT activity was determined essentially according to Beetstra 
et al. (1991). Microsomes (1 mg/ml) were incubated for 30 min at 37°C with 1 uM (50,000 
cpm) [125I]T4 in the presence or absence (blank) of 5 mM UDPGA in 200 ul 75 mM Tris-HCl 
(pH 7.8), containing 3.75 mM MgCl2 and 0.1 mM PTU. Reactions were stopped by the addition 
of 0.2 ml ice-cold methanol. After centrifugation, 0.2 ml supernatant was mixed with 0.75 ml 
0.1 M HC1 and analyzed for glucuronide formation on Sephadex LH-20 minicolumns (Beetstra 
etal, 1991). 
Dl activity. Hepatic Dl activity was determined as previously described (Mol and Visser, 
1985). Shortly, microsomes (20 ug protein/ml) were incubated for 30 min at 37°C with 1 uM 
(100,000 cpm) [125I]rT3 in 0.1 M phosphate buffer (pH 7.2), containing 2 mM EDTA and 5 
mM DTT. The reaction was stopped on ice by the addition of 750 ul 0.1 M HC1. The tubes 
were centrifuged and radioiodide was determined in the supernatant by Sephadex LH-20 
chromatography as described before (Rutgers etal, 1989). 
D2 activity. Brain D2 activity was measured essentially as described by Visser et al. (1982) 
with slight modifications as described in Morse et al (1993). The final incubation conditions 
were 100 mM phosphate buffer (pH 7.2), 25 mM DTT, 1 mM PTU, 1 mM EDTA, 2 nM 
(50,000 cpm) [125I]T4,0.5 uM T3 and brain homogenate (0.8 mg protein/ml) in a total volume 
of 200 ul. Incubations were carried out at 37°C for 60 min. The reaction was stopped on ice 
by the addition of 100 ul BSA (70 mg/ml), followed by 500 ul trichloroacetic acid (10% w/v). 
The tubes were then centrifuged and the radioiodide released was further isolated from the 
supernatant by LH-20 chromatography. 
SULTactivity. Iodothyronine SULT activity was determined using 3,[3'-125I]T2 as described 
by Kaptein et al (1997). In short, cytosol was incubated for 30 min at 37 °C with 1 uM (80,000 
cpm) 3,[3'-125I]T2 and 50 uM PAPS in 200 ul 75 mM Tris-HCl (pH 7.2) and 1.5 mM EDTA. 
The reaction was stopped on ice by addition of 750 ul 0.1 M HC1. The labelled 3,3'-T2S 
generated was isolated on Sephadex LH-20 minicolumns (Kaptein et al, 1997) and counted 
for radioactivity. The cytosolic protein concentrations were 12.5,25 and 50 ug/ml for maternal 
liver, 100 ug/ml for fetal liver, 50 ug/ml for maternal brain, and 100 ug/ml for fetal brain. 
Statistics 
Treatment-related effects were evaluated by one-way analysis of variance followed by a least 
significant difference test using the SPSS statistical software package. Data are presented as 
the means ± SEM. 
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Results 
Very similar data were obtained in untreated and corn oil (vehicle)-injected controls. In the 
following section, findings in animals exposed to Aroclor 1254 or PCP are compared with those 
obtained in corn oil-treated animals. 
Body and organ weights 
All body and organ weights of dams on GD20 are presented in Table 8.1. Maternal body 
weights were decreased significantly by about 10% after treatment with PCP, but no change 
was observed with Aroclor 1254. Treatment of dams with Aroclor 1254 resulted in significantly 
higher absolute and relative liver weights. PCP treatment caused only an increase in relative 
liver weights in dams. Absolute, but not relative, brain weights were decreased in PCP-treated 
dams. Placenta weight was decreased by both Aroclor 1254 and PCP. 
Treatment-related effects were also found on body and organ weights of fetuses (Table 
8.2). Body weights of fetuses were significantly decreased by 22% after maternal exposure to 
PCP, but not after Aroclor 1254 treatment. PCP treatment also caused a significant decrease 
in absolute brain weights and absolute liver weights, a significant increase in relative brain 
weights, but had no statistically significant effect on relative liver weights. Exposure of dams 
to Aroclor 1254 on the other hand resulted in an increase in relative liver weights in the fetuses. 
Effects of treatment of dams from GD10 until GDI 8 with Aroclor 1254 or PCP on 
the progeny are shown in Table 8.3. The number of implantations and resorptions were not 
significantly affected by either Aroclor 1254 or PCP treatment. One of nine PCP-treated dams 
was found to have total (12) resorptions. No visible malformations were detected in the fetuses 
at autopsy. 
Serum and tissue PCP, PCB and 4-OH-PeCB levels 
In order to have an estimation of the concentration of compound transferred from the dam to 
the fetus, GC analyses were performed on single serum and pooled tissue samples. For the 
Aroclor 1254-treated rats, data were already obtained in an earlier study performed under 
almost the same conditions. Therefore, only serum samples were analysed to confirm the 
previous findings (Morse et al, 1996). As in the previous study, 4-OH-2,3,5,3',4'-
pentachlorobipheynyl (4-OH-PeCB) was the dominating metabolite and the levels were 1155 
and 800 ng/g fresh weight in fetal and maternal serum, respectively. The concentration of 4-
OH-PeCB was higher in fetal serum compared with maternal serum, which confirms the earlier 
finding of high placental transfer of these phenolic metabolites of PCBs (Morse et al., 1996). 
In PCP-treated dams, high concentrations of PCP were found in serum (7100 ng/g 
fresh weight), liver (221 ng/g lipid) and brain (11 ng/g lipid). The liver PCP concentration in 
fetuses (210 ng/g lipid) was almost equal to that in the treated dam, indicating considerable 
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transplacental transfer. The PCP concentrations in fetal brain even exceeded the maternal brain 
levels by almost 4-fold (40 ng/g lipid). 
Serum thyroid hormones 
Maternal serum levels. Serum thyroid hormone and T4S concentrations are presented in Figures 
8.1-8.3. Maternal TT4 serum levels were significantly decreased after treatment with Aroclor 
1254 and PCP by 73% and 30%, respectively (Figure 8.1 A). Serum FT4 levels in dams were 
also significantly decreased by 29% after exposure to Aroclor 1254 (Figure 8.IB). PCP 
exposure, however, caused a significant increase in FT4 levels by 30%. Maternal TT3 levels 
(Figure 8.2A) were not changed by either Aroclor 1254 or PCP. Serum levels of rT3 in dams 
were significantly decreased by 52% after exposure to Aroclor 1254 (Figure 8.2B). Treatment 
with PCP, however, resulted in a large increase in rT3 serum levels to 326% of controls. Serum 
levels of T4S were very low in control dams, and even somewhat lower, although not 
significantly, in Aroclor 1254-treated animals (Figure 8.3). In PCP-treated dams the T4S levels 
were slightly but not significantly higher than in control dams, whereas the T4S/FT4 ratio was 
not changed. 
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Figure 8.2 Serum total T3 
(A) and rT3 (B) levels in 
dams and fetuses following 
prenatal exposure to 
Aroclor 1254 or PCP from 
GD10 to 18. Results are 
presented as mean ± SEM. 
*) denotes a significant 
difference (p<0.05) with 
the corn oil (vehicle 
control) group. 
Fetal serum levels. Fetal serum TT4 levels were dramatically decreased by treatment with 
Aroclor 1254 and PCP to 15% and 22% of control, respectively (Figure 8.1 A). Fetal FT4 serum 
levels were decreased by 17% after exposure to Aroclor 1254, whereas PCP treatment had no 
effect (Figure 8.IB). T3 levels in fetal serum were undetectable (<0.15 nmol/1). Serum rT3 
levels were reduced to 28% of control after exposure to Aroclor 1254, whereas PCP treatment 
had no effect (Figure 8.2B). Serum T4S levels were very low in control fetuses and unaffected 
by treatment with Aroclor 1254 or PCP (Figure 8.3). T3S levels were found to be even lower 
than T4S levels in pooled serum samples from untreated fetuses (not shown). 
Figure 8.3 Serum T4S 
levels in dams and fetuses 
following prenatal exposure 
to Aroclor 1254 or PCP 
from GD10 to 18. Results 
are presented as mean ± 
SEM. *) denotes a 
significant difference 
(p<0.05) with the corn oil 
PCP (vehicle control) group. 
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Enzyme activities 
Hepatic EROD and T4 UGT activities. Maternal exposure to Aroclor 1254 resulted in an 200-
fold induction of EROD activity in maternal liver and a 5-fold induction in fetal liver (Figure 
8.4A). PCP treatment did not affect maternal or fetal EROD activity. 
T4 UGT activity in maternal liver was induced about 4 times by Aroclor 1254 but T4 
UGT activity in fetal liver was not affected (Figure 8.4B). PCP treatment did not affect the T4 
UGT activity in maternal or fetal liver. 
Figure 8.4 Hepatic 
EROD (A) and T4 UGT 
(B) activities in dams and 
fetuses following prenatal 
exposure to Aroclor 1254 
or PCP from GD10 to 18. 
Data are presented as mean 
± SEM. *) denotes a 
significant difference 
(p<0.05) with the corn oil 
(vehicle control) group. 
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Deiodinase activities. Maternal hepatic Dl activity was significantly decreased by 56% after 
Aroclor 1254 treatment (Figure 8.5 A). Exposure to PCP caused a slight but significant decrease 
in Dl activity in maternal liver. Dl activity was also decreased in fetal liver after maternal 
exposure to Aroclor 1254 or PCP. 
Maternal brain D2 activity was slightly (but not significant) increased in Aroclor 1254-
exposed rats (Figure 8.5B). PCP treatment, however, resulted in a significant 58% decrease 
in maternal D2 activity. In fetal brain, Aroclor 1254 treatment caused a significant 62% 
increase, whereas PCP exposure resulted in a slight and non-significant decrease in D2 activity. 
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Figure 8.5 Hepatic Dl 
activity (A) and brain D2 
activity (B) in dams and 
fetuses following prenatal 
exposure to Aroclor 1254 
or PCP from GDI0 to 18. 
Results are presented as 
mean ± SEM. *) denotes a 
significant difference 
(p<0.05) with the corn oil 
group. 
SULTactivities. Figure 8.6 shows the 3,3'-T2 SULT activities in fetal and maternal liver. In 
maternal liver, treatment with the SULT inhibitor PCP caused a significant increase in 3,3'-T2 
SULT activity, whereas Aroclor 1254 had no effect. In fetal liver, PCP treatment resulted in 
lower 3,3'-T2 SULT activities, whereas Aroclor 1254 treatment showed no effect. In maternal 
brain, 3,3'-T2 SULT activity was higher after PCP treatment and unchanged after Aroclor 1254 
treatment. SULT activities in fetal brain were not affected by Aroclor 1254 or PCP exposure. 
Figure 8.7A shows the 3,3'-T2 SULT activity in pooled (equally from all samples) fetal 
liver cytosol (final protein concentration 100 ug/ml) as a function of the substrate concentration 
(0.1-10 uM). Exposure to PCP or Aroclor 1254 resulted in lower SULT activities at most 3,3'-
T2 concentrations used. Figure 8.7B shows the 3,3'-T2 SULT activities in maternal liver as a 
function of the cytosolic protein concentration (12.5-50 ug/ml). In control liver cytosol, the 
3,3'-T2 sulfation rate decreases on dilution of the protein concentration. However, in liver from 
PCP-exposed dams, 3,3'-T2 sulfation did not decrease with the cytosol concentration, 
suggesting that the effect of the competitive inhibitor PCP is diluted out, and PCP treatment 
may have resulted in an increased enzyme concentration. 
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Figure 8.6 Hepatic (A) 
and brain (B) 3,3'-T2 SULT 
activity in dams and fetuses 
following prenatal exposure 
to Aroclor 1254 or PCP 
from GD10 to 18. The 
cytosol ic protein 
concentrations were 25 
ug/ml for maternal liver, 
100 ug/ml for fetal liver, 
maternal brain, and fetal 
brain. Results are presented 
as mean ± SEM. *) denotes 
a significant difference 
(p<0.05) with the corn oil 
group. 
B. 
maternal 
I icorn oil Y///A Aroclor PCP 
Figure 8.7 Hepatic 3,3'-
T2 SULT activity in fetuses 
(A) and dams (B) following 
prenatal exposure to PCP or 
Aroclor 1254 from GD10 
to 18. Activities were 
measured in duplicate using 
pooled fetal liver samples 
(100 ug protein/ml) and a 
concentration series of the 
3,3'-T2 substrate (A). 
Maternal liver cytosol 
samples (N=8-9) were used 
in different cytosolic 
protein concentrations and 
1 uM 3,3'-T2. Results are 
presented as means ± SEM. 
*) denotes a significant 
difference (p<0.05) with 
the corn oil group. 
cytosolic protein (ug/ml) 
I born oil V77\ Aroclor KXXl PCP 
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Discussion 
Sulfation is an important metabolic pathway for the elimination of thyroid hormone in the adult 
rat. However in fetal rats, sulfation is suggested to play an important role in the regulation of 
T4 and T3 levels, which may be recovered by desulfation of T4S and T3S by sulfatases (Santini 
et al., 1992a; Spaulding et al, 1992). Recently, we have demonstrated that hydroxylated 
metabolites of PCBs as well as PCP are potent inhibitors of 3,3'-T2 sulfation in vitro (Schuur 
et al, 1998b; Chapter 5). Moreover, perinatal exposure to PCBs results in neurodevelopmental 
changes in the offspring (reviewed by Tilson et al., 1990; Brouwer et al., 1995; Jacobsonand 
Jacobson, 1997). Taken together, the possible inhibition of thyroid hormone sulfation may be 
a probable mechanism for PCBs to disrupt thyroid hormone. 
Thus, the major aim of this study was to investigate the potential impact of prenatal 
exposure to Aroclor 1254 or PCP on the thyroid hormone metabolism of both dams and fetuses, 
with special emphasis on the sulfation of thyroid hormone. This discussion is divided into 3 
parts, starting with some general aspects of the animal experiment, followed by a summary of 
effects of PCBs on thyroid hormone metabolism and levels. Finally, the effect of the well-know 
phenol sulfation inhibitor PCP on in vivo thyroid hormone sulfation is discussed, and compared 
to the effect of Aroclor treatment. Finally, the discussion is concluded with some remarks on 
the importance of these effects. 
Overall, no gross toxic effects were observed neither in dams nor in fetuses following Aroclor 
1254 exposure. PCP treatment produced some mild toxic effects, such as a slightly reduced 
maternal body weight and brain weight, and a non-statistically significant increase in fetal 
death. Induction of liver weight was observed in dams both after Aroclor 1254 and PCP 
treatment. EROD activity, a well-known marker of Ah receptor-mediated responses (Safe, 
1994) was highly induced in maternal and fetal liver, whereas no effects were observed with 
PCP. The induction of EROD activity in fetal liver after maternal exposure to PCBs has been 
reported before (Morse et al., 1996). 
Our findings indicate a high placental transfer of both PCP and 4-OH-PeCB. The PCP 
concentration in fetal liver was almost equal to that in maternal liver. More striking is the 4-fold 
higher concentration of PCP in fetal brain compared with maternal brain. 4-OH-PeCB has 
previously been identified as one of the major metabolites retained in blood after exposure to 
Aroclor 1254 and was also found to accumulate in fetal brain tissue (Morse et al., 1996). The 
higher 4-OH-PeCB concentration in fetal than in maternal serum is also in keeping with the 
latter study. Other reports have also demonstrated that hydroxylated PCB metabolites 
accumulate in the fetal rat after maternal exposure to 4-chlorobiphenyl (Lucier et al., 1978) 
or 3,3',4,4'-tetrachlorobiphenyl (Darnerud et al, 1996; Morse et al., 1995). 
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Thyroid hormone metabolism and levels are affected by treatment with PCBs in different ways 
as shown in Figure 8.8. The reduction of maternal serum TT4 and FT4 levels by Aroclor 1254 
treatment are in agreement with previous studies (Bastomsky, 1974; Gray et al, 1993; Byrne 
et al, 1987; Brouwer, 1989; Beetstra et al, 1991). These changes are most likely caused by 
an increased hepatic T4 glucuronidation as well as competitive inhibition of T4 binding to TTR 
by hydroxylated PCB metabolites (Rickenbacher et al, 1986; Lans et al, 1993; 1994: Lans, 
1995). The reduction of fetal serum TT4 by Aroclor 1254 treatment is also in line with earlier 
observations by Morse et al. (1996). High serum levels of the hydroxylated PCB metabolite 
4-OH-PeCB were detected in this and the previous study (Morse et al, 1996). Decreased 
maternal supply of T4, as well as competitive inhibition of T4 binding to fetal TTR by 4-OH-
PeCB, may contribute to the low fetal serum T4 levels. Fetal hepatic T4 glucuronidation was 
not induced in Aroclor 1254-exposed animals. 
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Figure 8.8 Overview of the interaction sites of PHAHs and their metabolites with the 
thyroid hormone metabolism. The vertical arrows indicate the effects of PHAHs on the 
serum levels or hepatic enzyme activities. 
PCP treatment also decreased T4 levels in damsand fetuses, probably due to inhibition of T4 
binding to TTR (Van den Berg et al, 1991; Den Besten et al., 1991). This is supported by the 
even higher FT4 levels in maternal serum after exposure to PCP. T4 glucuronidation was not 
changed by PCP in both dams and fetuses and, therefore, does not play a role in decreasing 
serum T4 levels. PCP is probably transported by TTR to the fetal compartment, where it also 
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serum T4 levels. PCP is probably transported by TTR to the fetal compartment, where it also 
causes a decrease in TT4 without changing the serum FT4. Jekat et al. (1994) reported on 
decreased serum T4 and T3, accompanied by decreased FT4 and FT3 levels. TSH was 
unexpectedly decreased, suggesting an interference of PCP at pituitary or hypothalamic levels, 
which was supported by reduced intrathyroidal hormone stores. 
The decreases in hepatic Dl activity in both dams and fetuses by Aroclor 1254 or PCP 
treatment may be due to direct inhibition of Dl by hydroxylated PCB metabolites (Adams et 
al, 1990; Rickenbacher et al, 1989; Lans, 1995) and PCP. Hepatic Dl activity has also been 
shown to be reduced after treatment with 3,3',4,4'-tetrachlorobiphenyl (Adams et al, 1990; 
Visser et al., 1993a) or with the Ah-receptor agonists 3-methylcholanthrene and TCDD (Visser 
et al, 1993; Raasmaja et al, 1996). However, other studies involving treatment with Aroclor 
1254 (Lans, 1995) or TCDD (Schuur et al, 1997; Chapter 2) have shown no effect on hepatic 
Dl activity in adult rats. Treatment of adult male rats with hexachlorobenzene, resulting in high 
PCP levels, also decreases hepatic Dl activity (Van Raaij et al, 1993). In addition to the 
inhibition of Dl activity by the administered PHAHs or their metabolites, Dl expression may 
also be decreased by the hypothyroid state possibly induced by these chemicals (Visser et al, 
1993a). 
Reduction of Dl activity usually results in increased serum rT3 levels (e.g. Eelkman 
Rooda et al, 1989). Indeed, PCP treatment resulted in highly increased maternal serum rT3 
levels, which may be explained by the decrease in hepatic Dl activity in combination with the 
increased FT4 (precursor) concentration. However, Aroclor 1254 treatment resulted in 
decreased rT3 concentrations in both fetal and maternal serum despite the decrease in hepatic 
Dl activity, which may in part be due to the decrease in FT4 levels. 
Brain D2 activity is under negative control of serum T4 which is thought to be an 
adaptative response to maintain T3 levels in brain constant when thyroid function changes 
(Silva and Matthews, 1984; Ruiz de Ona et al, 1988; Obregon et al, 1991). D2 activity in 
maternal and fetal brain was significantly increased after treatment with Aroclor 1254, which 
is explained by the decreased serum FT4 levels. Such increased brain D2 activities were 
reported before in adult rats after treatment with TCDD (Lans, 1995) and in fetal and neonatal 
rats after treatment with 3,3',4,4',5,5'-hexachlorobiphenyl (Morse et al, 1993) and Aroclor 1254 
(Morse et al, 1996). In fact, despite the dramatic reduction in brain T4 levels, the T3 levels 
in fetal brain remained unaffected, supporting an increased conversion of T4 into T3 by D2 
(Morse et al, 1996). PCP treatment significantly reduced D2 activity in maternal brain in 
agreement with the increase in serum FT4 concentration. 
The well-known sulfation inhibitor PCP was included in this animal experiment as a positive 
control. Remarkably, PCP treatment resulted in significantly higher 3,3'-T2 SULT activities 
in maternal liver at low but not at high cytosol concentrations. The results suggest that PCP 
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not only competitively inhibits 3,3'-T2 SULT activity but also increases the hepatic expression 
of 3,3'-T2 SULT(s), probably indirectly. Using almost similar concentrations of PCP compared 
with our study, Meerman et al. (1983) were able to lower the amount of harmol sulfates formed, 
using ex vivo techniques. Singer et al. (1984) reported on increased hepatic sulfotransferase 
activity after treatment with PCP. Extrapolating our results obtained with 1 uM 3,3'-T2 and 
different cytosolic protein concentrations to the in situ conditions with undiluted cytosol, these 
opposing effects may result in a net reduction in iodothyronine sulfation in the liver of PCP-
treated dams in vivo. In the fetal liver, PCP treatment caused a clear inhibition of the 3,3'-T2 
SULT activity, demonstrated best in the pooled samples using a range of substrate 
concentrations. The different effects of PCP treatment on 3,3'-T2 SULT activity in maternal 
and fetal liver is in agreement with the higher cytosolic protein concentration (and thus higher 
PCP concentration) required to assay fetal liver SULT activity. This is in agreement with the 
concentration of PCP detected in fetal and maternal liver, which was about the same per ng 
lipid,with lower lipid levels in fetal liver. In fetal brain, no effect of PCP on 3,3'-T2 SULT 
activity was shown under the in vitro assay conditions used. 
Aroclor 1254 treatment did not affect 3,3'-T2 SULT activity in maternal liver and 
brain. In the fetal liver, Aroclor 1254 treatment caused a clear inhibition of the 3,3'-T2 SULT 
activity, demonstrated best in the pooled samples using a range of substrate concentrations. 
In fetal brain, no effect of Aroclor 1254 on 3,3'-T2 SULT activity was shown under the in vitro 
assay conditions used. 
Inhibition of fetal hepatic iodothyronine SULT activity by maternal exposure to Aroclor 1254 
or PCP did not result in a decrease in fetal serum T4S levels, even though serum FT4 was also 
decreased in Aroclor 1254-treated animals. A possible explanation for this is that the clearance 
of T4S is simultaneously decreased by inhibition of fetal hepatic Dl activity. Although the 
regulation of thyroid hormone bioactivity is directly affected by the reversible 
sulfation/desulfation of T3, we did not attempt to analyze the effects of SULT inhibitors on 
fetal serum T3S, since we found that T3S levels in untreated fetal rats are even lower than T4S 
levels. 
These low iodothyronine sulfate levels are in contrast to the high levels found in fetal 
human and sheep serum (Wu et al, 1992a; 1992b; 1993a; 1993b; Santini et al, 1993). They 
cannot be explained by low hepatic iodothyronine SULT activity or high hepatic Dl activity, 
which catalyzes the breakdown of T4S and T3S, in the 20-day old rat fetus. In our study and 
that of Hurd et al. (1993), it was shown that fetal hepatic 3,3'-T2 or T3 SULT activities are 
about half the activities in maternal liver on GD20. Since SULT1C1 is only expressed in adult 
male liver (Dunn and Klaassen, 1996; Liu and Klaassen, 1996), the isoenzyme responsible for 
iodothyronine sulfation in fetal liver may be SULT1B1, but this remains to be demonstrated. 
Iodothyronine SULT activity in fetal brain is 6-10 times lower than in maternal brain (Hurd 
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et al., 1993; this study). Fetal hepatic Dl activity has been reported to be very low during fetal 
life, starting to increase only at GD20 (Harris et al., 1978; Ruiz de Ona et al, 1991). We indeed 
found that Dl activity on GD20 was still 20 times lower in fetal than in maternal liver. 
Sulfation of iodothyronines in adult male rat liver is catalyzed by both SULT1B1 and 
SULT1C1 isoenzymes (Yamazoe etal, 1994; Sakakibara et al., 1995; Visser etal, 1998a). 
SULT1B1 is equally expressed in male and female liver (Yamazoe et al., 1994; Sakakibara 
et al., 1995), whereas SULT1C1 is not expressed in female liver (Nagata et al, 1993; Dunn 
and Klaassen, 1996; Liu and Klaassen, 1996). Therefore, SULT1B1 is the only isoenzyme 
known to be involved in the sulfation of iodothyronines in female liver. Neither SULT1B1 nor 
SULT1C1 is expressed in rat brain (Sakakibara et al, 1995; Dunn and Klaassen, 1996). 
Therefore, the isoenzyme(s) responsible for thyroid hormone sulfation in rat brain is (are) 
unknown. We previously showed similar patterns for the inhibition of 3,3'-T2 sulfation by four 
hydroxylated PCB metabolites in male rat liver cytosol, female rat liver cytosol and 
recombinant rat SULT1C1 (Schuur et al, 1998c; Chapter 6). However, it was demonstrated 
that 3-hydroxy-2,3',4,4',5-pentachlorobiphenyl was much less potent in inhibiting 3,3'-T2 SULT 
activity in rat brain than in male or female rat liver cytosol or SULT1C1. These results are 
explained by the above findings that the SULT isoenzyme(s) involved in the sulfation of thyroid 
hormone in brain differ(s) from those (SULT1B1 and SULT1C1) catalyzing the sulfation of 
iodothyronines in rat liver. 
In conclusion, perinatal exposure to PCP resulted in placental transfer of PCP to fetal rat 
tissues. Thyroid hormone levels and metabolism were affected after PCP exposure, including 
decreased FT4 and TT4 levels in dams and fetuses, decreased fetal and maternal Dl activity, 
and decreased maternal D2 activity. The effect of PCP and Aroclor 1254 on thyroid hormone 
sulfation is not unequivocal, and may be dependent on the in situ balance between the 
concentrations of substrate thyroid hormone, the enzyme sulfotransferase and the competitive 
inhibitor PCP/PCB-OH. The prenatal administration of PCP or Aroclor 1254 in this study did 
not result in a decrease in fetal serum T4S levels, perhaps because degradation of T4S by 
hepatic Dl is simultaneously decreased. Moreover, in fetal rats, sulfation seems to play a less 
important role in the metabolism of thyroid hormone than in fetal humans or sheep, considering 
the low T4S levels in fetal serum. 
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CHAPTER 9 
SUMMARY AND CONCLUDING REMARKS 
This thesis deals with the possible interactions of polyhalogenated aromatic hydrocarbons 
and/or their metabolites with thyroid hormone metabolism. This chapter summarizes firstly 
the effects of thyroid hormone on the induction of biotransformation enzymes by PHAHs. 
Secondly, the results on the inhibition of thyroid hormone sulfation by hydroxylated metabolites 
of PHAH are summarized. Some conclusions and remarks on the overall implications of the 
results are given at the end of this chapter. 
The effects of thyroid hormone on the induction of biotransformation enzymes 
by polyhalogenated aromatic hydrocarbons 
The first part of this thesis focussed on the question whether or not the PHAH-induced decrease 
of plasma T4 is an adaptive endocrine response of the animal to cope with the onset of toxic 
effects by PHAHs. For this purpose, the possible regulatory effect of thyroid hormones on 
biotransformation enzymes was investigated, using rats differing in thyroid state which were 
exposed to TCDD or PCBs as model inducers of biotransformation enzymes. 
In Chapter 2, the thyroid state of euthyroid (Eu), thyroidectomized (Tx) and Tx rats 
in which T3 or T4 levels are restored using osmotic minipumps were compared. The decreased 
circulatory levels of plasma T4 and T3, the increased pituitary feedback response (plasma TSH 
levels), as well as changed functional responses (decreased hepatic Dl and malic enzyme 
activities, and increased brain D2 activities) in Tx rats were largely restored to Eu levels in 
Tx+T4 rats and, except for plasma TT4 and brain D2 activity, in Tx+T3 rats. These results 
indicated that the thyroid hormone-replaced Tx rats were valid models to study peripheral 
effects of TCDD. Three days after exposure to 10 ug TCDD/kg body weight, plasma TT4 and 
FT4 levels were significantly reduced in Eu rats and in Tx+T4 rats, and plasma T3 was 
significantly reduced in Tx+T3 but not in Eu or Tx+T4 rats. Hepatic T4 UGT activity was 
induced by TCDD while T3 UGT activity was only slightly increased in the different exposed 
groups. These results strongly suggest that the thyroid hormone-decreasing effects of TCDD 
are predominantly extrathyroidal and mediated by the marked induction of hepatic T4 UGT 
activity. 
The effects of thyroid state modulation on the induction of detoxification enzymes 
by TCDD in experimental animals are described in Chapter 3. In all rats, TCDD largely 
induced CYP1 Al/1 A2 activity (EROD), CYP1 Al protein content, and CYP1 Al mRNA levels. 
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TCDD exposure also resulted in higher total hepatic cytochrome P450 content, hepatic p-
nitrophenol UGT activity, and GST 1-1 protein levels, but had no effect on hepatic NADPH 
cytochrome P450 reductase activity, overall GST activity and GST 2-2, 3-3, and 4-4 protein 
levels and iodothyronine sulfotransferase activity. Thyroid state did not affect the total 
cytochrome P450, and GST activity and protein levels, but slightly decreased CYP1A1/2 
activity, NADPH cytochrome P450 reductase activity, PNP UGT activity and iodothyronine 
sulfotransferase activity were demonstrated in Tx rats, as compared to Eu rats. 
In the second animal experiment, the interaction between thyroid state and PCBs in 
the regulation of CYP1 Al and CYP2B expression is described {Chapter 4). Male Tx Sprague-
Dawley rats, Eu rats, and rats made hyperthyroid by infusing T3 were treated with a single ip 
dose of the CYP2B inducer PCB 153 and the CYP1A inducer PCB 126. The thyroid states of 
the rats were confirmed by measurement of plasma T4, T3 and TSH and of functional 
parameters such as hepatic Dl activity, malic enzyme activity and a-glycerolphosphate 
dehydrogenase activity. Total hepatic cytochrome P450 content was increased by PCB 
treatment in all groups, but was not affected by thyroid state. NADPH cytochrome P450 
reductase activity was decreased in Tx rats and increased in hyperthyroid rats, while PCB 
treatment had no effect. PCB 126 specifically induced T4 UGT activity, measured in the 
absence of detergent, and CYP1A activity, protein and mRNA levels, whereas PCB 153 
induced T4 UGT activity, measured in the presence of the detergent Brij 56, and CYP2B 
activity, protein and mRNA levels. Thyroid state, neither hypo nor hyper, significantly affected 
T4 UGT activity or CYP1A and CYP2B activities, protein or mRNA levels. 
The almost complete lack of response of basal and PCB- or TCDD-induced activities 
of biotransformation enzymes to changes in thyroid state observed in our studies is in contrast 
to effects published by others (Kato and Takahashi et al., 1968; Rumbaugh et al., 1978; Leakey 
et al., 1982; Muller et al., 1983a/b; Skett, 1987; Yamazoe et al., 1989; Arlotto and Parkinson, 
1989; Murayama et al., 1991; Chowdhury et al., 1983; Moscioni and Gartner, 1983; Pennington 
et al., 1988; Goudonnet et al, 1990; Williams et al, 1986; Pimental et al, 1993). This may 
be due to differences in strain and sex of the animals, the severity and duration of the hypo-
and hyperthyroid states induced as well as the duration and dose of TCDD/PCB treatment. 
Overall, it can be concluded that hepatic NADPH cytochrome P450 reductase activity is 
dependent on thyroid state, whereas total cytochrome P450 as well as CYP1 Al and CYP2B 
together with UGT, GST and sulfotransferase activities show little or no thyroid hormone 
dependence. These slight effects are unlikely to represent an endocrine adaptation to a chemical 
stressor (TCDD). Therefore, the PHAH-induced decreased T4 levels, as well as other aspects 
of PHAH-induced alterations in thyroid hormone metabolism, are most likely a direct reflection 
of the developing toxicological response of the animals toward PHAH exposure. 
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Inhibition of thyroid hormone sulfation by hydroxylated metabolites of 
polyhalogenated aromatic hydrocarbons. 
The second part of this thesis focussed on the question whether or not hydroxylated metabolites 
of PHAHs (PHAH-OHs) are able to inhibit thyroid hormone sulfation in vitro as well as in vivo. 
Chapter 5 presents the investigations concerning the possible inhibitory effects of 
PHAH-OHs on iodothyronine sulfotransferase (SULT) activity. Rat liver cytosol was used as 
a source of sulfotransferase in an in vitro assay with l25I-labelled T2 as a model substrate. 
Hydroxylated metabolites of PCBs, PCDDs and PCDFs were found to be potent inhibitors of 
T2 SULT activity in vitro with IC50 values in the low micromolar range (0.2-3.8 uM). The 
most potent inhibitor of T2 SULT activity within our studies was the PCB metabolite 3-
hydroxy-2,3',4,4',5-pentachlorobiphenyl with an IC50 value of 0.2 uM. A hydroxyl group in 
the para or meta position appeared to be an important structural requirement for T2 SULT 
inhibition by PCB metabolites. Ortho hydroxy PCBs were much less potent and none of the 
parent PHAHs were capable of inhibiting T2 SULT activity. In addition, the formation of T2 
SULT-inhibiting metabolites from individual brominated diphenyl ethers and nitrofen as well 
as from some commercial PHAH mixtures (e.g. Bromkal, Clophen A50 and Aroclor 1254) by 
CYP450 catalyzed hydroxylation was also demonstrated. 
Consequently, the inhibition of thyroid hormone sulfation by PHAH-OHs was studied 
in more detail, investigating isozyme specificity and inhibition kinetics (Chapter 6). The 
difference in inhibition pattern demonstrated for SULT activity present in rat liver and brain 
cytosol, is probably caused by a difference in isozyme pattern. It was shown that PCB-OHs 
inhibited T2 sulfation by interacting with the rat isozyme SULT 1C1 and an additional isozyme 
responsible for T2 sulfation in female liver cytosol, probably rat SULT 1B1, but not SULT 1A1. 
On the other hand, human phenol SULT1 Al was inhibited by PCB-OHs, but not the human 
isozyme SULT1A3. In conclusion, we suggested that at least human SULT1A1, and rat 
SULT1C1 and perhaps rat SUL1B1 are involved in the inhibition of T2 sulfation by PCB-OHs. 
However, more information is needed about the various isozymes involved in iodothyronine 
sulfation in humans as well as in rats, before definite conclusions can be drawn. 
Furthermore, it is shown that T2 is a good model substrate for the active hormone T3 
when investigating the inhibition of thyroid hormone sulfation by hydroxylated metabolites 
of PHAHs. The inhibition kinetics strongly suggested that the nature of the T2 sulfation 
inhibition by PCB-OHs is competitive. To obtain more decisive information, tests with purified 
isozymes should be performed. It was also demonstrated that PCDD-OHs and PCB-OHs 
themselves are substrates -albeit poor- for SULT enzymes, which further supports the 
competitive inhibition of thyroid hormone sulfation by PHAH-OHs. 
To bridge the gap between in vitro experiments using cytosol and the in vivo situation, 
we investigated the inhibition of thyroid hormone sulfation in hepatoma cell lines (Chapter 
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7). Two PCB-OHs, 4-hydroxy-2',3,3',4,,5-pentachlorobiphenyl and 4-hydroxy-3,3',4',5-
tetrachlorobiphenyl, together with the known sulfation inhibitor pentachlorophenol (PCP) were 
tested in the rat hepatoma cell line FaO and the human hepatoma cell line HepG2. PCP 
inhibited T2 sulfation in vitro in FaO and HepG2 cells, although it was 1000 times less potent 
in whole cells than in rat liver cytosol. Micromolar concentrations of the two tested PCB-OHs 
hardly affected T2 conjugation in FaO cells, but reduced T2 sulfate formation in HepG2 cells. 
Inhibition of T2 sulfation was more pronounced using medium without FCS than in medium 
with 5% FCS, due to a lower uptake of inhibitor by the cells in the presence of serum, as 
demonstrated using radiolabeled PCP. 
These in vitro results indicate that hydroxylated PHAHs are potent inhibitors of thyroid 
hormone sulfation. Since thyroid hormone sulfation may play an important role in regulating 
"free" hormone levels in the fetus, and hydroxylated PCB metabolites are known to accumulate 
in fetal tissues after maternal exposure to PCBs, these observations in vitro might have 
implications for fetal thyroid hormone homeostasis and development. 
The in vivo experiment in which was tested if PHAH-OHs are able to inhibit T2 
sulfation, was described in Chapter 8. Pregnant rats were exposed to 25 mg Aroclor 1254/kg 
body weight or to the well-known phenol sulfation inhibitor PCP (25 mg/kg body weight) from 
day 10 till day 18 of gestation. Fetuses and dams were sacrificed on gestation day 20 (GD20). 
PCP and PCB metabolite levels in fetal serum and tissues were high. Aroclor 1254, but not 
PCP exposure resulted in an induction of hepatic EROD and T4 UGT activity in dams. 
PHAHs are known for their disrupting effects on thyroid hormone metabolism, as 
shown in Figure 9.1. In this animal experiment, Aroclor 1254 exposure caused an increase in 
T4 UGT activity, resulting in decreased TT4 levels. Treatment with PCP also resulted in 
decreased serum TT4 levels, but increased FT4 levels, in dams and fetuses. The ratio FT4/TT4 
was increased indicating a reduced plasma TTR binding capacity in fetuses and dams following 
both treatments. Dl activity in liver decreased in dams and fetuses after treatment with Aroclor 
1254 and PCP. This decrease is probably caused indirectly by the lowered T4 levels. D2 activity 
in brain decreased by exposure to PCP in dams but no effect was found in fetuses, and increased 
by exposure to Aroclor 1254 in fetuses, with no effect in dams. The increasing D2 activity is 
a response of the brain to low T4 levels, to maintain the T3 homeostasis. 
The positive control PCP was shown to increase the T2 SULT activity measured in 
maternal liver and brain cytosol. Studies using varying T2 concentrations and different protein 
concentrations suggested competitive inhibition of PCP carried over in the in vitro assay as 
well as true induction of T2 SULT activity. This effect of PCP on thyroid hormone sulfation 
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Figure 9.1 Overview of the interaction sites of PHAHs and their metabolites with the 
thyroid hormone metabolism. The vertical arrows indicate the effects of PHAHs on the 
serum levels or hepatic enzyme activities. 
in vivo apparently did not result in lower levels of the product T4S, since fetal and maternal 
serum levels of T4S were not changed after treatment with PCP. This negative answer may be 
explained by an increased availability of substrate (FT4; maternal) together with a reduced Dl 
activity by PCP treatment, resulting in a reduced enzymatic breakdown of T4S. 
Exposure to Aroclor 1254, which resulted in the formation of hydroxylated 
metabolites, did not significantly change the T2 SULT activity in maternal or fetal brain or liver 
cytosol, nor the serum levels of T4S. 
Remarkably, the T3S and T4S levels were very low in fetal rat serum in this study, 
especially when compared with the reported high iodothyronine sulfate levels in fetal human 
and sheep serum. This can not be explained by low SULT activity levels or high Dl activity 
levels in rat fetuses on day 20. 
Overall implications of the observed PHAH effects on thyroid hormone 
metabolism 
PHAHs induce a wide spectrum of toxic effects in rats. Some effects have been suggested to 
be linked to a hypothyroid situation, such as the "wasting syndrome", decreased feed intake, 
and increased cholesterol concentrations. Indeed, reduced serum T4 concentrations have been 
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and increased cholesterol concentrations. Indeed, reduced serum T4 concentrations have been 
observed following exposure to PHAHs (Bastomsky et al, 1977; Gorski and Rozman, 1987; 
Hermansky et al, 1988; Brouwer, 1989; Beetstra et al, 1991), and it is tempting to speculate 
about a relationship between the hypothyroxinemia and the observed toxic responses. However, 
induction of a hypothyroid situation or a hypothyroxinemia by PHAHs could also be regarded 
as an adaptive endocrine response to diminish the PHAH-induced toxicity. One argument in 
support of this interpretation is the observed protective effect of thyroidectomy on TCDD-
induced lethality and immune toxicity (Rozman et al, 1985). 
In this study, it is proposed that the T4 decrease could well have a regulatory role in the 
induction of hepatic biotransformation enzymes, as was reported before (see Chapter 1). The 
present investigations suggest that the lowering effects of PHAHs on T4 levels are only a toxic 
effect of PHAHs and not an adaptive response to regulate the induction of biotransformation 
enzymes. The differences with other reports on modulating effects of thyroid hormone state 
on biotransformation enzymes may be explained by differences in the time and dose of inducers 
as well as by a difference in hypo- or hyperthyroid state. Nevertheless, the T4 decreases in the 
hypothyroid animals in our study are similar to the PHAH-induced T4 decreases. Therefore, 
the model was good enough to investigate our hypothesis. 
The second part of this thesis demonstrated that the sulfotransferase enzyme is another thyroid 
hormone-binding protein, besides Dl and TTR, which can be competitively inhibited by 
hydroxylated metabolites of PHAHs. In a relatively narrow range of low micromolar 
concentrations, PHAH-OHs were able to competitively inhibit T2 SULT acttivity in vitro, in 
a SULT isozyme and tissue specific manner. 
Studies using a perinatal exposure setup were performed to test inhibition of T2 sulfation 
in vivo. It was demonstrated that the well-known sulfation inhibitor PCP was able to indeed 
competively inhibit T2 SULT activity, but also was able to upregulate the sulfotransferase 
protein amounts. Aroclor 1254 exposure resulted in a slight inhibition of T2 SULT activity, 
probably caused by hydroxylated metabolites formed. This inhibition, together with lower 
substrate (FT4) levels found after Aroclor treatment did not result in decreased serum T4S 
levels, which is probably caused by a concomitantly decreased inactivation route, i.e. a 
decreased Dl activity, together with a higher availibility of substrate (FT4) after PCP exposure. 
Remarkably, the serum T4S levels in fetal rat are low compared to the levels in sheep 
and human fetal serum samples (Wu et al, 1992a/b; 1993a/b; Santini etal, 1993). This could 
not be explained by already higher Dl activities or a relatively low sulfation activity in the 
control fetus around GD20. For this reason, we concluded that the fetal rat probably is not a 
very good model for humans in terms of investigating the impact of toxic compounds on fetal 
thyroid hormone sulfation. However, it should be mentioned that, although PHAHs and their 
metabolites interfere at many sites with thyroid hormone transport and metabolism, the fetus 
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apparently is able to cope with those changes and can keep its homeostasis in T3. 
Another interesting point deduced from this study, is that PCP, which could be a model 
for PCB-OHs, itself showed effects on thyroid hormone levels and metabolism, indicating the 
importance of phenolic organohalogens compounds for disrupting effects on the thyroid 
hormone system. This also indicates that the disrupting effects of PCBs on the thyroid hormone 
system are for a large part caused by the hydroxylated metabolites formed. The own toxicity 
of PCB-OHs and related phenolic organohalogens inducing a separate set of effects together 
with the recently observed high fetal accumulation of hydroxy-PHAHs, give reason to further 
investigate the potential toxicity of these compounds on thyroid hormone metabolism and 
transport (see also Figure 9.1). It is worth mentioning that besides the "old" organohalogen 
pollutants that have been phased out since the 1980's, there is a wide range of new products 
on the market, such as brominated diphenylethers (PBDEs), chlorinated benzenes, bisphenol 
A and so on. PBDEs, which are nowadays used as flame retardants, have been demonstrated 
at increasing levels in our environment (De Boer et al, 1989; Sellstrom et al, 1996), and are 
probably able to cause similar effects as PHAHs. Serum T4 decreases have already been 
reported in rats after exposure to PBDEs (Darnerud et al, 1996) or PCDEs (Rosiak et al, 
1997). Also, hydroxylated metabolites of PBDEs have been found to competitively inhibit the 
T4 binding to TTR in vitro (Meerts et al, 1998). 
The human diet contains a diverse spectrum of naturally occuring and xeno-compounds 
that affect thyroid hormone metabolism. These include the organohalogens and related 
contaminants, and in addition, a large number of food components. Flavones and flavonoids 
have been reported to interfere with thyroid hormone binding proteins such as Dl (Auf mkolk 
et al, 1986; Cody et al, 1989) and TTR (Lueprasitsakul et al, 1990; Kohrle et al, 1986). 
Flavonoids such as quercetin were similarly found to be able to inhibit phenol sulfotransferase 
activity in vitro (Walle et al, 1995; Eaton et al, 1996), and also other food additives were 
potent inhibitors of phenol sulfation (Bamforth et al, 1993). The potential adverse human 
health impact of these compounds depends on a number of factors, including dietary intake, 
metabolism and pharmacokinetics, compound potency, serum concentrations, relative binding 
to serum proteins, and interactions or cross-talk with other endocrine pathways. In a risk 
evaluation, it should be taken into account that humans are exposed to a mixture of compounds 
with effects on thyroid hormone metabolism. If the mechanism of interference is similar for 
all these classes of compounds, the effects might very well be additive, or interactive. 
Additionally, the very persistent PHAHs are probably of more importance from a risk 
assessment point of view than the natural food components having a higher degradation rate. 
The effects of PHAHs on the thyroid hormone system in this study have been obtained 
in rats, are the results relevant for the human situation. Occupational or accidental exposure 
to high levels of PCBs or PBBs results in changes in serum T4 levels as was found by Bahn 
et al. (1980), Kreiss et al (1982), Murai et al. (1987), and Emmet et al (1988). Moreover, in 
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pregnant women exposed to background levels of PHAHs mainly through diet, a significant 
negative correlation was observed between human milk levels of PHAHs and plasma T4 and 
T3 levels (Koopman-Esseboom et al, 1994). In addition, increases in plasma TSH and both 
increases and decreases in plasma T4 levels were found in newborn babies following exposure 
to increasing PHAH levels through in utero and lactational transfer (Pluim et al, 1993; 
Koopman-Esseboom et al, 1994). Besides, prenatal exposure to PCBs is related to disorders 
in neurological development of children, found in some in epidemiologic studies (Rogan et 
al, 1986; Jacobson et al, 1990). It still is however not clear if these effects of PHAHs on 
thyroid hormone levels and metabolism may have possible effects on (brain) development. 
138 
REFERENCES 
Adams C, Lans M.C., Klasson-Wehler E., Van Engelen J.G.M., Visser J., and Brouwer A. (1990). 
Hepatic thyroid hormone 5'-deiodinase, another target-protein for monohydroxy metabolites of 
3,3',4,4'-tetrachlorobiphenyl. In: Hutzinger O., and Fielder H. (eds.). Organohalogen Compounds 
1, Ecoinforma Press, Bayreuth, Germany, 51-54. 
Araki Y., Sakakibara Y., Boggaram V., Katafuchi J., Suiko M., Nakajima H., and Liu M.C. (1997). 
Tissue-specific and developmental stage-dependent expression of a novel rat Dopa/tyrosine 
sulfotransferase. Int. J. Biochem. Cell. Biol. 29, 801-806. 
Arlotto M.P., and Parkinson A. (1989). Identification of cytochrome P-450a (P450IIA1) as the principal 
testosterone 7a-hydroxylase in rat liver microsomes and its regulation by thyroid hormones. Arch. 
Biochem. Biophys., 270, 458-471. 
Auf mkolk M., Kohrle J., Hesch R.-D., and Cody V. (1986). Inhibition of rat liver iodothyronine 
deiodinase. Interaction of aurones with the iodothyronine ligand-binding site. J. Biol. Chem., 261, 
11623-11630. 
Bahn A.L., Mills J.L., Snyder P.J., Gann P.H., Houten L., Bialik O., Hollman L., and Utiger R.D. 
(1980). Hypothyroidism in workers exposed to polybrominated biphenyls. The New England 
Journal of Medicine 302, 31-33. 
Bamforth K.J., Jones A.L., Roberts R.C., and Coughtrie M.W.H. (1993). Common food additives are 
potent inhibitors of human liver 17a-ethinyloestradiol and dopamine sulphotransferases. Biochem. 
Pharmacol. 46, 1713-1720. 
Barter R.A., and Klaassen CD. (1992a). UDP-glucuronosyltransferase inducers reduce thyroid 
hormone levels in rats by an extrathyroidal mechanism. Toxicol. Appl. Pharmacol. 113, 36-42. 
Barter R.A., and Klaassen CD. (1992b). Rat liver microsomal UDP-glucuronosyltransferase activity 
toward thyroxine: characterization, induction, and form specificity. Toxicol. Appl. Pharmacol. 
115,261-267. 
Barter R.A., and Klaassen CD. (1994). Reduction of thyroid hormone levels and alteration of thyroid 
function by four representative UDP-glucuronosyltransferase inducers in rats. Toxicol. Appl. 
Pharmacol. 128,9-17. 
Bastomsky CH. (1974). Effects of a polychlorinated biphenyl mixture (Aroclor 1254) and DDT on 
biliary thyroxine excretion in rats. Endocrinol., 95: 1150-1155. 
Bastomsky CH. (1977). Enhanced thyroxine metabolism and high uptake goiters in rats after a single 
dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin. Endocrinol. 101, 292-296. 
Beckett G.J., Boyd R., Beddows S.E., and Hayes J.D. (1988). Decreased hepatic glutathione 
S-transferase A, AA and L concentration produced by prolonged thyroid hormone administration. 
Biochem. Pharmacol. 37, 3201-3204. 
Beetstra J.B., Van Engelen J.G.M., Karels P., Van der Hoek H.J., De Jong M., Docter R., Krenning 
E.P., Hennemann G., Brouwer A., and Visser T.J (1991). Thyroxine and 3,3',5-triiodothyronine 
are glucuronidated in rat liver by different uridine diphosphate-glucuronyltransferases. 
139 
References 
Endocrinology 128, 741-746. 
Bergman A., Klasson-Wehler E., and Kuroki H. (1994). Selective retention of hydroxylated PCB 
metabolites in blood. Environ. Health Persp. 102, 464-469. 
Bergman A., Klasson-Wehler E., Kuroki H., Nilsson A., and Rydberg P. (1995). Synthesis and mass 
spectrometry of methoxy-polychlorobiphenyls. Chemosphere 30, 1921-1938. 
Binder T.P, and Duffel M.W. (1988). Sulfation of benzylic alcohols catalyzed by arylsulfotransferase 
IV. Mol. Pharmacol. 33, 477-479. 
Bock K.W., Frohling W., Remmer H., and Rexer B. (1973). Effects of phenobarbital and 
3-methylcholanthrene on substrate specificity of rat liver microsomal UDP-glucuronyltransferase. 
Biochim. Biophys. Acta 327, 46-56. 
Bogaards J.J.P., Van Ommen B., and Van Bladeren P.J. (1989). An improved method for the separation 
and quantification of glutathione S-transferase subunits in rat tissue using high-performance liquid 
chromatography. J. Chromatogr. 474, 435-440. 
Bradford M.M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of 
protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254. 
Braverman L.E. (1994). Deiodination of thyroid hormones. Exp. Clin. Endocrinol. 102, 355-363. 
Brouwer A. (1989). Inhibition of thyroid hormone transport in plasma of rats by polychlorinated 
biphenyls. Arch. Toxicol. 13,440-445. 
Brouwer A., and Van den Berg K.J. (1986). Binding of a metabolite of 3,4,3',4'-tetrachlorobiphenyl 
to transthyretin reduces serum vitamin A transport by inhibiting the formation of the protein 
complex carrying both retinol and thyroxin. Toxicol. Appl. Pharmacol. 85, 301-312. 
Brouwer A., Blaner W.S., Kukler A., and Van den Berg K.J. (1988). Study on the mechanism of 
interference of 3,4,3',4'-tetrachlorobiphenyl with the plasma retinol-binding proteins in rodents. 
Chem.-Biol. Interactions 68, 203-217. 
Brouwer A., Klasson-Wehler E., Bokdam M., Morse D.C., and Traag W.A. (1990). Competitive 
inhibition of thyroxin binding to transthyretin by monohydroxy metabolites of 
3,4,3',4'-tetrachlorobiphenyl. Chemosphere 20, 1257-1262. 
Brouwer A., Ahlborg U.G., Van dem Berg M.., Birnbaum L.S., Boersma E.R., Bosveld B., Denison 
M.S., Gray L.E., Hagmar, L., Holene E., Winneke G. et al. (1995). Functional aspects of 
developmental toxicity of polyhalogenated aromatic hydrocarbons in experimental animals and 
human infants. Eur. J. Pharmacol, Environ. Toxicol. Pharmacol. Section 293, 1-40. 
Brouwer A., Morse D.C., Lans M.C., Schuur A.G., Murk A.J., Klasson-Wehler E., Bergman A., and 
Visser T.J. (1998). Interactions of persistent environmental organohalogens with the thyroid 
hormone system: Mechanisms and possible consequences for animal and human health. Toxicol. 
Industr. Health 14, 59-84. 
Burke M.D., Prough R.A., and Mayer R.T. (1977). Characteristics of a microsomal cytochrome 
P-448-mediated reaction. Drug Metabol. Dispos. 5, 1-8. 
Burke M.D., Thompson S., Weaver R.J., Wolf R.C., and Mayer R.T. (1994). Cytochrome P450 
specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem. Pharmacol. 48, 
923-936. 
Byrne J.J., Carbone J.P., and Hanson E.A. (1987). Hypothyroidism and abnormalities in the kinetics 
140 
References 
of thyroid hormone metabolism in rats treated chronically with polychlorinated biphenyl and 
polybrominated biphenyl. Endocrinol. 121, 520-527. 
Campbell N.R.C., Van Loon J.A., Sundaram R.S., Ames M.M., Hansch C, and Weinshilboum R. 
(1987). Human and rat liver phenolsulfotransferase: structure-activity relationships for phenolic 
substrates. Mol. Pharmacol. 32, 813-819. 
Castelein H., Gulick T., Declercq P.E., Mannaerts G.P., Moore D.D., and Baes M.I. (1994). The 
peroxisome proliferator activated receptor regulates malic enzyme gene expression. J. Biol. Chem. 
269, 26754-26758. 
Chopra I.J., Wu S.Y., Chua Teco G.N., and Santini F. (1992). A radioimmunoassay for measurement 
of 3,5,3'-triiodothyronine sulfate: studies in thyroidal and nonthyroidal diseases, pregnancy, and 
neonatal life. J. Clin. Endocrinol. Metab. 7, 189-194. 
Chowdhury J.R., Chowdhury N.R., Moscioni A.D., Tukey R., Tephly T., and Arias I.M. (1983). 
Differential regulation by triiodothyronine of substrate-specific uridinediphosphoglucuronate 
glucuronosyl transferases in rat liver. Biochim. Biophys. Acta 761, 58-65. 
Christenson W.R., Becker B.D., Hoang H.D., Wahle B.S., Moore K.D., Dass P.D., Lake S.G., Stuart 
B.P., Van-Goethem D.L., Sangha G.K., and Thyssen J.H. (1995). Extrathyroidally mediated 
changes in circulating thyroid hormone concentrations in the male rat following administration 
of an experimental oxyacetamide (FOE 5043). Toxicol. Appl. Pharmacol. 132, 253-262. 
Cody V., Kohrle J., and Hesch R.-D. (1989). Structure-activity relationships of flavonoid as inhibitors 
of iodothyronine deiodinase. In: Gaitan E. (ed.). Environmental Goitrogenesis, CRC Press Inc., 
Boca Raton, Florida, USA, 57-72. 
Collins W.T., and Capen C.C. (1980a). Biliary excretion of 1251-thyroxine and fine structural 
alterations in the thyroid glands of gunn rats fed polychlorinated biphenyls (PCB). Lab. Invest. 
43, 158-164. 
Collins W.T., and Capen C.C. (1980b). Ultrastructural and functional alterations of the rat thyroid 
gland produced by polychlorinated biphenyls compared with iodide excess and deficiency, and 
thyrotropin and thyroxine administration. Virchows Arch. B Cell Path. 33, 213-231. 
Collins W.T. Jr., and Capen C.C. (1980c). Fine structural lesions and hormonal alterations in thyroid 
glands of perinatal rats exposed in utero and by the milk to polychlorinated biphenyls. Am. J. 
Pathol. 99, 125-142. 
Collins W.T. Jr., Capen C.C, Kasza L., Carter C, and Dailey R.E. (1977). Effect of polychlorinated 
biphenyl (PCB) on the thyroid gland of rats. Am. J. Pathol. 89, 119-136. 
Connor K., Safe S., Jefcoate C.R., and Larsen M. (1995). Structure-dependent induction of Cyp2B by 
polychlorinated biphenyl congeners in female Sprague-Dawley rats. Biochem. Pharmacol. 50, 
1913-1920. 
Connor K., Ramamoorthy K., Moore M., Mustain M.,Chen I., Safe S., Zacharewski T., Gillesby B., 
Joyeux A., and Balaguer P. (1997). Hydroxylated polychlorinated biphenyls (PCBs) as estrogens 
and antiestrogens: structure-activity relationships. Toxicol. Appl. Pharmacol. 145, 111-123. 
Cruickshank D., and Sansom L.N. (1993). Inhibition of rat liver aryl sulphotransferase by the food 
additive vanillin. Eur. J. Pharmac. Sciences 1, 41-47. 
Darnerud P.O., Sinjari T., and Jonsson C.J. (1996). Foetal uptake of coplanar polychlorinated biphenyl 
141 
References 
(PCB) congeners in mice. Pharmacol. Toxicol. 78, 187-192. 
Dawson J.R., Adams D.J., and Wolf C.R. (1985). Induction of drug metabolizing enzymes in human 
liver cell line Hep G2. FEBS Letters 183, 219-222. 
De Boer J. (1989). Organochlorine compounds and bromodiphenylethers in livers of atlantic cod 
(Gadus morhua) from the North sea, 1977-1987. Chemosphere 18, 2131-2140. 
De Haan L.H.J., Van Dijk L., and Brouwer A. (1994). Effects of hydroxylated PCBmetabolites on the 
gap-junctional intercellular communication between mouse hepalclc7 cells. In: Organohalogen 
Compounds 20, 491-495. 
De Herder W.W., Bonthuis F., Rutgers M., Often M.H., Hazenberg M.P., and Visser T.J. (1988). 
Effects of inhibition of type I iodothyronine deiodinase and phenol sulfotransferase on the biliary 
clearance of triiodothyronine in rats. Endocrinology 122, 153-157. 
De Jong M, Rolleman E.J., and Bernard H.F. (1995). T2 and triac are sulfated in HEPG2 cells, 
whereas T3 sulfation is absent. Thyroid 5, suppl. 1, S125. 
Den Besten C, Vet J.J.R.M., Besselink H.T., Kiel G.S., Van Berkel B.J.M., Beems R., and Van 
Bladeren P. J. (1991). The liver, kidney, and thyroid toxicity of chlorinated benzenes. Toxicol. Appl. 
Pharmacol. 111,69-81. 
De Sandro V., Chevrier M, Boddaert A., Meldion C, Cordier A., and Richert L. (1991). Comparison 
of the effects of propylthiouracil, amiodarone, diphenylhydantoin, phenobarbital, and 
3-methylcholanthrene on hepatic and renal T4 metabolism and thyroid gland function in rats. 
Toxicol. Appl. Pharmacol. I l l , 263-278. 
De Sandro V., Catinot R., Krizt W., Cordier A., and Richert L. (1992). Male rat hepatic 
UDP-glucuronosyltransferase activity toward thyroxine. Activation and induction properties -
relation with thyroxine plasma disappearance rate. Biochem. Pharmacol. 43, 1563-1569. 
De Vito M.J., and Birnbaum L.S. (1994). Toxicology of dioxins and related chemicals. In: Schecter 
A. (ed.). Dioxins and Health, Plenum Press, New York, 139-162. 
De Voogt P., and Brinkman U.A.Th. (1989). Production, properties and usage of polychlorinated 
biphenyls. In: Kimbrouth, and Jensen (eds.). Halogenated biphenyls, terphenyls, naphthalenes, 
dibenzodioxins and related products. Chapter 1, 3-45. 
Duffel M.W., and Jakoby W.B. (1981). On the mechanism of aryl sulfotransferase. J. Biol. Chem. 256, 
11123-11127. 
Dunn R.T., and Klaassen CD. (1996). Tissue specific expression of sulfotransferase enzymes in the 
rat. The Toxicologist 30, 318. 
Eaton E.A., Walle U.K., Lewis A.J., Hudson T, Wilson A.A., and Walle T. (1996). Flavonoids, potent 
inhibitors of the human p-form phenolsulfotransferase. Drug Metab. Dispos. 24, 232-237. 
Eelkman Rooda S.J., Kaptein E., Rutgers M, and Visser T.J. (1989). Increased plasma 3,3,3'-
triiodothyronine sulfate in rats with inhibited type I iodothyronine deiodinase activity as measured 
by radioimmuoassay. Endocrinology 125, 740-745. 
Eltom S.E., Babish J.G., and Ferguson D.C. (1992). The interaction of L-triiodothyronine and 
2,3,7,8-tetrachlorodibenzo-p-dioxin on Ah-receptor-mediated hepatic phase I and phase II enzymes 
and iodothyronine 5'-deiodinase in thyroidectomized rats. Toxicol. Letters 61, 125-139. 
Emmett E.A., Maroni M., Jefferys J., Schmith J., Levin B.K., and Alvares (1988). Studies of 
142 
References 
transformer repair workers exposed to PCBs: II. Results of clinical laboratory investigations. Am. 
J. Ind. Med. 14, 47-62. 
Escobar-Morreale F., Obregon M.J., Hernandez A., Escobar del Rey F., and Morreale de Escobar G. 
(1997). Regulation of iodothyronine deiodinase activity as studied in thyroidectomized rats infused 
with thyroxine or triiodothyronine. Endocrinology 138, 2559-2568. 
Falany C.N. (1991). Molecular enzymology of human liver cytosolic sulfotransferases. TiPS 12, 
255-259. 
Falany C.N. (1997). Sulfation and sulfotransferases 3. Enzymology of human cytosolic 
sulfotransferases. FASEBJ. 11, 206-216. 
Fielden M.R., Chen I., Chittim B., Safe S.H., and Zacharewski T.R. (1997). Examination of the 
estrogenicity of 2,4,6,2',6'-pentachlorobiphenyl (PCB 104), its hydroxylated metabolite 
2,4,6,2',6'-pentachloro-4-biphenylol (HO-PCB 104), and a further chlorinated derivative, 
2,4,6,2',4',6'-hexachlorobiphenyl(PCB 155). Environ. Health Perspect. 105, 1238-1248. 
Foldes A., and Meek J.L. (1973). Rat brain phenolsulfotransferase-partial purification and some 
properties. Biochim. Biophys. Actaill, 365-374. 
Fujita K., Nagata K., Ozawa S., Sasano H., and Yamazoe Y. (1997). Molecular cloning and 
characterization of rat ST1B1 and human ST1B2 cDNAs, encoding thyroid hormone 
sulfotransferase. J. Biochem. 122, 1052-1061. 
Ganguly T.C., Krasnykh V., and Falany C.N. (1995). Bacterial expression and kinetic characterization 
of the human monoamine-sulfating form of phenol sulfotransferase. Drug Metab. Disp. 23, 
945-950. 
Garrib A., and McMurray W.C. (1984). A sensitive, continuous spectrophotometric method for 
assaying a-glycerophosphate dehydrogenase: activation by menadione. Anal. Biochem. 139, 
319-321. 
Gibb C, Glover V., and Sandler M. (1987). In vitro inhibition of phenol sulphotransferase by food and 
drink constituents. Biochem. Pharmacol. 36, 2325-2330. 
Glatt H., Christoph S., Czich A., Pauly K., Schwierzok A., Seider A., Coughtrie M.W.H., Doehmer 
J., Falany C.N., Phillips D.H., Yamazoe Y., and Bartsch I. (1996). Rat and human sulfotransferase 
expressed in Ames's Salmonella typhimurium strains and Chinese hamster V79 cells for the 
activation of mutagens. In: Oesch F., and Hengstler J.G. (eds.). Control Mechanisms of 
Carcinogenesis, Tieme Meissen, Germany, 98-115. 
Gong D.W., Murayama N., Yamazoe Y., and Kato R. (1992). Hepatic triiodothyronine sulfation and 
its regulation by growth hormone and triiodothyronine in rats. J. Biochem. 112, 112-116. 
Gorski J.R., and Rozman K. (1987). Dose-response and time course of hypothyroxinemia and 
hypoinsulinemia and characterization of insulin hypersensitivity in 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-treated rats. Toxicology 44, 297-307. 
Gorski J.R., Muzi G., Weber L.W.D., Pereira D.W., Arceo R.J., Iatropoulos M.J., and Rozman K. 
(1988). Some endocrine and morphological aspects of the acute toxicity of 
2,3,7,8-tetrachlorodibenzo-p-dioxin(TCDD). Toxicol. Pathol. 16,313-320. 
Goudonnet H., Magdalou J., Mounie J., Naoumi A., Viriot M.L., Escousse A., Siest G., and Truchot 
R. (1990). Differential action of thyroid hormones and chemically related compounds on the 
143 
References 
activity of UDP-glucuronosyltransferases. Biochim. Biophys. Acta 1035, 12-19. 
Graham D.L., and Skett P. (1987). Endocrine regulation of the metabolism of 1-naphthol in the rat. 
J. Pharmacol. Exp. Ther. 242, 344-348. 
Gray E.L. Jr., Ostby J., Marshall R., and Andrews J. (1993). Reproductive and thyroid effects of 
low-level polychlorinated biphenyl (Aroclor 1254) exposure. Fund. Appl. Toxicol. 20, 288-294. 
Gupta B.N., Vos J.G., Moore J.A., Zinkl J.G., and Bullock B.C. (1973). Pathologic effects of 
2,3,7,8-tetrachlorodibenzo-p-dioxin in laboratory animals. Environ. Health Perspect. 5, 125-140. 
Gupta B.N., McConnell E.E., Goldstein J.A., Harris M.W., and Moore J.A. (1983). Effects of a 
polybrominated biphenyl mixure in the rat and mouse. I. Six-month exposure. Toxicol. Appl. 
Pharmacol. 68, 1-18. 
Habig W.H., Pabst M.J., and Jakoby W.B. (1974). Glutathione S-transferases. The first enzymatic step 
in mercapturic acid formation. J. Biol. Chem. 249, 7130-7139. 
Harris A.R.C., Fang S.-L., Prosky J., Braverman L.E., and Vagenakis A.G. (1978). Decreased outer 
ring monodeiodination of thyroxine and reverse triiodothyronine in the fetal and neonatal rat. 
Endocrinology 103, 2216-2222. 
Henry E.C., and Gasiewicz T.A. (1986). Effects of thyroidectomy on the Ah receptor and enzyme 
inducibility by 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat liver. Chem.-Biol. Interactions 59, 
29-42. 
Henry E.D., and Gasiewicz T.A. (1987). Changes in thyroid hormone and thyroxine glucuronidation 
in Hamsters compared with rats following treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin. 
Toxicol. Appl. Pharmacol. 89, 165-174. 
Her C.T., Kaur G.P, Athwal R.W., and Weinshilbou R.M. (1997). Human sulfotransferase SULT1C1: 
cDNA cloning, tissue-specific expression, and chromosomal localization. Genomics 41, 467-470. 
Hermansky S.J., Holcslaw T.L., Murray W.J., Markin R.S., and Stohs S.J. (1988). Biochemical and 
functional effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on the heart of female rats. 
Toxicol. Appl. Pharmacol. 95, 175-184. 
Hovander L., Athansiadou M., Asplund L., and Klasson-Wehler E. (1998). A method for analysis of 
phenolic and neutral organohalogen compounds. Submitted. 
Hsu R.Y., and Lardy H.A. (1967). Pigeon liver malic enzyme. II. Isolation, crystallization, and some 
properties. J. Biol. Chem. 242, 520-526. 
Huang W.S., Kuo S.W., Chen W.L., Hsieh K.S., and Wu S.Y. (1996). Maturation of hepatic desulfation 
activity in developing rats. J. Formos. Med. Assoc. 95, 435-439. 
Hurd R.E., Santini F., Lee B., Nairn P., and Chopra I.J. (1993). A study of the 3,5,3'-triiodothyronine 
sulfation activity in the adult and the fetal rat. Endocrinol. 133, 1951-1955. 
Ikegwuonu F.I., Ganem L.G., Larsen C. M., Shen X., and Jefcoate C.R. (1996). The regulation by 
gender, strain, dose, and feeding status of the induction of multiple forms of cytochrome P450 
isozymes in rat hepatic microsomes by 2,4,5,2',4',5'-hexachlorobiphenyl. Toxicol. Appl. Pharmacol. 
139,33-41. 
Jacobson J.L., and Jacobson S.W. (1997). Evidence for PCBs as neurodevelopmental toxicants in 
humans. Neurotoxicol. 18, 415-424. 
Jacobson J.L., Jacobson S.W., and Humphrey H.E.B. (1990). Effects of in utero exposure to 
144 
References 
polychlorinated biphenyls and related contaminants on cognitive functioning in young children. 
J. Pediatr. 116, 38-45. 
Jekat F.W, Meisel M.L., Eckard R., and Winterhoff H. (1994). Effects of pentachlorophenol (PCP) 
on the pituitary and thyroidal hormone regulation in the rat. Toxicol. Letters 71, 9-25. 
Jones M.K., Weisenburger W.P., Sipes I.G., and Haddock Russell D. (1987). Circadian alterations in 
prolactin, corticosterone, and thyroid hormone levels and down-regulation of prolactin receptor 
activity by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol. Appl. Pharmacol. 87, 337-350. 
Jones A.L., Hagen M., Coughtrie M.W.H., Roberts R.C., and Glatt H. (1995). Human platelet 
phenolsulfotransferases: cDNA cloning, stable expression in V79 cells and identification of a novel 
allelic variant of the phenol-sulfating form. Biochem. Biophys. Res. Commun. 208, 855-862. 
Kaplan M.M. (1986). Regulatory influences on iodothyronine deiodination in animal tissues. In: 
Hennemann G. (ed.). Thyroid hormone metabolism. Marcel Dekker Inc., New York, USA, 231-
253. 
Kaptein E., Van Haasteren G.A.C., Linkels E., De Greef W.J., and Visser T.J. (1997) Characterization 
of iodothyronine sulfotransferase activity in rat liver. Endocrinology 138, 5136-5143. 
Kato R., and Takahashi A. (1968). Thyroid hormone and activities of drug-metabolizing enzymes and 
electron transport systems of rat liver microsomes. Mol. Pharmacol. 4, 109-120. 
Kato Y., Haraguchi K., Kawashima M., Yamada S., Isogai M., Masuda Y., and Kimura R. (1995). 
Characterization of hepatic microsomal cytochrome P450-from rats treated with methylsulphonyl 
metabolites of polychlorinated biphenyl congeners. Chem.-Biol. Interact. 95, 269-278. 
Kelling C.K., Menahan L.A., and Peterson R.E. (1987). Hepatic indices of thyroid status in rats treated 
with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biochem. Pharmacol. 36, 283-291. 
Kirsch R., Fleischner G., Kamisaka K., and Arias I.M. (1975). Structural and functional studies of 
ligandin, a major renal organic anion-binding protein. J. Clin. Invest. 55, 1009-1019. 
Klasson-Wehler E., Brunstrom B., Rannug U., and Bergman A. (1990). 3,3',4,4'-tetrachlorobiphenyl: 
metabolism by the chick embryo in ovo and toxicity of hydroxylated metabolites. Chem.-Biol. 
Interactions 73, 121-132. 
Klasson-Wehler E., Kuroki H., Athanasiadou M., and Bergman A. (1992). Selective retention of 
hydroxylated PCBs in blood. In: Organohalogen Compounds 10, 121-122. 
KogaN., Beppu M., and Yoshimura H. (1990). Metabolism in vivo of 3,4,5,3',4'-pentachlorobiphenyl 
and toxicological assessment of the metabolite in rats. J. Pharmacobio-Dyn. 13, 39-48. 
Kohrle J. (1996). Thyroid hormone deiodinases - a selenoenzyme family acting as gate keepers to 
thyroid hormone action. Acta Med. Austriaca 23, 17-30. 
Kohrle J., Auf mkolk M., Rokos H., Hesch R.-D., and Cody V. (1986). Rat liver iodothyronine 
monodeiodinase. Evaluation of the iodothyronine ligand-binding site. J. Biol. Chem. 261, 
11613-11622. 
Kohrle J., Brabant G., and Hesch R.-D. (1987). Metabolism of the thyroid hormones. Hormone Res. 
26, 58-78. 
Koopman-Esseboom C, Morse D.C., Weisglas-Kuperus N., Lutkeschipholt I.J., Van der Paauw C.G., 
Tuinstra L.G.M.T., Brouwer A., and Sauer P. (1994). Effects of dioxins and polychlorinated 
biphenyls on thyroid hormone status of pregnant women and their infants. Pediatric Res. 36, 
145 
References 
468-473. 
Korach K.S., Sarver P., Chae K., McLachlan J.A., and McKinney J.D. (1988). Estrogen 
receptor-binding activity of polychlorinated hydroxybiphenyls: conformationally restricted 
structural probes. Mol. Pharmacol. 33, 120-126. 
Koster H., Halsema I., Scholtens E., Meerman J.H.N., Pang K.S., and Mulder G.J. (1982) Selective 
inhibition of sulfate conjugation in the rat - pharmacokinetics and characterization of the inhibitory 
effect of 2,6-dichloro-4-nitrophenol. Biochem. Pharmacol. 31, 1919-1924. 
Kumar A., Raphael C, and Adesnik M. (1983). Cloned cytochrome P-450 cDNA. J. Biol. Chem. 258, 
11280-11284. 
Kreiss K., Roberts C , and Humphren H.E.B. (1982). Serial PBB levels, PCB levels and clinical 
chemistries in Michigan's PBB cohort. Arch. Env. Health 378, 141-146. 
Lans M.C. (1995). Thyroid hormone binding proteins as novel targets for hydroxylated 
polyhalogenated aromatic hydrocarbons (PHAHs): possible implications for toxicity. Thesis, 
Landbouwuniversiteit Wageningen, The Netherlands, ISBN 90-5485-430-8. 
Lans M.C, Kubiczak G., Douwes J., and Brouwer A. (1990). In vitro effects of 
3,3',4,4'-tetrachlorobiphenyl and its hydroxymetabolites on mitochondrial function. In: 
Organohalogen Compounds 1, 103-106. 
Lans M.C, Klasson-Wehler E., Willemsen M., Meussen E., Safe S., and Brouwer A. (1993). 
Structure-dependent, competitive interaction of hydroxy-polychlorobiphenyls, -dibenzo-p-dioxins 
and -dibenzofurans with human transthyretin. Chem. Biol. Interactions 88, 7-21. 
Lans M.C, Spiertz C , Brouwer A., and Koeman J.H. (1994). Different competition of thyroxine 
binding to transthyretin and thyroxine-binding globulin by hydroxy-PCBs, PCDDs and PCDFs. 
Eur. J. Pharmacol. 270, 129-136. 
Larsen P.R. (1997). Update on the human iodothyronine selenodeiodinases, the enzymes regulating 
the activation and incativation of thyroid hormone. Biochem. Soc. Transact. 25, 588-592. 
Larsen CM., and Jefcoate C.R. (1995). Phenobarbital induction of CYP2B1, CYP2B2, and CYP3A1 
in rat liver: genetic differences in a common regulatory mechanism. Arch. Biochem. Biophys. 321, 
467-476. 
Larsen C. M., Brake P.B., Parmar D., and Jefcoate CR. (1994). The induction of five rat hepatic P450 
cytochromes by phenobarbital and similarly acting compounds is regulated by a sexually 
dimorphic, dietary-dependent endocrine factor that is highly strain specific. Arch. Biochem. 
Biophys. 315, 24-34. 
Leakey J.E.A., Mukhtar H., Fouts J.R., and Bend J.R. (1982). Thyroid hormone-induced changes in 
the hepatic monooxygenase sytem, heme oxygenase activity and epoxide hydrolase activity in adult 
male, female and immature rats. Chem.-Biol. Interactions 40, 257-264. 
Leonard J.L., Silva J.E., Kaplan M.M., Mellon S.A., Visser T.J., and Larsen P.R. (1984). Acute 
posttransriptional regulation of cerebrocortical and pituitary iodothyronine 5'-deiodinase by thyroid 
hormone. Endocrinology 114, 998-1004. 
Liu L., and Klaassen CD. (1996). Ontogeny and hormonal basis of male-dominant rat hepatic 
sulfotransferases. Mol. Pharmacol. 50, 565-572. 
Liu J., Liu W., Barter R.A., and Klaassen CD. (1995). Alteration of thyroid homeostasis by 
146 
References 
UDP-glucuronosyltransferase inducers in rats: a dose-response study. J. Pharmacol. Exp. Therap. 
273, 977-985. 
Lucier G.W., McDaniel O.S., Schiller CM., and Matthews H.B. (1978). Structural requirements for 
the accumulation of clorinated biphenyl metabolites in the fetal rat intestine. Drug Metabolism 
and Disposition 6, 584-590. 
Lueprasitsakul W., Alex S., Fang S.L., Pino S., Irmscher K., Kohrle J., and Braverman L.E. (1990). 
Flavonoid administration immediately displaces thyroxine (T4) from serum transthyretin, increases 
serum free T4, and decreases serum thyrotropin in the rat. Endocrinol. 126, 2890-2895. 
Masmoudi T., Planells R., Mounie J., Artur Y., Magdalou J., and Goudonnet H. (1996). Opposite 
regulation of bilirubin and 4-nitrophenol UDP-glucuronosyltransferase mRNA levels by 3,3',5 
triiodo-L-thyronine in rat liver. FEBSLett. 379, 181-185. 
Mason G., and Safe S. (1986). Synthesis, biologic and toxic effects of the major 
2,3,7,8-tetrachlorodibenzo-p-dioxin metabolites in the rat. Toxicology 41, 153-159. 
Matsui M., and Homma H. (1994). Biochemistry and molecular biology of drug-metabolizing 
sulfotransferase. Int. J. Biochem. 26, 1237-1247. 
McClain R.M., Levin A.A., Posch R., and Downing J.C. (1989). The effect of phenobarbital on the 
metabolism and excretion of thyroxine in rats. Toxicol. Appl. Pharmacol. 99, 216-228. 
McKinney J.D., Chae K., Oatley S.J., and Blake C.C.F. (1985). Molecular interactions of toxic 
chlorinated dibenzo-p-dioxins and dibenzofurans with thyroxine binding prealbumin. J. Med. 
Chem. 28,375-381. 
Meerman J.H.N., Sterenborg H.M.J., and Mulder G.J. (1983). Use of pentachlorophenol as long-term 
inhibitor of sulfation of phenols and hydroxamic acids in the rat in vivo. Biochem. Pharmacol. 
32, 1587-1593. 
Meerts I.A.T.M., Marsh G., Van Leeuwen-Bol I., Luijks E.A.C., Jakobsson E., Bergman A., and 
Brouwer A. (1998). Interaction of polybrominated diphenyl ether metabolites (PBDE-OH) with 
human trasnthyretin in vitro. In: Organohalogen Compounds 37, 309-312. 
Mol J.A., and Visser T.J. (1985). Rapid and selective inner ring deiodination of thyroxine sulfate by 
rat liver deiodinase. Endocrinology 111, 8-12. 
Morse D.C. (1996). Polychlorinated biphenyl-induced alterations of thyroid hormone homeostasis and 
brain development in the rat. Thesis, Landbouwuniversiteit Wageningen, The Netherlands, ISBN 
90-5485-375-1. 
Morse D.C, Groen D., Veerman M., Van Amerongen C.J., Koeter H.B.W.M., Smits-Van Prooije A.E., 
Visser T.J., Koeman J.H., and Brouwer A. (1993). Interference of polychlorinated biphenyls in 
hepatic and brain thyroid hormone metabolism in fetal and neonatal rats. Toxicol. Appl. 
Pharmacol. Ill, 27-33. 
Morse D.C, Van Bladeren P.J.., Klasson-Wehler E., and Brouwer A. (1995). B-naphthoflavone- and 
self-induced metabolism of 3,3',4,4'-tetrachlorobiphenyl in hepatic microsomes of the male, 
pregnant female and foetal rat. Xenobiotica 25, 245-260. 
Morse D.C, Klasson-Wehler E., Wesseling W., Koeman J.H., and Brouwer A. (1996). Alterations in 
rat brain thyroid hormone status following pre- and postnatal exposure to polychlorinated 
biphenyls (Aroclor 1254). Toxicol. Appl. Pharmacol. 136, 269-279. 
147 
References 
Moscioni A.D., and Gartner L.M. (1983). Thyroid hormone and hepatic UDP-glucuronosyl transferase 
activity: contrary effects in rat and mouse. Res. Commun. Chem. Pathol. Pharmacol. 39,445-462. 
Mulder G.J., and Scholtens E. (1977). Phenol sulphotransferase and uridine diphosphate 
glucuronyltransferase from rat liver in vivo and in vitro. Biochem. J. 165, 553-559. 
Mulder G.J., and Jakoby W.B. (1990). Sulfation. In: Mulder G.J. (ed.). Conjugation reactions in drug 
metabolism. Taylor &Francis Ltd., London, 107-161. 
Miiller D., Greiling K., Greiling H., and Klinger W. (1983a). The influence of triiodothyronine (T3) 
on the postnatal development of drug metabolism in rat liver. Biomed. Biochim. Acta 42, 981 -987. 
Miiller D., Greiling K., Greiling H., and Klinger W. (1983b). The influence of triiodothyronine (T3) 
and inducers on hepatic drug metabolism in rats of different ages. Biomed. Biochim. Acta 44, 
1171-1179. 
Miinzel P.A., Brack M., and Bock K.W. (1994). Tissue-specific constitutive and inducible expression 
of rat phenol UDP-glucuronosyltransferase. Biochem. Pharmacol. 47, 1445-1448. 
Miinzel P.A., Bookjans G., Mehner G., Lehmkoster T., and Bock K.W. (1996). Tissue-specific 
2,3,7,8-tetrachlorodibenzo-p-dioxin-inducible expression of human UDP-glucuronosyltransferase 
UGT1A6. Arch. Biochem. Biophys. 335, 205-210. 
Murai K., Okamura K., Tsuji H., Kajjiwara E., Watanabe H., Akagi K., and Fujishima (1987). Thyroid 
function in "Yusho" patients exposed to polychlorinated biphenyls. Environ. Res. 44, 179-187. 
MurayamaN., Shimada M., Yamazoe Y., and Kato R. (1991). Difference in the susceptibility of two 
phenobarbital-inducible form, P450IIB1 and P450IIB2, to thyroid hormone- and growth 
hormone-induced suppression in rat liver: phenobarbital-inducible P450IIB2 suppression by 
thyroid hormone acting directly, but not through the pituitary. Mol. Pharmacol. 39, 811-817. 
Muzi G., Gorski J.R., and Rozman K. (1989). Mode of metabolism is altered in 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-treated rats. Toxic. Letters 47, 77-86. 
Nagata K., Ozawa S., Miyata M., Shimada M., Gong D.W., Yamazoe Y., and Kato R. (1993) Isolation 
and expression of a cDNA encoding a male-specific rat sulfotransferase that catalyze activation 
of N-hydroxy-2-acetylaminofluorene. J. Biol. Chem. 268, 24720-24725. 
Narasimhan T.R., Kim H.L. and Safe S.H. (1991). Effects of hydroxylated polychlorinated biphenyls 
on mouse liver mitochondrial oxidative phosphorylation. J. Biochem. Toxicol. 6, 229-236. 
Ness D.K., Schantz S.L., Moshtaghian J., and Hansen L.G. (1993). Effects of perinatal exposure to 
specific PCB congeners on thyroid hormone concentrations and thyroid histology in the rat. 
Toxicol. Letters 68, 311-323. 
Obregon M.J., Ruiz de Ona C , Calvo R., Escobar del Rey F., and Morreale de Escobar G. (1991). 
Outer ring iodothyronine deiodinase and thyroid hormone economy: responses to iodine deficiency 
in the rat fetus and neonate. Endocrinology 129, 2663-2673. 
Okey A.B., Riddick D.S., and Harper P.A. (1994). Molecular biology of the aromatic hydrocarbon 
(dioxin) receptor. TiPS 15, 226-232. 
Omura T., and Sato R. (1964). The carbon monoxide-binding pigment of liver microsomes. I. Evidence 
for its hemoprotein nature. J. Biol. Chem. 239 2370-2385. 
Oppenheimer J.H., Silva E., Schwartz H.L., and Surks M.I. (1977). Stimulation of hepatic 
mitochondrial a-glycerophophate dehydrogenase and malic enzyme by 1-triiodothyronine. 
148 
References 
Characteristics of the response with specific nuclear thyroid hormone binding sites fully saturated. 
J. Clin. Invest. 59,517-427. 
Orn U., Eriksson L., Jakobsson E., and Bergman A. (1996). Synthesis and characterization of 
polybrominated diphenyl ethers - unlabelled and radiolabeled tetra-, penta- and hexa-
bromodiphenyl ethers. Acta Chem. Scand. 50, 802-807. 
Otten M.H., Mol J.A., and Visser T.J. (1983). Sulfation preceding deiodination of iodothyronines in 
rat hepatocytes. Science 221, 81-83. 
Owens I.S. (1977). Genetic regulation of UDP-glucuronosyltransferase induction by polycyclic 
aromatic compounds in mice. Co-segregation with aryl hydrocarbon (benzo[a]pyrene) hydroxylase 
induction. J. Biol. Chem. 252, 2827-2833. 
Pellizas C.G., Coleoni A.H., Cabanillas A.M., Masini-Repiso A.M., and Costamagna M.E. (1996). 
Response of triiodothyronine-dependent enzyme activities to insulin-like growth factor I and 
growth hormone in cultured rat hepatocytes. Eur. J. Endocrinol. 134, 215-220. 
Pacifici G.M., Vannucci L., Bencini C , Tusini G., and Mosca F. (1991). Sulphation of 
hydroxybiphenyls in human tissues. Xenobiotica 21, 1113-1118. 
Pazdernik T.L., and Rozman K.K. (1985). Effect of thyroidectomy and thyroxine on 
2,3,7,8-tetrachlorodibenzo-p-dioxin-induced immunotoxicity. Life Sciences 36, 695-703. 
Pennington J., Scott A.K., Reid I.W., and Hawksworth G.M. (1988). Changes in rat hepatic 
UDP-glucuronosyltransferase activity after induction of hyper- or hypo-thyroidism are substrate 
dependent. Biochem. Soc. Trans. 16, 802-803. 
Peterson R.E., Theobald H.M., and Kimmel G.L. (1993). Developmental and reproductive toxicity of 
dioxins and related compounds: cross-species comparisons. Crit. Revs. Toxicol. 23, 283-335. 
Pimental R.A., Liang B., Yee G.K., Wilhelmsson A., Poellinger L., and Paulson K.E. (1993). Dioxin 
receptor and C/EBP regulate the function of the glutathione S-transferase Ya gene xenobiotic 
response element. Mol. Cell. Biol. 13, 4365-4373. 
Pluim H.J., De Vijlder J.J.M., Olie K., Kok J.H, Vulsma T., Van Tijn D.A., Van der Slikke J.W., and 
Koppe J.G. (1993). Effects of pre- and postnatal exposure to chlorinated dioxins and furans on 
human neonatal thyroid hormone concentrations. Environ. Health Perspect. 101, 504-508. 
Pohjanvirta R., Kulju T., Morselt A.D.W., Tuominen R., Juvonen R., Rozman K., Mannisto P., Collan 
Y., Sainio E.-L., and Tumisto J. (1989). Target tissue morphology and serum biochemistry 
following 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) exposure in a TCDD-susceptible and a 
TCDD-resistant strain. Fund. Appl. Toxicol. 12, 698-712. 
Poland A., and Knutson J.C. (1982). 2,3,7,8-tetrachlorodibenzo-p-dioxin and related halogenated 
aromatic hydrocarbons: examination of the mechanism of toxicity. Ann. Rev. Pharmacol. Toxicol. 
22,517-554. 
Polk D.H., Reviczky A., Wu S.Y., Huang W.S., and Fisher D.A. (1994). Metabolism of sulfoconjugated 
thyroid hormone derivatives in developing sheep. Am. J. Phys. 266 {Endocrinol. Metab. 29): 
E892-E896. 
Potter C.L., Sipes G.I., and Russell D.H. (1983). Hypothyroxinemia and hypothermia in rats in response 
to 2,3,7,8-tetrachlorodibenzo-p-sioxin in administration. Toxicol. Appl. Pharmacol. 69, 89-95. 
Potter C.L., Moore R.W., Inhorn S.L., Hagen T.C., and Peterson R.E. (1986). Thyroid status and 
149 
References 
thermogenesis in rats treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol. Appl. Pharmacol. 
84, 45-55. 
Raasmaja A., Viluksela M., and Rozman K.K. (1996). Decreased liver type I 5'-deiodinase and 
increased brown adipose tissue type II 5'-deiodinase activity in 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD)-treated long-evans rats. Toxicology 114, 199-205. 
Ram P.A., and Waxman D.J. (1991). Hepatic P450 expression in hypothyroid rats: differential 
responsiveness of male-specific P450 forms 2a (IIIA2), 2c (IIC11), and RLM2 (IIA2) to thyroid 
hormone. Mol. Endocrinol. 5, 13-20. 
Ram P.A., and Waxman D.J. (1992). Thyroid hormone stimulation of NADPH P450 reductase 
expression in liver and extrahepatic tissues. J. Biol. Chem. 267, 3294-3301. 
Ramsey J.C., Hefner J.G., Karbowski R.J., Braun W.H., and Gehring P.J. (1982). The in vivo 
biotransformation of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the rat. Toxicol. Appl. 
Pharmacol. 65, 180-184. 
Rein G., Glover V., and Sandler M. (1982). Multiple forms of phenolsulphotransferase in human 
tissues. Biochem. Pharmacol. 31, 1893-1897. 
Rickenbacher U., McKinney J.D., Oatley S.J., and Blake C.C.F. (1986). Structurally specific binding 
of halogenated biphenyls to thyroxine transport protein. J. Med. Chem. 29, 641-648. 
Rickenbacher U., Jordan S., and McKinney J.D. (1989). Structurally specific interaction of halogenated 
dioxin and biphenyl derivatives with iodothyronine-5'-deiodinase in rat liver. In: ProbingBioactive 
Mechanisms, ACS Symp. Ser. 413, Chapter 22, 354-365. 
Rogan W.J., Gladen B.C., McKinney J.D., Carreras N., Hardy P., Thullen J., Tinglestad J., and Tully 
M. (1986). Neonatal effects of transplacental exposure to PCBs and DDE. J. Pediatr. 109, 
335-341. 
Rosenberg D.W., Drummond G.S., and Smith T.J. (1995). Depletion of cytochrome P-450 by thyroid 
hormone and cobalt -protoporphyrin IX in rat liver: evidence that susceptibility varies among forms 
of the heme protein. Pharmacology 51, 254-262. 
Rosiak K., Li M.H., Degitz S.J., Skalla D.W., Chu I., and Francis B.M. (1997). Maternal and 
developmental toxicity of polychlorinated diphenyl ethers (PCDEs) in Swiss-Webster mice and 
Sprague-Dawley rats. Toxicology 121, 191-204. 
Roth W., Voorman R. and Aust S.D. (1988). Activity of thyroid hormone-inducible enzymes following 
treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol. Appl. Pharmacol., 92: 65-74. 
Rozman K., Rozman T., and Greim H. (1984). Effect of thyroidectomy and thyroxine on 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCCD) induced toxicity. Toxicol. Appl. Pharmacol. 11, 
372-376. 
Rozman K., Hazelton G.A., Klaassen CD., Arlotto M.P., and Parkinson A. (1985). Effect of thyroid 
hormones on liver microsomal enzyme induction in rats exposed to 
2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicology 37', 51-63. 
Rozman K., Rozman T., Scheufler E., Pazdernik T., and Greim H. (1985). Thyroid hormones modulate 
the toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). J. Toxicol. Environ. Health 16, 
481-491. 
Rozman K., Pereira D., and Iatropoulos M.J. (1986). Histopathology of interscapular brown adipose 
150 
References 
tissue, thyroid and pancreas in 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-treated rats. Toxicol. 
Appl. Pharmacol. 82, 551-559. 
Rozman K., Gorski J.R., Dutton D., and Parkinson A. (1988). Effect of vitamin A and/or thyroidectomy 
on liver microsomal enzymes and their induction in 2,3,7,8-tetrachlorodibenzo-p-dioxin-treated 
rats. Toxicology id, 107-117. 
Ruiz de Ona C, Obregon M.J., Escobar del Rey F., and Morreale de Escobar G. (1988). Developmental 
changes in rat brain 5"-deiodinase and thyroid hormones during the fetal period: the effects of fetal 
hypothyroidism and maternal thyroid hormones. Pediatr. Res. 24, 588-594. 
Ruiz de Ona C, Morreale de Escobar G., Calvo R., Escobar del Rey F., and Obregon M.J. (1991). 
Thyroid hormones and 5'-deiodinase in the rat fetus late in gestation: effects of maternal 
hypothyroidism. Endocrinol. 128, 422-432. 
Rumbaugh R.C., Kramer R.E., and Colby H.D. (1978). Dose-dependent actions of thyroxine on hepatic 
drug metabolism in male and female rats. Biochem. Pharmacol. 27, 2027-2031. 
Runge-Morris M., and Wilusz J. (1994). Suppression of hydroxysteroid sulfotransferase-a gene 
expression by 3-methylcholanthrene. Toxicol. Appl. Pharmacol., 125, 133-141. 
Rutgers M., Pigmans G.A.J., Bonthuis F., Docter R., and Visser T.J. (1989). Effects of propylthiouracil 
on the biliary clearance of thyroxine (T4) in rats: decreased excretion of 3,5,3'-triiodothyronine 
glucuronide and increased excretion of 3,3',5'-triiodothyronine glucuronide and T4 sulfate. 
Endocrinology 125, 2175-2186. 
Safe S.H. (1986). Comparative toxicology and mechanism of action of polychlorinated 
dibenzo-p-dioxins and dibenzofurans. Ann. Rev. Pharmacol. Toxicol., 26: 371-399. 
Safe S. (1989). Polyhalogenated aromatics: uptake, disposition and metabolism. In: Kimbrough R.D., 
and Jensen A.A. (eds.). Halogenated biphenyls, terphenyls, naphtalenes, dibenzodioxins and 
related products. Elsevier, Amsterdam, 131-159. 
Safe S. (1990). Polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs), dibenzofurans 
(PCDFs), and related compounds: environmental and mechanistic considerations which support 
the development of toxic equivalency factors (TEFs). Crit. Revs. Toxicol. 21, 51-88. 
Safe S. (1992). Toxicology, structure-function relationship, and human and environmental health 
impacts of polychlorinated biphenyls: progress and problems. Environ. Heath Perspect. 100, 
259-268. 
Safe S.H. (1994). Polychlorinated biphenyls (PCBs): environmental impact, biochemical and toxic 
responses, and implications for risk assessment. Crit. Revs. Toxicol. 24, 87-149. 
Safe S.H. (1995). Modulation of gene expression and endocrine response pathways by 
2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds. Pharmacol. Ther. 2, 247-281. 
Safe S.H., and Safe L.M. (1984). Synthesis and characterization of twenty-two purified polychlorinated 
dibenzofuran congeners. J. Agric. Food Chem. 32, 68-71. 
Saito K., Kaneko H., Sato K., Yoshitake A., and Yamada H. (1991). Hepatic 
UDP-glucuronyltransferase(s) activity toward hormones in rats: induction and effects on serum 
thyroid hormone levels following treatment with various enzyme inducers. Toxicol. Appl. 
Pharmacol. 111,99-106. 
Sakakibara Y., Takami Y., Zwieb C, Nakayama T., Suiko M., Nakajima H., and Liu M.C. (1995). 
151 
References 
Purification, characterization, and molecular cloning of a novel rat liver Dopa/tyrosine 
sulfotransferase. J. Biol. Chem. 270, 30470-30478. 
Santini F., Chopra I.J., Wu S.Y., Solomon D.H., and Teco G.N.C. (1992a). Metabolism of 
3,5,3'-triiodothyronine sulfate by tissues of the fetal rat: A consideration of the role of desulfation 
of 3,5,3'-triiodothyronine sulfate as a source of T3. Pediatr. Res. 31, 541-544. 
Santini F., Hurd R.E., and Chopra I.J. (1992b). A study of metabolism of deaminated and 
sulfoconjugated iodothyronines by rat placental iodothyronine 5-monodeiodinase. Endocrinology 
131, 1689-1694. 
Santini F., Cortelazzi D., Baggiani A.M., Marconi A.M., Beck-Peccoz P., and Chopra I.J. (1993). A 
study of the serum 3,5,3-triiodothyronine sulfate concentration in normal and hypothyroid fetuses 
at various gestational stages. J. Clin. Endocrinol. Metab. 76, 1583-1587. 
Schantz S.L. (1996). Developmental neurotoxicity of PCBs in humans: what do we know and where 
do we go from here?. Nenrotoxicol. Teratol. 18, 217-227. 
Schuur A.G., Boekhorst F.M., Brouwer A., and Visser T.J. (1997). Extrathyroidal effects of 2,3,7,8-
tetrachlorodibenzo-p-dioxin on thyroid hormone turnover in male Sprague-Dawley rats. 
Endocrinology 138, 3727-3734. 
Schuur A.G., Tacken P.J., Visser T.J., and Brouwer A. (1998a). Modulating effects of thyroid state 
on the induction of biotransformation enzymes by 2,3,7,8-tetrachlorodibenzo-p-dioxin. ETAP 5, 
7-16. 
Schuur A.G., Legger F.F., Van Meeteren M.E., Moonen M.J.H., Van Leeuwen-Bol I., Bergman A., 
Visser T.J., and Brouwer A. (1998b). In vitro inhibition of thyroid hormone sulfation by 
hydroxylated metabolites of polyhalogenated aromatic hydrocarbons. Chem Res Tox. 11, 1075-
1081. 
Schuur A.G., Van Leeuwen-Bol I., Jong W.M.C., Bergman A., Coughtrie M.W.H., Brouwer A., and 
Visser T.J. (1998c). In vitro inhibition of thyroid hormone sulfation by polychlorobiphenylols: 
isozyme specificity and inhibition kinetics. Toxicol. Sci., in press. 
Schuur A.G., Bergman A., Brouwer A., and Visser T.J. (1998d). Inhibition of thyroid hormone 
sulfation by pentachlorobiphenyl and 4-OH-2,3,3',4',5-pentachlorobiphenol in a rat and a human 
hepatoma ceil line, submitted. 
Seah V.M.Y., and Wong K.P. (1994). 2,6-dichloro-4-nitrophenol (DCNP), an alternate-substrate 
inhibitor of phenolsulfotransferase. Biochem. Pharmacol. 47, 1743-1749. 
Seegal R.F. (1996). Epidemiological and laboratory evidence of PCB-induced neurotoxicity. Crit. Revs. 
Toxicol. 26, 709-737. 
Seegal R.F., Bush B., and Shain W. (1990). Lightly chlorinated ortho-substituted PCB congeners 
decrease dopamine in non-human primate brain and in tissue culture. Toxicol. Appl. Pharmacol. 
106, 136-144. 
Sekura R.D., Sato K., Cahnmann H.J., Robbins J., and Jakoby W.B. (1981). Sulfate transfer to thyroid 
hormones and their analogs by hepatic aryl sulfotransferases. Endocrinology 108, 454-456. 
Sellstrom U., Kierkegaard A., De Wit C, Jansson B., Asplund L., Bergander L., Bignert A., Odsjo T., 
and Olsson M. (1996).Polybrominated diphenyl ethers (PBDE) in the Swedish environment - a 
summary, vitro.ln: Organohalogen Compounds 28, 526-529. 
152 
References 
Sepkovic D.W., and Byrne J.J. (1984). Kinetic parameters of L-[125I]triiodothyronine degradation 
in rats pretreated with polyhalogenated biphenyls. Fd. Chem. Toxic. 22, 743-747. 
Sewall C.H., Flagler N., Vanden Heuvel J.P., Clark G.C., Tritscher A.M., Maronpot R.M., and Lucier 
G.W. (1995). Alterations in thyroid function in female sprague-dawley rats following chronic 
treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol. Appl. Pharmacol. 132, 237-244. 
Shain W., Bush B., and Seegal R.F. (1991). Neurotoxicity of polychlorinated biphenyls: Structure-
activity relationships of individual congers. Toxicol. Appl. Pharmacol. I l l , 33-42. 
Shali N.A., Curtis C.G., Powell G.M., and Roy A.B. (1991). Sulphation of the flavonoids quercetin 
and catechin by rat liver. Xenobiotica 21, 881-893. 
Shephard E.A., Phillips I.R., Pike S.F., Ashworth A., and Rabin B.R. (1982). Differential effect of 
phenobarbital and beta-naphtoflavone on the mRNAs coding for cytochrome P450 and NADPH 
cytochrome P450 reductase. FEBSLett. 150, 375-380. 
Shwed J.A., Walle U.K., and Walle T. (1992). Hep G2 cell line as a human model for sulphate 
conjugation of drugs. Xenobiotica 22, 973-982. 
Silberhorn E.M., Glauert H.P., and Robertson L.W. (1990). Carcinogenicity of halogenated biphenyls: 
PCBs and PBBs. Crit. Revs. In Toxicol. 20, 439-396. 
Silva J.E., and Matthews P.S. (1984). Production rates and turnover of triiodothyronine in 
rat-developing cerebral cortex and cerebellum. Responses to hypothyroidism. J. Clin. Invest. 74, 
1035-1049. 
Sipes I.G., and Schnellmann R.G. (1987). Biotransformation of PCBs: metabolic pathways and 
mechanisms. In: Safe S. (ed.). Polychlorinated biphenyls (PCB's): mammalian and environmental 
toxicology. Springer, Berlin, 98-11. 
Skett P. (1987). Hormonal regulation and sex differences of xenobiotic metabolism. Progress in Drug 
Metabol. 10, 85-140. 
Skett P., and Weir A. (1982). Thyroid control of hepatic drug metabolism in the rat. Brit. J. Pharmacol. 
n,4\i. 
Spaulding S.W., Smith T.J., Hinkle P.M., Davis F.B., Kung M.P., and Roth J.A. (1992). Studies on 
the biological activity of triiodothyronine sulfate. J. Clin. Endocrinol. Metab. 74, 1062-1067. 
St. Germain D.L., and Galton V.A. (1997). The deiodinase family of selenoproteins. Thyroid 7, 
655-668. 
Stripp B.R., Lund J., Mango G.W., Doyen K.C., Johnston C, Hultenby K., Nord M., and Whitsett J.A. 
(1996). Clara cell secretory protein: a determinant of PCB bioaccumulation in mammals. Am. J. 
Physiol. 271, L656-L664. 
Sutter T.R., and Greenlee W.F. (1992). Classification of members of the Ah gene battery. Chemosphere 
25, 223-226. 
Tilson H.A., Jacobson J.L., and Rogan W.J. (1990). Polychlorinated biphenyls and the developing 
nervous system: cross-species comparisons. Neurotoxicol. Teratol. 12, 239-248. 
Tryphonas H. (1994). Immunotoxicity of polychlorinated biphenyls: present status and future 
considerations. Exp. Clin. Immunogenet. 11, 149-162. 
Tryphonas L., Truelove J., Zawidzka Z., Wong J., Mes J., Charbonneau S., Grant D.L., and Campbell 
J.S. (1984). Polychlorinated biphenyl (PCB) toxicity in adult cynomolgus monkeys (M 
153 
References 
fascicularis): A pilot study. Toxicologic Pathology 12, 10-25. 
Utesch D., and Oesch F. (1992). Dependency of the in vitro stabilization of differentiated functions 
in liver parenchymal cells on the type of cell line used for co-culture. In Vitro Cell. Dev. Biol. 28A, 
193-198. 
Van Birgelen A.P.J.M., Smit E.A., Kampen I.M., Groeneveld C.N., Fase K.M., Van der Kolk J., Poiger 
H., Van den Berg M., Koeman J.H., and Brouwer A. (1995). Subchronic effects of 2,3,7,8-TCDD 
or PCBs on thyroid hormone metabolism: use in risk assessment. Eur. J. Pharmacol, Environ. 
Toxicol. Pharmacol. Section 293, 77-85. 
Van den Berg K.J., Van Raaij J.A.G.M., Bragt P.C., and Notten W.R.F. (1991). Interactions of 
halogenated industrial chemicals with transthyretin and effects on thyroid hormone levels in vivo. 
Arch. Toxicol. 65, 15-19. 
Van Iersel M.L.P.S., Ploemen, J.H.T.M., Struik I , Van Amersfoort A.C., Keyzer A.E., Schefferlie J.G., 
and Van Bladeren P.J. (1996). Inhibition of glutathione S-transferase activity in human melanoma 
cells by cs,P-unsaturated carbonyl derivatives. Effects of acrolein, cinnamaldehyde, citral, 
crotonaldehyde, curcumin, ethacrynic acid, and trans-2-hexenal. Chem. Biol. Interact. 102, 117-
132. 
Van Raaij J.A.G.M., Frijters C.M.G., and Van den Berg K.J. (1993). Hexachlorobenzene-induced 
hypothyroidism. Involvement of different mechanisms by parent compound and metabolite. 
Biochem. Pharmacol. 46, 1385-1391. 
Van Stralen P.G.J., Van der Hoek H.J., Docter R., De Jong M., and Krenning E. (1993). Reduced T3 
deiodination by the human hepatoblastoma cell line HepG2 caused by deficient T3 sulfation. 
Biochim. Biophys. Acta 1157, 114-118. 
Vermilion J.L., and Coon M.J. (1978). Purified liver microsomal NADPH-cytochrome P450 reductase. 
J. of Biol. Chem. 253, 2694-2704. 
Visser T.J. (1990). Importance of deiodination and conjugation in the hepatic metabolism of thyroid 
hormone. In: M.A. Greer (Ed.). The Thyroid Gland. Raven Press, New York, Chapter 8, 255-283. 
Visser T.J. (1994a). Sulfation and glucuronidation pathways of thyroid hormone metabolism. In: Wu 
S.Y., and Visser T.J. (eds.). Thyroid hormone metabolism: molecular biology and alternate 
pathways. CRC Press, Boca Raton, 85-117. 
Visser T.J. (1994b). Role of sulfation in thyroid hormone metabolism. Chem. -Biol. Interact. 92, 
293-303. 
Visser T.J., Fekker D., Docter R., and Hennemann G. (1978). Sequential deiodination of thyroxine 
in rat liver homogenate. Biochem. J. 174, 221-229. 
Visser T.J., Leonard J.L., Kaplan M.M., and Larsen P.R. (1982). Kinetic evidence suggesting two 
mechanisms for iodothyronine 5'-deiodination in rat cerebral cortex. Proc. Natl. Acad. Sci. USA 
79, 5080-5084. 
Visser T.J., Often M.H., Mol J.A., Docter R., and Henneman G. (1984). Sulfation facilitates hepatic 
deiodination of iodothyronines. Hormone and Metabolic Research 14, 35-41. 
Visser T.J., Van Buuren J.C.J., Rutgers, M., Eelkman Rooda S.J., and De Herder W.W. (1990). The 
role of sulfation in thyroid hormone metabolism. TEM, 211-218. 
Visser T.J., Kaptein E., Gijzel A.L., De Herder W.W., Ebner T., and Burchell B. (1993a). 
154 
References 
Glucuronidation of thyroid hormone by human bilirubin and phenol UDP-glucuronyltransferase 
isoenzymes. FEBSLetters 324, 358-360. 
Visser T.J., Kaptein E., Raaij J.A.G.M., Van den Berg K.J., Tjong Tjin Joe C, Van Engelen J.G.M., 
and Brouwer A. (1993b). Glucuronidation of thyroid hormone in rat liver. Effects of in vivo 
treatment with microsomal enzyme inducers and in vitro assay conditions. Endocrinology 133, 
2177-2186. 
Visser T.J., Kaptein E., Gijzel A., De Herder W.W., Cannon M.L., Bonthuis F., and De Greef W.J. 
(1996a). Effects of thyroid status and thyrostatic drugs on hepatic glucuronidation of 
iodothyronines and other substrates in rats. Endocrine 4, 79-85. 
Visser T.J., Kaptein E. Glatt H. Bartsch I. Hagen M., and Coughtrie M.W.H. (1996b). Characterization 
of thyroid hormone sulfotransferases. Thyroid 6 (Suppl. 1 ), S-23. 
Visser T.J., Kaptein E., Glatt H., Bartsch I., Hagen M., and Coughtrie M.W.H. (1998a) 
Characterization of thyroid hormone sulfotransferases. Chem. Biol. Interact. 109, 279-291. 
Visser T.J., Kaptein E., Kester M.H.A., Roest T., Tibboel D., Bartsch I., Hagen M., Glatt H., and 
Coughtrie M.W.H (1998b). Characterization of human iodothyronine sulfotransferases. In 
preparation. 
Walle T., Eaton E.A., and Walle U.K. (1995). Quercetin, a potent and specific inhibitor of the human 
p-form phenolsulfotransferase. Biochem. Pharm. 50, 731-734. 
Wang J., Falany J.L., and Falany C.N. (1998). Expression and characterization of a novel thyroid 
hormone-sulfating form of cytosolic sulfotransferase from human liver. Mol. Pharmacol. 53, 
274-282. 
Waxman D.J., Morrissey J.J., and Leblanc G.A. (1989). Hypophysectomy differentially alters P450 
protein levels and enzyme activities in rat liver: pituitary control of hepatic NADPH cytochrome 
P450 reductase. Mol. Pharmacol. 34, 519-525. 
Weinshilboum R.M., Otterness D.M., Aksoy I.A., Wood T.C., Her C, and Raftogianis R.B. (1997). 
Sulfation and sulfotransferases I. Sulfotransferase molecular biology: cDNAs and genes. FASEB 
J. 11,3-14. 
Whittemore R.M., Pearce L.B., and Roth J.A. (1986). Purification and kinetic characterization of a 
phenol-sulfating form of phenol sulfotransferase from human brain. Arch. Biochem. Biophys. 249, 
464-471. 
Wilborn T.W., Comer K., Dooley T.P., Reardon I.M., Heinrikson R.L., and Falany C.N. (1993). 
Sequence analysis and expression of the cDNA for the phenol-sulfating form of human liver 
phenol sulfotransferase. Mol. Pharmacol. 34, 70-77. 
Williams M.T., Carrington H., and Herrera A. (1986). Stimulation of mouse liver glutathione 
S-transferase activity in propylthiouracil-treated mice in vivo by tri-iodothyronine. Biochem. J. 
233, 595-598. 
Wu S.Y., Polk D., Wong S., Reviczky A. Vu R., and Fisher D.A. (1992a). Thyroxine sulfate is a major 
thyroid hormone metabolite and a potential intermediate in the monodeiodination pathways in fetal 
sheep. Endocrinology 131, 1751-1756. 
Wu S., Huang W.S., Polk D., Florsheim W.H., Green W.L., and Fisher D.A. (1992b). Identification 
of thyroxine sulfate (T4S) in human serum and amniotic fluid by a novel T4S radioimmunoassay. 
155 
References 
Thyroid 2, 101-105. 
Wu S.Y., Huang W.S., Polk D., Chen W.L., Reviczky A., Williams J., Chopra I.J., and Fisher D.A. 
(1993a). The development of a radioimmunoassay for reverse triiodothyronine sulfate in human 
serumand amniotic fluid. J. Clin. Endocrinol. Metab. 76, 1625-1630. 
Wu S.Y., Polk D.H., Huang W.S., Reviczky A., Wang K. and Fisher D.A. (1993b). Sulfate conjugates 
of iodothyronines in developing sheep: effect of fetal hypothyroidism. Am. J. Physiol. 265 
{Endocrinol. Metab. 28), E115-E120. 
Wu S.Y., Polk D.H, Chen, W.L., Fisher D.A., Huang, W.S., and Yee B. (1994). A 3,3'-diiodothyronine 
sulfate cross-reactive compound in serum from pregnant women. J. Clin. Endocrinol. Metab. 78, 
1505-1509. 
Wu S.Y., Huang W.S., Chopra I.J., Jordan M, Alvarez D., and Santini F. (1995). Sulfation pathway 
of thyroid hormone metabolism in selenium-deficient male rats. Am. J. Physiol. 268, {Endocrinol. 
Metab. 31), E572-579. 
Yamazoe Y., Shimada M., Murayama N., and Kato R. (1987). Suppression of levels of 
phenobarbital-inducible rat liver cytochrome P-450 by pituitary hormone. J. Biol. Chem. 262, 
7423-7428. 
Yamazoe Y., MurayamaN., Shimada M., and Kato R. (1989). Thyroid hormone suppression of hepatic 
levels of phenobarbital-inducible P-450b and P-450e and other neonatal P-450S in 
hypophysectomized rats. Biochem. Biophys. Res. Commun. 160, 609-614. 
Yamazoe Y., Nagata K., Ozawa S., and Kato R. (1994). Structural similarity and diversity of 
sulfotransferases. Chem. -Biol. Interact. 92, 107-117. 
Young W.F., Gorman C.A., and Weinshilboum R.M. (1988). Triiodothyronine: a substrate for the 
thermostable and thermolabile forms of human phenol sulfotransferase. Endocrinology 111, 
1816-1824. 
156 
SAMENVATTING EN SLOTOPMERKINGEN 
Dit proefschrift handelt over de interactie van polygehalogeneerde aromatische 
koolwaterstoffen (PHAKs) met het schildklierhormoon metabolisme. Dit laatste hoofdstuk 
begint met een samenvatting van de effecten van schildklierhormoon op de door PHAKs 
gei'nduceerde biotransformatie-enzymen. Vervolgens worden de resultaten van de remming 
van schildklierhormoonsulfatering door gehydroxyleerde metabolieten van PHAKs besproken. 
Tot besluit worden enkele opmerkingen gemaakt met betrekking tot de implicaties van in deze 
studie gevonden resultaten. 
Effecten van schildklierhormoon op de inductie van biotransformatie-enzymen 
door polygehalogeneerde aromatische koolwaterstoffen 
Het eerste deel van dit proefschrift is gericht op de vraag of de door PHAKs gei'nduceerde 
afname van plasma T4 een hormonale aanpassing van het lichaam is, zodat het dier beter kan 
omgaan met de toxische effecten veroorzaakt door PHAKs. Om dit uit te zoeken werd de 
mogelijk regulerende rol van schildklierhormonen op biotransformatie-enzymen bestudeerd, 
waarbij gebruik werd gemaakt van ratten met een verschillende schildklierhormoonstatus. 
Hiervoor werden ratten behandeld met TCDD of PCBs als modelinductoren van 
biotransformatie-enzymen. 
Hoofdstuk 2 beschrijft de verschillen in de schildklierhormoonstatus van euthyroide 
(Eu) ratten, gethyroidectomeerde (Tx) ratten en Tx ratten behandeld met T3 of T4. De verlaagde 
plasmaniveaus van T4 en T3, de verhoogde hypofyse respons (hogere plasma TSH 
concentraties) samen met de veranderde functionele respons (verlaagde Dl en malic enzym 
activiteit in de lever, verhoogde D2 activiteit in de hersenen) in Tx ratten werden in Tx+T4 
ratten hersteld tot Eu niveaus. Dit werd tevens in Tx+T3 ratten gevonden met uitzondering van 
de plasma T4 en D2 activiteit. Uit deze resultaten blijkt dat de met schildklierhormoon 
behandelde Tx ratten een goed model zijn om perifere effecten van TCDD te bestuderen. Drie 
dagen na blootstelling aan 10 ug TCDD/kg lichaamsgewicht waren plasma TT4 en FT4 
concentraties significant verlaagd in Eu en Tx+T4 ratten. Plasma T3 concentraties waren 
significant verlaagd in Tx+T3 ratten maar niet in Eu of Tx+T4 ratten. T4 UGT activiteit in de 
lever werd gei'nduceerd door TCDD behandeling, terwijl T3 UGT activiteit alleen licht 
verhoogd was in de verschillende groepen. Deze resultaten suggereren dat de 
schildklierhormoonverlaging veroorzaakt door TCDD voornamelijk buiten de schildklier plaats 
vindt en gemedieerd wordt door de sterke verhoging van T4 UGT activiteit in de lever. 
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De effecten van modulering van de schildklierhormoonstatus op de inductie van 
detoxificerende enzymen door TCDD in laboratoriumdieren is beschreven in Hoofdstuk 3. In 
alle ratten induceerde TCDD een sterke verhoging van CYP1A1/1A2 activiteit (EROD), 
CYP1A1 eiwithoeveelheid en van CYP1 Al mRNA-niveaus. TCDD-blootstelling resulteerde 
ook in verhoogde totaal cytochroom P450 hoeveelheden, p-nitrofenol UGT activiteit, en GST 
1-1 eiwitconcentraties in de lever. Daarentegen werd geen effect van TCDD gevonden op 
NADPH cytochroom P450 reductase activiteit, totale GST activiteit en GST 2-2, 3-3 en 4-4 
eiwitconcentraties en iodothyronine sulfotransferase activiteit in de lever. 
Schildklierhormoonstatus had geen effect op de totaal cytochroom P450 hoeveelheid, GST 
activiteit en GST eiwitconcentraties. In Tx ratten werd echter een kleine verlaging 
geconstateerd in CYP1A1/2 activiteit, NADPH cytochroom P450 reductase activiteit, PNP 
UGT activiteit en iodothyronine sulfotransferase activiteit in Tx ratten vergeleken met Eu 
ratten. 
In het tweede dierexperiment is de interactie onderzocht tussen de 
schildklierhormoonstatus en PCBs op de regulatie van CYP1A1- en CYP2B-expressie 
(Hoofdstuk 4). Mannelijke Sprague-Dawley Tx ratten, Eu ratten en hyperthyroide ratten (door 
behandeling met T3) werden blootgesteld aan een eenmalige ip dosis van de CYP2B inductor 
PCB 153 en de CYP1A inductor PCB 126. De schildklierhormoonstatus werd gecontroleerd 
door plasma T4, T3 en TSH concentraties te bepalend en door functionele parameters te meten, 
zoals Dl, malic enzym en a-glycerolfosfaatdehydrogenase activiteiten in de lever. De 
hoeveelheid totaal cytochroom P450 in de lever was verhoogd in alle groepen na PCB 
blootstelling, maar werd niet be'rhvloed door schildklierhormoonstatus. De NADPH cytochroom 
P450 reductase activiteit was verlaagd in Tx ratten en verhoogd in hyperthyroide ratten, terwijl 
de blootstelling aan PCB hierop geen effect had. PCB 126 induceerde specifiek T4 UGT 
activiteit gemeten in de afwezigheid van detergens, en verhoogde de mRNA-niveuas, 
eiwitconcentraties en de activititeit van CYP1 A. PCB 153 induceerde juist T4 UGT activiteit 
ge meten in de aanwezigheid van het detergens Brij 56, en verhoogde de mRNA-niveuas, 
eiwitconcentraties en de activititeit van CYP2B. Schildklierhormoonstatus, zowel een hypo-
als een hyperthyroide status, had geen effect op beide T4 UGT activiteiten of op de mRNA-
niveaus, eiwitconcentraties of activiteiten van CYP1A en CYP2B. 
Het bijna volledig afwezig zijn van een respons van basale of door PCB- of TCDD-
gei'nduceerde effecten op biotransformatie-enzymen door veranderingen in 
schildklierhormoonstatus in onze studies is niet in overeenstemming met eerder gevonden 
effecten (Kato and Takahashi, 1968; Rumbaugh et al., 1978; Leakey et al., 1982; Miiller et al., 
1983a/b; Skett, 1987; Yamazoe et al, 1989; Arlotto and Parkinson, 1989; Murayama et al, 
1991; Chowdhury et al, 1983; Moscioni and Gartner, 1983; Pennington et al, 1988; 
Goudonnet et al., 1990; Williams et al., 1986; Pimental et al., 1993). Deze verschillen zouden 
veroorzaakt kunnen worden door verschillen in stam en geslacht van de gebruikte dieren, de 
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mate en tijdsduur van de hypo- of hyperthyroide status als wel van de mate en tijdsduur van 
de TCDD/PCB dosering. Concluderend, NADPH cytochroom P450 reductase activiteit in de 
lever is afhankelijk van de schildklierhormoonstatus, terwijl er geen of bijna geen 
veranderingen werde waargenomen in de hoeveelheid totaal cytochroom P450 evenals in 
CYP1A1 en CYP2B, UGT, GST en sulfotransferase activiteiten bij een verschil in 
schildklierhormoonstatus. Deze kleine verschillen zijn zeer waarschijnlijk geen endocriene 
aanpassing aan een chemische stressor (TCDD). De door PHAKs gei'nduceerde T4 verlaging 
evenals andere aspecten van schildklierhormoonmetabolisme zijn daarom zeer waarschijnlijk 
een directe aanwijzing van een zich ontwikkelende toxicologische respons van deze dieren op 
de PHAK blootstelling. 
De remming van schildklierhormoonsulfatering door gehydroxyleerde 
metabolieten van polygehalogeneerde aromatische koolwaterstoffen 
Het tweede deel van dit proefschrift handelt over de vraag of gehydroxyleerde metabolieten 
van PHAKs in staat zijn om schildklierhormoonsulfatering te remmen, in vitro en in vivo. 
In Hoofdstuk 5 wordt het onderzoek beschreven naar het mogelijk remmende effect 
van gehydroxyleerde metabolieten van PHAHs op iodothyronine sulfotransferase activiteit. 
Rattenlevercytosol werd gebruikt als bron voor sulfotransferase in een in vitro methode met 
125I-gelabeld T2 als een modelsubstraat. Aangetoond werd dat gehydroxyleerde metabolieten 
van PCBs, PCDDs en PCDFs sterke remmers zijn van T2 sulfotransferase activiteit in vitro 
met IC50 waarden in het laag micromolaire gebied (0.2-3.8 uM). De PCB-metaboliet 3-
hydroxy-2,3',4,4',5-pentachlorobiphenyl was de sterkste remmer van T2 sulfotransferase 
activiteit in onze studie met een IC50 waarde van 0.2 uM. Een belangrijke structurele 
voorwaarde voor remming van T2 sulfotransferase activiteit door PCB-metabolieten blijkt een 
hydroxyl groep op de para of meta positie te zijn. Ortho gehydroxyleerde PCBs zijn veel minder 
potent, en geen van de geteste PCBs was zelf in staat om T2 sulfotransferase activiteit te 
remmen. Tevens werd aangetoond dat omzetting van individuele gebromeerde diphenylethers, 
nitrofen, en commerciele PHAK mengsels (zoals Bromkal, Clophen A50 en Aroclor 1254) met 
behulp van cytochroom P450 resulteerde in de vorming van gehydroxyleerde metabolieten die 
in staat waren om T2 sulfotransferase activiteit te remmen. 
In Hoofdstuk 6 is de remming van schildklierhormoon sulfatering door PHAK-OHs 
in meer detail bestudeerd met behulp van isoenzymen en remmingskinetiek. Het verschil in 
remmingspatronen voor sulfotransferase activiteit gevonden tussen rattenlever- en 
rattenhersencytosol wordt waarschijnlijk veroorzaakt door een verschil in isoenzym patroon. 
T2 sulfatering werd geremd door PCB-OHs via een interactie met SULT1C1 en een ander 
isoenzym wat verantwoordelijk is voor T2 sulfatering in vrouwelijk levercytosol, waarschijnlijk 
159 
Samenvatting 
rat SULT1B1, maar niet SULT1 Al. Daarentegen geldt voor humaan fenol sulfotransferase, 
dat SULT1 Al geremd werd door PCB-OHs, en niet het isoenzym SULT1 A3. Tenslotte wijzen 
de resultaten erop dat tenminste het humane SULT1 Al, en het rat SULT1C1 en misschien ook 
rat SULT1B1 betrokken zijn bij de remming van T2 sulfatering door PCB-OHs. Het is echter 
noodzakelijk om meer informatie te verkrijgen over de verschillende isoenzymen die betrokken 
zijn bij de iodothyronine sulfatering in mensen en ratten. 
Tevens is aangetoond dat T2 een goed model substraat is voor het actieve hormoon 
T3 bij de bestudering van de remming van schildklierhormoonsulfatering door gehydroxyleerde 
metabolieten van PHAKs. De kinetiek van de remming van T2 sulfatering door PCB-OHs duidt 
op een competitieve remming. Definitief bewijs wacht op experimenten met gezuiverde 
isoenzymen. Tenslotte werd aangetoond dat PCDD-OHs en PCB-OHs zelf ook enigzins als 
substraat kunen dienen voor sulfotransferase enzymen, wat een tweede aanwijzing is voor een 
competitieve remming. 
Om de stap van in vitro experimenten met gebruik van cytosol naar de in vivo situatie 
te verkleinen, is de remming van schildklierhormoonsulfatering onderzocht in hepatoma 
cellijnen {Hoofdstuk 7). Twee PCB metabolieten, 4-hydroxy-2',3,3',4',5-pentachlorobiphenyl 
en 4-hydroxy-3,3',4',5-tetrachlorobiphenyl alsook de bekende sulfateringsremmer 
pentachlorophenol (PCP) zijn getest in de rattenhepatoma cellijn FaO en de humane hepatoma 
cellijn HepG2. Aangetoond is dat PCP de T2 sulfatering in vitro remt in FaO en HepG2 cellen, 
hoewel PCP 1000 keer minder aktief was in cellen in vergelijking met rattenlevercytosol. 
Micromolaire concentraties van 2 geteste PCB-OHs bei'nvloedden de T2 conjugatie nauwelijks 
in FaO cellen, maar reduceerden wel de sulfaatvorming in HepG2 cellen. De remming van T2 
sulfatering was sterker in medium zonder serumtoevoeging in vergelijking met medium met 
5% serum. Dit laatste wordt veroorzaakt door een lagere opname van de remmer door de cellen 
in aanwezigheid van serum zoals aangetoond werd met behulp van radioactief gelabeld PCP. 
Deze in vitro resultaten tonen aan dat gehydroxyleerde PHAKs sterke remmers zijn 
van de schildklierhormoonsulfatering. Schildklierhormoonsulfatering speelt waarschijnlijk een 
belangrijke rol in de regulatie van "vrije" hormoonconcentraties in de foetus. Daarnaast is 
bekend dat gehydroxyleerde PCB metabolieten accumuleren in foetale weefsels na blootstelling 
van de moeder aan PCBs. De remming van T2 sulfatering zou dus eventueel een effect kunnen 
hebben op de foetale schildklierhormoonhomeostase en ontwikkeling. 
Het in vivo experiment waarin de mogelijke remming van T2 sulfatering door PHAK 
metabolieten werd getest, is beschreven in Hoofdstuk 8. Drachtige ratten werden blootgesteld 
aand Aroclor 1254 of aan de bekende fenolsulfotransferase remmer PCP op dag 10 tot en met 
dag 18 van de dracht. Op dag 20 van de dracht werd sectie uitgevoerd op foetussen en 
moederdieren. De concentraties van PCP en PCB metaboliet waren hoog in foetaal serum en 
weefsels. Aroclor 1254 blootstelling resulteerde in verhoogde EROD en T4 UGT activiteit in 
de lever van moederdieren, terwijl PCP geen effect had op deze parameters. 
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PHAKs staan bekend om hun verstorend effect op schildklierhormoonmetabolisme, 
zoals aangegeven in Figuur 9.1 (Chapter 9). In dit dierexperiment veroorzaakte Aroclor 1254 
blootstelling een verhoogde T4 UGT activiteit in de lever, wat resulteerde in verlaagde TT4 
niveaus. Blootstelling aan PCP leidde ook tot verlaagde serum TT4 concentraties, maar tot 
verhoogde FT4 concentraties in zowel foetussen als moederdieren. De ratio FT4/TT4 was 
verhoogd, wat duidt op een verlaagde bindingscapaciteit voor T4 aan TTR in foetussen en 
moederdieren als gevolg van de beide behandelingen. Dl activiteit in de lever was verlaagd 
in moederdieren en foetussen na behandeling met Aroclor 1254 en PCP. Deze verlaging wordt 
waarschijnlijk indirect veroorzaakt door de verlaagde T4 concentraties. D2 activiteit in de 
hersenen was verlaagd door blootstelling aan PCP in moederdieren, terwijl er geen effect was 
in de foetussen. Blootstellling aan Aroclor 1254 verhoogde de D2 activiteit in foetale hersenen, 
en gaf geen effect te zien bij de moederdieren. De verhoogde D2 activiteit is een respons van 
de hersenen op lage T4 concentraties, nodig om de T3 homeostase te bewaren. 
In tegenstelling met de verwachting liet de positieve controle PCP juist een verhoging 
van de T2 SULT activiteit in lever- en hersencytosol van de moeder zien. Experimenten waarbij 
varierende T2 concentraties en verschillende eiwitconcentraties werden gebruikt, suggereren 
dat PCP in staat is sulfotransferase activiteit competitief te remmen en tevens de hoeveelheid 
sulfotransferase-eiwit te verhogen. Dit effect van PCP op schildklierhormoonsulfatering leidt 
blijkbaar niet tot lagere concentraties van het schildklierhormoonsulfaat, aangezien de serum 
T4S concentraties in moederdieren en foetussen niet verlaagd zijn na behandeling met PCP. 
Dit negatieve effect zou het gevolg kunnen zijn van een verhoogde beschikbaarheid van het 
substraat (FT4; in de moederdieren) samen met een verlaagde Dl activiteit door PCP, wat 
resulteert in een verlaagde enzymatische afbraak van T4S. 
Blootstelling aan Aroclor 1254, waarvan gehydroxyleerde metabolieten gevormd 
worden, veroorzaakte geen significante verschillen in de T2 sulfotransferase activiteit in lever-
of hersencytosol van moeders of foeten, noch in T4 serum concentraties. 
De T3S en T4S concentraties waren opmerkelijk laag in foetaal rat serum in deze 
studie, in vergelijking met de hoge waarden van iodothyronine sulfaten in foetaal humaan en 
schapenserum. Dit kan niet verklaard worden door een lage sulfotranferase activiteit of reeds 
hoge Dl activiteiten in rattenfoeten op dag 20. 
Implicaties van de geobserveerde PHAK-effecten op het 
schildklierhormoonmetabolisme 
PHAKs induceren een breed spectrum aan toxische effecten in ratten. Van sommige effecten, 
zoals het "wasting syndrome", afname van voedelinname en verhoogde serum cholesterol 
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concentraties, is gesuggereerd dat ze in verband staan met een hypothyroide situatie. Inderdaad 
worden er verlaagde serum T4 concentraties gevonden na blootstelling aan PHAKs (Bastomsky 
etal, 1977; Gorski andRozman, 1987; Hermansky et al., 1988; Brouwer, 1989; Beetstraef 
al., 1991). Daardoor is het verleidelijk om te speculeren over een relatie tussen de 
hypothyroxinemie en de geobserveerde toxische responsen. De inductie van een hypothyroide 
situatie of een hypothyroxinemie door PHAKs kan echter ook beschouwd worden als een 
hormonale aanpassing om de PHAK-gei'nduceerde toxiciteit op te kunnen vangen. Een 
argument voor deze interpretatie, is de observatie van een beschermend effect van een 
thyroidectomie op door TCDD-gei'nduceerde lethaliteit en immuuntoxiciteit (Rozman et al, 
1985). 
In dit onderzoek gaan we uit van de hypothese dat de T4 verlaging een regulerende 
rol zou kunnen hebben in de inductie van biotransformatie-enzymen in de lever, zoals reeds 
eerder is gerapporteerd (zie Hoofdstuk 1). De resultaten van het huidige onderzoek suggereren 
dat de verlaging van T4 concentraties door PHAKs alleen maar een toxisch effect is van de 
PHAKs en geen adaptieve respons om de inductie van biotransformatie-enzymen te reguleren. 
Het verschil met andere onderzoeken over modulerende effecten van schildklierhormoonstatus 
op biotransformatie-enzymen kan eventueel verklaard worden door verschillen in tijd en dosis 
van de inductoren als mede door een verschil in de hypo- of hyperthyroide status. De T4 
verlagingen in de hypothyroide dieren in onze studie waren echter vergelijkbaar aan door 
PHAKs gei'nduceerde T4 verlagingen. Daarom was het model goed genoeg om onze hypothese 
te onderzoeken. 
Het tweede deel van dit proefschrift laat zien dat, naast het type I dejodase en transthyretine, 
het sulfotransferase enzym ook competitief geremd kan worden door gehydroxyleerde 
metabolieten van PHAKs. In een vrij smal concentratiegebied (uM) zijn PHAK-OHs in staat 
om T2 sulfotransferase activiteit in vitro competitief te remmen op een sulfotransferase 
isoenzym- en weefselspecifieke manier. 
Ratten perinataal blootgesteld aan PCBs werden gebruikt om T2 sulfateringsremming 
te testen in vivo. Er werd aangetoond dat de bekende sulfateringsremmer PCP in staat was de 
T2 sulfotransferase activiteit te verhogen, waarschijnlijk als een indirect gevolg van competieve 
remming resulterend in verlaagde niveaus van gesulfateerd product. Door gebruik te maken 
van verschillende cytosol eiwitconcentraties en een concentratiereeks van het substraat T2 in 
de in vitro assay kon geconcludeerd worden dat PCP de T2 sulfotransferase activiteit 
competitief remde, hoewel niet zo sterk als verwacht. Aroclor 1254 blootstelling resulteerde 
in een kleine verlaging in T2 sulfotransferase activiteit, hetgeen waarschijnlijk veroorzaakt 
wordt door remming door gevormde gehydroxyleerde PCB metabolieten. Deze remming samen 
met de gevonden verlaagde substraat (FT4) concentratie gevonden na blootstelling aan Aroclor 
1254, resulteerde niet in verlaagde T4S serum niveaus. Dit zou verklaard zou kunnen worden 
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door een tegelijkertijd verminderde aibraakroute, namelijk de verlaagde Dl activiteit, als ook 
door een verhoogde substraatbeschikbaarheid (FT4) na blootstelling aan PCP. 
De serum T4S niveaus in foetale ratten zijn opmerkelijk laag in vergelijking met 
foetale concentraties in humaan en schapenserum (Wu et al., 1992a/b; 1993a/b; Santini et al., 
1993). Dit kan niet verklaard worden uit een al verhoogde Dl activiteit of een relatief lage 
sulfateringsactiviteit in de foetus rond dag 20 van de dracht. Vanwege die lage concentraties 
zou de rat wellicht niet zo'n goed model kunnen zijn voor het bestuderen van de effecten van 
toxische stoffen op foetaal schildklierhormoonsulfatering bij de mens. Er moet wel opgemerkt 
worden dat ondanks het feit dat PHAKs en hun metabolieten op verschillende wijze kunne 
interfereren met het schildklierhormoontransport en -metabolisme, de foetus blijkbaar in staat 
is om te gaan met deze veranderingen en de homeostase kan bewaren. 
Een ander interessant punt uit deze studie is dat PCP, wat als model voor een PCB-OH 
zou kunnen dienen, ook effecten liet zien op schildklierhormoonniveaus en -metabolisme. Dit 
duidt erop dat de effecten van PCBs op schildklierhormoonniveaus en -metabolisme niet alleen 
door PCBs zelf maar ook door hun gevormde gehydroxyleerde metabolieten veroorzaakt kunnen 
worden. De door PCB-OHs en andere fenolische organohalogenen veroorzaakte effecten geeft 
aanleiding tot meer onderzoek naar de potentiele toxiciteit van deze stoffen op 
schildklierhormoontransport en -metabolisme. Daarnaast moet ook opgemerkt worden dat naast 
de "oude" organohalogeenvervuilers die niet meer gebruikt mogen worden sinds de tachtiger 
jaren, er een breed spectrum aan nieuwe producten op de markt is gekomen zoals gebromeerde 
diphenylethers (PBDEs), gechloreerde benzenen, bisphenol A enzovoort. Tegenwoordig worden 
PBDEs veel gebruikt als vlamvertragers, en zijn aangetoond in toenemende hoeveelheden in 
ons milieu (De Boer, 1989; Sellstrom et al, 1996). Waarschijnlijk zijn ze in staat om 
soortgelijke effecten als PHAKs te veroorzaken. Serum T4 verlagingen zijn al gerapporteerd 
in ratten na blootstelling aan PBDEs (Darnerud et al, 1996) of PCDEs (Rosiak et al, 1997). 
Eveneens werd gevonden dat gehydroxyleerde metabolieten van PBDEs in staat zijn de binding 
van T4 aan TTR in vitro te verhinderen (Meerts et al., 1998). 
Tevens is bekend dat een groot aantal voedselcomponenten in staat zijn het 
schildklierhormoontransport en -metabolisme te verstoren. Over flavonen en flavonoiden is 
gerapporteerd dat ze interfereren met schildklierhormoon-bindende eiwitten zoals Dl 
(Auf mkolk et al, 1986; Cody et al, 1989) en TTR (Lueprasitsakul et al, 1990; Kohrle et al, 
1986b). Flavonoiden zoals quercetine zijn in staat tot het remmen van phenol sulfotransferase 
activiteit in vitro (Walle et al, 1995; Eaton et al, 1996), evenals andere voedseladditieven 
(Bamforth et al, 1993). Het humane dieet bevat een breed spectrum aan van nature 
voorkomende en non-nutrionele bestanddelen die een effect kunnen hebben op 
schildklierhormoonmetabolisme. Het mogelijke negatieve effect op de gezondheid van de mens 
hangt af van een aantal factoren, zoals de voedselinname, metabolisme en pharmacokinetiek, 
de potentie van de stof, de serumconcentraties, de relatieve binding aan serumeiwitten en van 
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interacties met andere endocriene routes. In een risico-evaluatie zal meegenomen moeten 
worden dat mensen blootgesteld worden aan een mengsel van stoffen met effecten of 
schidlklierhormoonmetabolisme. Indien het mechanisme gelijk is voor deze stofgroepen, zouden 
de effecten additief kunnen zijn. Daarnaast zijn de zeer persistenst PHAKs waarschijnlijk 
belangrijker voor een risico-evaluatie dan de natuurlijk voorkomende voedselcomponenten, 
vanwege hun hogere afbreekbaarheidsgraad. 
De effecten van PHAKs op het schildklierhormoonsysteem in deze studie zijn alien 
geobserveerd ratten, maar wat is nu eigenlijk de relevantie voor de mens? Beroepsmatige of 
accidentele blootstelling aan hoge concentraties van PCBs of PBBS resulteerde in veranderingen 
in serum T4 concentraties, zoals gevonden door Bahn et al. (1980), Kreiss et al. (1982), Murai 
et al. (1987) en Emmet et al. (1988). Daarnaast werd in zwangere vrouwen blootgesteld aan 
achtergrondniveaus van PHAKs door voeding, een significant negatieve correlatie gevonden 
tussen PHAK-concentraties in moedermelk en plasma T3 en T4 niveaus (Koopman-Esseboom 
et al, 1994). Eveneens werden toenames in plasma TSH en zowel toenames als afname in 
plasma T4 levels gevonden in pasgeboren babies na blootstelling aan toenemende PHAK-
concentraties in de baarmoeder en via borstvoeding (Pluim et al., 1993; Koopman-Esseboom 
et al, 1994). Daarnaast zijn er neurologische verstoringen gerelateerd aan perinatale 
blootstelling aan PCBs gevonden in kinderen in epidemiologische studies (Rogan et al., 1986; 
Jacobson etal., 1990). Het is echter nog steeds niet duidelijk of deze effecten van PHAKs op 
schildklierhormoonconcentraties en -metabolisme mogelijke effecten kunnen hebben op 
(hersen)ontwikkeling. 
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3MC 3-methylcholanthrene 
Ah-receptor Arylhydrocarbon receptor 
bw body weight 
CNS central nervous system 
CYP cytochrome P450 
Dl type I deiodinase 
D2 type II deiodinase 
D3 type III deiodinase 
EROD ethoxyresorufin O-deethylase 
Eu euthyroid 
FCS fetal calf serum 
FT4 free T4 
GD gestation day 
GST glutathione S-transferase 
IC50 inhibition concentration at 50% 
ip intraperitoneaal 
PAPS phospho-adenosine phosphosulphate 
PB phenobarbital 
PCB polychlorinated biphenyl 
PCP pentachlorophenol 
PCB 126 3,3',4,4',5-pentachlorobiphenyl 
PCB 153 2,2',4,4',5,5'-hexachlorobiphenyl 
PCDD polychlorinated dibenzo-p-dioxin 
PCDF polychlorinated dibenzofiiran 
PHAH polyhalogenated aromatic hydrocarbon 
PHAH-OH hydroxylated polyhalogenated aromatic hydrocarbon 
PNP p-nitrophenol 
rT3 reverse T3; 3,3',5'-triiodothyronine 
SULT sulfotransferase 
T2 3,3'-diiodothyronine 
T3 3,3',5-triiodothyronine 
T4 thyroxine; 3,3',5,5'-tetraiodothyronine 
TCDD 2,3,7,8-tetrachlorodibenzo-p-dioxin 
TSH thyroid stimulating hormone 
TTR transthyretin 
Tx thyroidectomized 
UDP uridinediphospho 
UGT UDP-glucuronyltransferase 
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